2-Amino-Bicyclo (3.1.0) Hexane-2,6-Dicarboxylic Ester Derivative

ABSTRACT

A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration 
     A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] 
     
       
         
         
             
             
         
       
     
     [wherein R 1  and R 2  are identical or different, and each represents a hydrogen atom, a C 1-10 alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR 3 R 4  or the like (wherein R 3  and R 4  are identical or different, and each represents a hydrogen atom, a C 1-10 alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a divisional of U.S. patent application Ser. No. 10/562,018filed Jun. 30, 2006, which is a National Stage Application filed under§371 of PCT Application No. PCT/JP2004/009398 filed Jun. 25, 2004. Theentire disclosures of the prior applications, U.S. patent applicationSer. No. 10/562,018 and PCT/JP2004/009398 are hereby incorporated byreference.

FIELD OF THE INVENTION

The present invention relates to a pharmaceutically effective2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof, a hydrate thereof or a prodrugcontaining the above as an active ingredient. More specifically, thepresent invention relates to a prodrug of2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative and so onthat are a compound that acts as an antagonist of mGlu2/mGluR3 belongingto sub group II of metabolic (metabotropic) glutamate receptors (mGluR),which is effective for the treatment and prevention of psychiatricdisorders such as schizophrenia, anxiety and related ailments thereof,depression, bipolar disorder and epilepsy; and also of neurologicaldiseases such as drug dependence, cognitive disorders, Alzheimer'sdisease, Huntington's chorea, Parkinson's disease, dyskinesia associatedwith muscular rigidity, cerebral ischemia, cerebral failure, myelopathyand head trauma.

Further, the present invention relates to the finding that a prodrug ofa compound that acts as an antagonist of mGluR2/mGluR3 shows highactivity in oral administration and increases the amount of exposure invivo of the parent compound.

BACKGROUND OF THE INVENTION

Metabotropic glutamate receptors are classified pharmacologically intothree groups. Of these, group II (mGluR2/mGluR3) bind withadenylcyclase, and inhibit the accumulation of the Forskolin stimulationof cyclic adenosine monophosphate (cAMP) (see Trends Pharmacol. Sci.,14, 13, 1993 (non-patent document 1 mentioned below)). Thus it issuggested that compounds that antagonize the action of group IImetabotropic glutamate receptors are effective for the treatment andprevention of acute and chronic psychiatric disorders and neurologicaldiseases. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acidderivative is a compound that has a strong antagonistic effect on groupII metabotropic glutamate receptors.

LIST OF RELATED DOCUMENTS Non-Patent Document 1

-   -   Trends Pharmacol. Sci., 14, 13, 1993

It is an object of the present invention to provide a drug that iseffective for the treatment and prevention of psychiatric disorders suchas schizophrenia, anxiety and related ailments thereof, depression,bipolar disorder and epilepsy; and also effective for the treatment andprevention of neurological diseases such as drug dependence, cognitivedisorders, Alzheimer's disease, Huntington's chorea, Parkinson'sdisease, dyskinesia associated with muscular rigidity, cerebralischemia, cerebral failure, myelopathy and head trauma; which is a drugthat antagonizes the action of group II metabotropic glutamate receptorsand shows high activity in oral administration.

DISCLOSURE OF THE INVENTION

The present inventors have conducted extensive examinations into2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivatives, and byconducting animal tests with a parent compound as the test drug,discovered that a prodrug of a2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative thataffects group II metabotropic glutamate receptors increases the amountof exposure in vivo of the parent compound, thereby completing thepresent invention.

The present invention provides a2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative,(hereinafter may be referred to as ‘the compound of the presentinvention’), a pharmaceutically acceptable salt thereof or a hydratethereof, represented by formula [I]

[wherein,R¹ and R² are identical or different, and each represents a C₁₋₁₀alkylgroup, a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl groupsubstituted by one or two aryl groups, a hydroxyC₂₋₁₀alkyl group, ahalogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkylgroup, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkylgroup, a farnesyl group, a 4-morpholinylC₁₋₁₀alkyl group, a C₁₋₁₀alkylgroup substituted by a group represented by formula —C(O)NR^(a)R^(b)(wherein R^(a) and R^(b) are identical or different, and each representsa hydrogen atom or a C₁₋₁₀alkyl group), a group represented by formula—CHR^(c)OC(O)ZR^(d) (wherein Z represents an oxygen atom, a nitrogenatom, a sulfur atom or a single bond; R^(c) represents a hydrogen atom,a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group; and R^(d)represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group), agroup represented by formula [i].

(wherein R^(d) is the same as described above) or a group represented byformula [ii]; or,

in the case where either R¹ or R² represents a hydrogen atom, the otherrepresents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynylgroup, a C₁₋₁₀alkyl group substituted by one or two aryl groups, ahydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkylgroup, an aminoC₂₋₁₀alkyl group, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, aC₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, a farnesyl group, a4-morpholinylC₁₋₁₀alkyl group, a C₁₋₁₀alkyl group substituted by a grouprepresented by formula —C(O)NR^(a)R^(b) (wherein R^(a) and R^(b) are thesame as described above), a group represented by formula—CHR^(c)OC(O)ZR^(d) (wherein Z, R^(c) and R^(d) are the same asdescribed above), a group represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii].

X represents a hydrogen atom or a fluorine atom. Y represents —OCHR³R⁴,—SR³, —S(O)_(n)R⁵, —SCHR³R⁴, —S(O)_(n)CHR³R⁴, —NHCHR³R⁴,—N(CHR³R⁴)(CHR^(3′)R^(4′)), —NHCOR³ or —OCOR⁵ (wherein R³, R^(3′), R⁴and R^(4′) are identical or different, and each represents a hydrogenatom, a C₁₋₁₀alkyl group, a C₁₋₁₀alkenyl group, a phenyl group, anaphthyl group, a naphthyl group substituted by one to seven halogenatoms, a heteroaromatic group or a phenyl group substituted by one tofive substituents selected from a group consisting of a halogen atom, aphenyl group, a C₁₋₁₀alkyl group, a C₁₋₁₀alkoxy group, a trifluoromethylgroup, a phenyl group, a hydroxycarbonyl group, an amino group, a nitrogroup, a cyano group and a phenoxy group; R⁵ represents a C₁₋₁₀alkylgroup, a C₁₋₁₀alkenyl group, a phenyl group, a naphthyl group, anaphthyl group substituted by one to seven halogen atoms, aheteroaromatic group or a phenyl group substituted by one to fivesubstituents selected from a group consisting of a halogen atom, aphenyl group, a C₁₋₁₀alkyl group, a C₁₋₁₀alkoxy group, a trifluoromethylgroup, a phenyl group, a hydroxycarbonyl group, an amino group, a nitrogroup, a cyano group and a phenoxy group; and n represents integer 1 or2)]

In an aspect of the present invention, it is preferred that in formula[I],

R¹ and R² are identical or different, and each represents a C₁₋₁₀alkylgroup, a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl groupsubstituted by one or two phenyl groups, a hydroxyC₂₋₁₀alkyl group, ahalogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkylgroup, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group or a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkylgroup; or,in the case where either R¹ or R² represents a hydrogen atom, the otherrepresents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynylgroup, a C₁₋₁₀alkyl group substituted by one or two phenyl groups, ahydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkylgroup, an aminoC₂₋₁₀alkyl group, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group or aC₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group.

In another aspect of the present invention, it is preferred that informula [I],

R¹ and R² are identical or different, and each represents a farnesylgroup, a C₁₋₁₀alkyl group substituted by one or two aryl groups, aC₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, a 4-morpholinylC₁₋₁₀alkyl group, aC₁₋₁₀alkyl group substituted by a group represented by formula—C(O)NR^(a)R^(b) (wherein R^(a) and R^(b) are identical or different,and each represents a hydrogen atom or a C₁₋₁₀alkyl group), a grouprepresented by formula —CHR^(c)OC(O)ZR^(d) (wherein Z represents anoxygen atom, a nitrogen atom, a sulfur atom or a single bond; R^(c)represents a hydrogen atom, a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group oran aryl group; and R^(d) represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenylgroup or an aryl group), a group represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]; or,

in the case where either R¹ or R² represents a hydrogen atom, the otherrepresents a farnesyl group, a C₁₋₁₀alkyl group substituted by one ortwo aryl groups, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, a4-morpholinylC₁₋₁₀alkyl group, a C₁₋₁₀alkyl group substituted by a grouprepresented by formula —C(O)NR^(a)R^(b) (wherein R^(a) and R^(b) are thesame as described above), a group represented by formula—CHR^(c)OC(O)ZR^(d) (wherein Z, R^(c) and R^(d) are the same asdescribed above), a group represented by formula

(wherein R^(d) is the same as described above) or a group represented byformula [ii];

In another aspect of the present invention, it is preferred that informula [I], R² represents a hydrogen atom.

In a further aspect of the present invention, it is preferred that informula [I], X represents a fluorine atom.

Further, in another aspect of the present invention, it is preferredthat in formula [I], Y represents —OCHR³R⁴, —SR³, —SCHR³R⁴,—S(O)_(n)CHR³R⁴, —NHCHR³R⁴ or —N(CHR³R⁴)(CHR^(3′)R^(4′)) (wherein R³,R^(3′), R⁴ and R^(4′) are the same as described above).

In another aspect of the present invention, it is preferred that informula [I], Y represents —SR³, —SCHR³R⁴, —S(O)_(n)CHR³R⁴, —NHCHR³R⁴ or—N(CHR³R⁴)(CHR^(3′)R^(4′)) (wherein R³, R^(3′), R⁴ and R^(4′) are thesame as described above).

It is preferred that in formula [I], R³, R^(3′), R⁴ and R^(4′) used fordescribing Y each independently represents a hydrogen atom, a phenylgroup, a naphthyl group or a phenyl group substituted by one to fivesubstituents selected from a group consisting of a halogen atom, aphenyl group, a C₁₋₁₀alkyl group, a C₁₋₁₀alkoxy group, a trifluoromethylgroup, a phenyl group, a hydroxycarbonyl group, an amino group, a nitrogroup, a cyano group and a phenoxy group. Of the above, it is morepreferred that R³, R^(3′), R⁴ and R^(4′) each independently represents ahydrogen atom, a phenyl group, a naphthyl group or a phenyl groupsubstituted by one to five halogen atoms.

In a further aspect of the present invention, it is preferred that informula [I], R¹ and R² each independently represents a hydrogen atom, aC₁₋₁₀alkyl group, a C₂₋₆alkenyl group, a C₂₋₆alkynyl group, a C₁₋₆alkylgroup substituted by one or two phenyl groups, a hydroxyC₂₋₆alkyl group,a halogenoC₁₋₆alkyl group, an azidoC₁₋₆alkyl group, an aminoC₂₋₆alkylgroup, a C₁₋₆alkoxyC₁₋₆alkyl group or a C₁₋₆alkoxycarbonylC₁₋₆alkylgroup. Of the above, it is more preferred that R² represents a hydrogenatom and R¹ represents a straight-chain or branched chain C₁₋₁₀alkylgroup, C₂₋₆alkenyl group, or C₁₋₆alkyl group substituted by one or twophenyl groups.

Further, in another aspect of the present invention, it is preferredthat in formula [I], R¹ and R² each independently represents a hydrogenatom, a farnesyl group, a C₁₋₆alkyl group substituted by one or two arylgroups, a C₁₋₆alkoxycarbonylC₁₋₆alkyl group, a 4-morpholinylC₁₋₆alkylgroup, a C₁₋₁₀alkyl group substituted by a group represented by formula—C(O)NR^(a)R^(b) (wherein R^(a) and R^(b) are the same as describedabove), a group represented by formula —CHR^(c)OC(O)ZR^(d) (wherein Z,R^(c) and R^(d) are the same as described above), a group represented byformula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii].

Of the above, it is more preferred that R² represents a hydrogen atom;and R¹ represents a farnesyl group, a C₁₋₆alkyl group substituted by oneor two unsubstituted or substituted phenyl groups, aC₁₋₆alkoxycarbonylC₁₋₆alkyl group, a 4-morpholinylC₁₋₆alkyl group, aC₁₋₁₀alkyl group substituted by a group represented by formula—C(O)NR^(a)R^(b) (wherein R^(a) and R^(b) are the same as describedabove), a group represented by formula —CHR^(c)OC(O)ZR^(d) (wherein Z,R^(c) and R^(d) are the same as described above), a group represented byformula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii].

It is preferred that in formula [I], R^(a) and R^(b) used to describe R¹and R² represent a hydrogen atom or a C₁₋₆alkyl group. It is preferredthat R^(c) represents a hydrogen atom, a C₁₋₆alkyl group, a C₂₋₆alkenylgroup or an aryl group. And it is preferred that R^(d) represents aC₁₋₆alkyl group, a C₂₋₆alkenyl group or an aryl group. The terms used inthe present invention are defined as follows. C_(n-m) means that thegroup following C_(n-m) has from n to m carbon atoms.

The C₁₋₁₀alkyl group means a straight-chain alkyl group having one toten carbon atoms, a branched chain alkyl group having three to tencarbon atoms or a cyclic alkyl group having three to ten carbon atoms.Examples of the straight-chain alkyl group include a methyl group, anethyl group, a propyl group, a butyl group, a pentyl group, a hexylgroup, a heptyl group, an octyl group, a nonyl group and a decyl group.Examples of the branched chain alkyl group include an isopropyl group,an isobutyl group, a 1-methylpropyl group, a t-butyl group, a1-methylbutyl group, a 2-methylbutyl group, a 3-methylbutyl group, a1-ethylpropyl group, a 1,1-dimethylpropyl group, a 2,2-dimethylpropylgroup, a 1,2-dimethylpropyl group, a 1-methylpentyl group, a2-methylpentyl group, a 3-methylpentyl group, a 4-methylpentyl group, a1-ethylbutyl group, a 2-ethylbutyl group, a 1,1-dimethylbutyl group, a1,2-dimethylbutyl group, a 1,3-dimethylbutyl group, a 2,2-dimethylbutylgroup, a 2,3-dimethylbutyl group, a 3,3-dimethylbutyl group, a5-methylhexyl group, a 3-ethylpentyl group, a 1-propylbutyl group, a1,4-dimethylpentyl group, a 3,4-dimethylpentyl group, a1,2,3-trimethylbutyl group, a 1-isopropylbutyl group, a4,4-dimethylpentyl group, a 5-methylheptyl group, a 6-methylheptylgroup, a 4-ethylhexyl group, a 2-propylpentyl group, a 2,5-dimethylhexylgroup, a 4,5-dimethylhexyl group, a 2-ethyl-3-methylpentyl group, a1,2,4-trimethylpentyl group, a 2-methyl-1-isopropylbutyl group, a3-methyloctyl group, a 2,5-dimethylheptyl group, a1-(1-methylpropyl)-2-methylbutyl group, a 1,4,5-trimethylhexyl group, a1,2,3,4-tetramethylpentyl group, a 7-methyloctyl group, a 6-methylnonylgroup, a 8-methylnonyl group, a 5-ethyl-2-methylheptyl group, a2,3-dimethyl-1-(1-methylpropyl)butyl group, a cyclopropylmethyl group, a2-(cyclopropyl)ethyl group, a 3,7-dimethyloctyl group, a3-(cyclobutyl)pentyl group, a cyclopentylmethyl group and acyclohexylmethyl group. Examples of the cyclic alkyl group include acyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexylgroup, a cycloheptyl group and a cyclooctyl group.

The C₂₋₁₀alkenyl group means a straight-chain alkenyl group having twoto ten carbon atoms with at least one double bond, a branched chainalkenyl group having three to ten carbon atoms or a cyclic alkenyl grouphaving five to ten carbon atoms, examples of which include a vinylgroup, an allyl group, a 3-butenyl group, a 4-pentenyl group, a5-hexenyl group, a 6-heptenyl group, a 7-octenyl group, a 8-noneylgroup, a 9-decenyl group, a 1-methyl-2-butenyl group, a2-methyl-2-butenyl group, a 2-methyl-3-butenyl group, a 2-pentenylgroup, a 2-methyl-2-hexenyl group and a 2-cyclopentenyl group.

The C₂₋₁₀alkynyl group means a straight-chain alkynyl group having twoto ten carbon atoms with at least one triple bond or a branched chainalkynyl group having four to ten carbon atom, examples of which includea 2-propynyl group, a 3-butynyl group, a 4-pentynyl group, a 5-hexynylgroup, a 6-heptynyl group, a 7-octynyl group, a 8-nonynyl group, a9-decinyl group, a 3-pentynyl group and a 4-methyl-2-pentynyl group.

The C₁₋₁₀alkyl group substituted by one or two aryl groups means, forexample, a benzyl group, a diphenylmethyl group, a 2-phenyethyl group, a2-phenylpropyl group, a 1-methyl-1-phenyethyl group, a1-methyl-2-phenylpentyl group, a 2-nitrobenzyl group, a 3-nitrobenzylgroup, a 4-nitrobenzyl group, a 2,4-dinitrobenzyl group, a2,4,6-trinitrobenzyl group, a 2-phenylbenzyl group, a 3-phenylbenzylgroup, a 4-phenylbenzyl group, a 2-hydroxybenzyl group, a3-hydroxybenzyl group, a 4-hydroxybenzyl group, a 2-chlorobenzyl group,a 3-chlorobenzyl group, a 4-chlorobenzyl group, a 2-fluorobenzyl group,a 3-fluorobenzyl group, a 4-fluorobenzyl group, a 2-beromobenzyl group,a 3-beromobenzyl group, a 4-beromobenzyl group, a 2-iodobenzyl group, a2-iodobenzyl group, a 2,3-dichlorobenzyl group, a 2,4-dichlorobenzylgroup, a 2,5-dichlorobenzyl group, a 2,6-dichlorobenzyl group, a3,4-dichlorobenzyl group, a 3,5-dichlorobenzyl group, a 2-methylbenzylgroup, a 3-methylbenzyl group, a 4-methylbenzyl group, a 2-ethylbenzylgroup, a 3-ethylbenzyl group, a 4-ethylbenzyl group, a 2-isopropylbenzylgroup, a 3-isopropylbenzyl group, a 4-isopropylbenzyl group, a2-methoxybenzyl group, a 3-methoxybenzyl group, a 4-methoxybenzyl group,a 2,3-dimethoxybenzyl group, a 2,4-dimethoxybenzyl group, a2,5-dimethoxybenzyl group, a 2,6-dimethoxybenzyl group, a3,4-dimethoxybenzyl group, a 3,5-dimethoxybenzyl group, a 2-ethoxybenzylgroup, a 3-ethoxybenzyl group, a 4-ethoxybenzyl group, a2-isopropoxybenzyl group, a 3-isopropoxybenzyl group, a4-isopropoxybenzyl group, a 2-methoxymethylbenzyl group, a3-methoxymethylbenzyl group, a 4-methoxymethylbenzyl group, a2-isopropyxymethylbenzyl group, a 3-isopropyxymethylbenzyl group, a4-isopropyxymethylbenzyl group, a 2-trifluoromethyl group, a3-trifluoromethyl group, a 4-trifluoromethyl group, a2-hydroxycarbonylbenzyl group, a 3-hydroxycarbonylbenzyl group, a4-hydroxycarbonylbenzyl group, a 2-aminobenzyl group, a 3-aminobenzylgroup, a 4-aminobenzyl group, a 2-aminomethylbenzyl group, a3-aminomethylbenzyl group, a 4-aminomethylbenzyl group, a 2-cyanobenzylgroup, a 3-cyanobenzyl group, a 4-cyanobenzyl group, a2-hydroxymethylbenzyl group, a 3-hydroxymethylbenzyl group, a4-hydroxymethylbenzyl group, a 2-phenoxybenzyl group, a 3-phenoxybenzylgroup and a 4-phenoxybenzyl group.

The aryl group means a phenyl group, a substituted phenyl group or apolycyclic aromatic group such as a 1-naphthyl group or a 2-naphthylgroup.

The substituted phenyl group means a phenyl group substituted by one tothree substituents selected from a group containing a halogen atom, ahydroxyl group, a phenyl group, a C₁₋₁₀alkyl group, a C₁₋₁₀alkoxy group,a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, a trifluoromethyl group, ahydroxycarbonyl group, an amino group, a nitro group, a cyano group, ahydroxymethyl group, a aminomethyl group and a phenoxy group. Examplesof the substituted phenyl group include a 2-nitrophenyl group, a3-nitrophenyl group, a 4-nitrophenyl group, a 2,4-dinitrophenyl group, a2,4,6-trinitrophenyl group, a 2-phenylphenyl group, a 3-phenylphenylgroup, a 4-phenylphenyl group, a 2-hydroxyphenyl group, a3-hydroxyphenyl group, a 4-hydroxyphenyl group, a 2-chlorophenyl group,a 3-chlorophenyl group, a 4-chlorophenyl group, a 2-fluorophenyl group,a 3-fluorophenyl group, a 4-fluorophenyl group, a 2-beromophenyl group,a 3-beromophenyl group, a 4-beromophenyl group, a 2-iodophenyl group, a2-iodophenyl group, a 2,3-dichlorophenyl group, a 2,4-dichlorophenylgroup, a 2,5-dichlorophenyl group, a 2,6-dichlorophenyl group, a3,4-dichlorophenyl group, a 3,5-dichlorophenyl group, a 2-methylphenylgroup, a 3-methylphenyl group, a 4-methylphenyl group, a 2-ethylphenylgroup, a 3-ethylphenyl group, a 4-ethylphenyl group, a 2-isopropylphenylgroup, a 3-isopropylphenyl group, a 4-isopropylphenyl group, a2-methoxyphenyl group, a 3-methoxyphenyl group, a 4-methoxyphenyl group,a 2,3-dimethoxyphenyl group, a 2,4-dimethoxyphenyl group, a2,5-dimethoxyphenyl group, a 2,6-dimethoxyphenyl group, a3,4-dimethoxyphenyl group, a 3,5-dimethoxyphenyl group, a 2-ethoxyphenylgroup, a 3-ethoxyphenyl group, a 4-ethoxyphenyl group, a2-isopropoxyphenyl group, a 3-isopropoxyphenyl group, a4-isopropoxyphenyl group, a 2-methoxymethylphenyl group, a3-methoxymethylphenyl group, a 4-methoxymethylphenyl group, a2-isopropyxymethylphenyl group, a 3-isopropyxymethylphenyl group, a4-isopropyxymethylphenyl group, a 2-trifluoromethyl group, a3-trifluoromethyl group, a 4-trifluoromethyl group, a2-hydroxycarbonylphenyl group, a 3-hydroxycarbonylphenyl group, a4-hydroxycarbonylphenyl group, a 2-aminophenyl group, a 3-aminophenylgroup, a 4-aminophenyl group, a 2-aminomethylphenyl group, a3-aminomethylphenyl group, a 4-aminomethylphenyl group, a 2-cyanophenylgroup, a 3-cyanophenyl group, a 4-cyanophenyl group, a2-hydroxymethylphenyl group, a 3-hydroxymethylphenyl group, a4-hydroxymethylphenyl group, a 2-phenoxyphenyl group, a 3-phenoxyphenylgroup and a 4-phenoxyphenyl group.

Of the above C₁₋₁₀alkyl groups substituted by one or two aryl groups,the C₁₋₁₀alkyl group substituted by one or two phenyl groups ispreferred.

The hydroxyC₂₋₁₀alkyl group means a C₂₋₁₀alkyl group substituted by atleast one hydroxyl group, examples of which include a 2-hydroxyethylgroup, a 3-hydroxypropyl group, a 4-hydroxybutyl group, a5-hydroxypentyl group, a 6-hydroxyhexyl group, a 7-hydroxyheptyl group,a 8-hydroxyoctyl group, a 9-hydroxynonyl group, a 10-hydroxydecyl group,a 2-hydroxypropyl group, a 2,3-dihydroxypropyl group and a2-hydroxy-3-methylbutyl group.

The halogenoC₁₋₁₀alkyl group means a C₁₋₁₀alkyl group substituted by atleast one fluorine atom, chlorine atom, bromine atom or iodine atom,examples of which include a 2-chloroethyl group, a 2-bromoethyl group, a2-iodoethyl group, a 3-chloropropyl group, a 3-bromopropyl group, a3-iodopropyl group, a 4-chlorobutyl group, a 4-bromobutyl group, a4-iodobutyl group, a 5-chloropentyl group, a 6-chlorohexyl group, a7-chloroheptyl group, a 8-chlorooctyl group, a 9-chlorononyl group, a10-chlorodecyl group, a 2-chloropropyl group, a 2-chlorobutyl group, a2,4-dichlorobutyl group and a 2-chloro-3-methylbutyl group.

The azidoC₁₋₁₀alkyl group means a C₁₋₁₀alkyl group substituted by atleast one azide group, examples of which include a 2-azidoethyl group, a3-azidopropyl group, a 4-azidobutyl group, a 5-azidopentyl group, a6-azidohexyl group, a 7-azidoheptyl group, a 8-azidooctyl group, a9-azidononyl group, a 10-azidodecyl group, a 2-azidopropyl group, a2-azidobutyl group and a 2-azido-3-methylbutyl group.

The aminoC₂₋₁₀alkyl group means a C₂₋₁₀alkyl group substituted by atleast one amino group, examples of which include a 2-aminoethyl group, a3-aminopropyl group, a 6-aminohexyl group, a 7-aminoheptyl group, a8-aminooctyl group, a 9-aminononyl group, a 10-aminodecyl group, a4-aminobutyl group and a 2,4-diaminobutyl group.

The C₁₋₁₀alkoxyC₁₋₁₀alkyl group means a alkyl group having one to tencarbons which is substituted by a straight-chain alkoxy group having oneto ten carbons, a branched chain alkoxy group having three to ten carbonatoms or a cyclic alkoxy group having three to ten carbon atoms,examples of which include a 2-methoxyethyl group, a 2-ethoxyethyl group,a 2-propoxyethyl group, a 2-isopropoxyethyl group, a 2-butoxyethylgroup, a 2-isobutoxyethyl group, a 2-t-butoxyethyl group, a2-pentyloxyethyl group, a 2-hexenyloxyethyl group, a 3-ethoxypropylgroup, a 4-ethoxybutyl group, a 4-ethoxy-3-methoxybutyl group and a4-ethoxy-3-methylpentyl group.

The C₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group means a alkyl group having oneto ten carbons which is substituted by a straight-chain alkoxycarbonylgroup having one to ten carbons, a branched chain alkoxycarbonyl grouphaving three to ten carbon atoms or a cyclic alkoxycarbonyl group havingthree to ten carbon atoms, examples of which include amethoxycarbonylmethyl group, an ethoxycarbonylmethyl group, apropyloxycarbonylmethyl group, an isopropoxycarbonylmethyl group, abutyltoxycarbonylmethyl group, an isobutoxycarbonylmethyl group, at-butoxycarbonylmethyl group, a pentyloxycarbonylmethyl group, ahexyloxycarbonylmethyl group, a 2-(ethoxycarbonyl)ethyl group, a3-(ethoxycarbonyl)propyl group, a 4-(ethoxycarbonyl)butyl group, a4-(ethoxycarbonyl)pentyl group and a 4-(ethoxycarbonyl)-3-methylpentylgroup.

The farnesyl group means a (2Z,6Z)-3,7,1-trimethyldodeca-2,6,10-trienylgroup.

The 4-morpholinylC₁₋₁₀alkyl means a alkyl group having one to tencarbons which is substituted by a 4-morpholinyl group, examples of whichinclude a 2-(4-morpholinyl)ethyl group, a 3-(4-morpholinyl)propyl group,a 4-(4-morpholinyl)butyl group, a 5-(4-morpholinyl)pentyl group, a6-(4-morpholinyl)hexyl group, a 7-(4-morpholinyl)heptyl group, a8-(4-morpholinyl)octyl group, a 9-(4-morpholinyl)nonyl group, a10-(4-morpholinyl)decyl group, a 2-(4-morpholinyl)pentyl group, and a1-methyl-3-(4-morpholinyl)butyl group.

The C₁₋₁₀alkyl group substituted by formula C(O)NR^(a)R^(b)(whereinR^(a) and R^(b) are identical or different, and each represents ahydrogen atom or a C₁₋₁₀alkyl group) means, for example, a2-(N,N-dimethylaminocarbonyl)ethyl group, a2-(N,N-diethylaminocarbonyl)ethyl group, a3-(N,N-diethylaminocarbonyl)propyl group, a2-(N-methylaminocarbonyl)ethyl group, a 2-(N-ethylaminocarbonyl)ethylgroup, a 2-(N,N-methylethylaminocarbonyl)ethyl group, a2-(N,N-ethylpropylaminocarbonyl)ethyl group or a2-(N,N-diethylaminocarbonyl)-1-methylethyl group.

The naphthyl group substituted by one to seven halogen atoms means anaphthyl group substituted by at least one fluorine atom, chloride atom,bromine atom or iodine atom, examples of which include a1-fluoro-2-naphthyl group, a 2-fluoro-1-naphthyl group, a1-chloro-2-naphthyl group, a 2-chloro-1-naphthyl group, a1-bromo-2-naphthyl group, a 2-bromo-1-naphthyl group, a1-iodo-2-naphthyl group, a 2-iodo-1-naphthyl group, and a1,3-difluoro-2-naphthyl group.

The heteroaromatic group means a monocyclic aromatic 5 membered or 6membered ring containing at least one atom selected from an oxygen atom,a nitrogen atom or a sulfur atom; a monocyclic ring such as above whichis fused with a benzene ring; or a hetrocyclic aromatic ring which isfused with one another. Examples of the hetero aromatic group includefuryl, pyrrolyl, thiophenyl, oxazoyl, isoxazoyl, imidazoyl, pyrazoyl,thiazoyl, isothiazoyl, oxadiazoyl, thiadiazoyl, benzofuranyl, indolyl,benzothiophenyl, indazoyl, benzoisoxazoyl, benzoisothiazoyl,benzoimidazoyl, benzooxazoyl, benzothiazoyl, pyrizinyl, quinolinyl,isoquinolinyl, pyrodazinyl, pyrimizinyl, pyradinyl, cinnolinyl,phthalazinyl, quinazolinyl and quinoxalinyl.

The C₁₋₁₀alkoxy group means a straight-chain or branched chain alkoxygroup having one to ten carbon atoms, examples of which include amethoxy group, an ethoxy group, a propoxy group, an isopropoxy group, abutoxy group, an isobutoxy group, a t-butoxy group, a pentyloxy groupand an isopentyloxy group.

The phenyl group substituted by one to five substituents selected from agroup containing a halogen atom, a phenyl group, a C₁₋₁₀alkyl group, aC₁₋₁₀alkoxy group, a trifluoromethyl group, a phenyl group, ahydroxycarbonyl group, an amino group, a nitro group, a cyano group anda phenoxy group means a phenyl group substituted by one to fivesubstituents selected from a fluorine atom, a chloride atom, a bromineatom, an iodine atom, a C₁₋₁₀alkyl group, a cyclicC₃₋₁₀alkyl group, aC₁₋₁₀alkoxy group, a cyclic C₃₋₁₀alkoxy group, a trifluoromethyl group,a phenyl group, a hydroxycarbonyl group, an amino group, a nitro group,a cyano group or a phenoxy group. Examples of the phenyl groupsubstituted by one substituent include a 2-fluorophenyl group, a3-fluorophenyl group, a 4-fluorophenyl group, a 2-chlorophenyl group, a3-chlorophenyl group, a 4-chlorophenyl group, a 2-bromophenyl group, a3-bromophenyl group, a 4-bromophenyl group, a 2-iodophenyl group, a3-iodophenyl group, a 4-iodophenyl group, a 2-methylphenyl group, a3-methylphenyl group, a 4-methylphenyl group, a 2-ethylphenyl group, a3-ethylphenyl group, a 4-ethylphenyl group, a 2-isopropylphenyl group, a3-isopropylphenyl group, a 4-isopropylphenyl group, a2-cyclopropylphenyl group, a 3-cyclopropylphenyl group, a4-cyclopropylphenyl group, a 2-cyclohexylphenyl group, a3-cyclohexylphenyl group, a 4-cyclohexylphenyl group, a 2-methoxyphenylgroup, a 3-methoxyphenyl group, a 4-methoxyphenyl group, a2-isopropoxyphenyl group, a 3-isopropoxyphenyl group, a4-isopropoxyphenyl group, a 2-cyclobutyloxyphenyl group, a3-cyclobutyloxyphenyl group, a 4-cyclobutyloxyphenyl group, a2-cyclohexyloxyphenyl group, a 3-cyclohexyloxyphenyl group, a4-cyclohexyloxyphenyl group, a 2-trifluoromethylphenyl group, a3-fluoromethylphenyl group, a 4-trifluoromethylphenyl group, a2-phenylphenyl group, a 3-phenylphenyl group, a 4-phenylphenyl group, a2-hydroxycarbonylphenyl group, a 3-hydroxycarbonylphenyl group, a4-hydroxycarbonylphenyl group, a 2-aminophenyl group, a 3-aminophenylgroup, a 4-aminophenyl group, a 2-nitrophenyl group, a 3-nitrophenylgroup, a 4-nitrophenyl group, a 2-cyanophenyl group, a 3-cyanophenylgroup, a 4-cyanophenyl group, a 2-phenoxyphenyl group, a 3-phenoxyphenylgroup and a 4-phenoxyphenyl group. Examples of the phenyl groupsubstituted by two substituents include a 2,3-difluorophenyl group, a2,4-difluorophenyl group, a 2,5-difluorophenyl group, a2,6-difluorophenyl group, a 3,4-difluorophenyl group, a3,5-difluorophenyl group, 2,3-dichlorophenyl group, a 2,4-dichlorophenylgroup, a 2,5-dichlorophenyl group, a 2,6-dichlorophenyl group, a3,4-dichlorophenyl group, a 3,5-dichlorophenyl group, a2,3-dibromophenyl group, a 2,4-dibromophenyl group, a 2,5-dibromophenylgroup, a 2,6-dibromophenyl group, a 3,4-dibromophenyl group, a3,5-dibromophenyl group, a 2,3-diiodophenyl group, a 2,4-diiodophenylgroup, a 2,5-diiodophenyl group, a 2,6-diiodophenyl group, a3,4-diiodophenyl group, a 3,5-diiodophenyl group, a3-chloro-4-fluorophenyl group, a 4-chloro-3-fluorophenyl group, a3-bromo-4-fluorophenyl group, a 4-bromo-3-fluorophenyl group, a4-bromo-3-chlorophenyl group, a 3-bromo-4-chlorophenyl group, a3-chloro-4-methylphenyl group, a 4-chloro-3-methylphenyl group, a3-fluoro-4-methylphenyl group, a 4-fluoro-3-methylphenyl group, a3-fluoro-4-methoxyphenyl group, a 4-fluoro-3-methoxyphenyl group, a3-bromo-4-methoxyphenyl group, a 4-bromo-3-methoxyphenyl group, a3-chloro-4-phenoxyphenyl group, a 4-chloro-3-phenoxyphenyl group, a3-chloro-4-nitrophenyl group, a 4-chloro-3-nitrophenyl group, a4-bromo-3-nitrophenyl group, a 3-bromo-4-nitrophenyl group, a3-amino-4-bromophenyl group, a 4-amino-3-bromophenyl group, a3-bromo-4-hydroxycarbonyl group, a 4-bromo-3-hydroxycarbonylphenylgroup, a 4-fluoro-3-hydroxycarbonyl group, a3-fluoro-4-hydroxycarbonylphenyl group, a 4-fluoro-3-hydroxycarbonylgroup, a 3-cyano-4-fluorophenyl group, a 3-cyano-4-fluorophenyl group, a4-cyano-3-methylphenyl group, a 3-cyano-4-methylphenyl group, a3-cyano-4-methoxyphenyl group and a 4-cyano-3-methoxyphenyl group.Examples of the phenyl group substituted by three substituents include a2,3,4-trifluorophenyl group, a 3,4,5-trifluorophenyl group, a3,4,5-trichlorophenyl group, a 3-chloro-2,6-difluorophenyl group, a3,5-dichloro-4-methoxyphenyl group and a 3,5-dibromo-4-methoxyphenylgroup. Examples of the phenyl group substituted by four substituentsinclude a 2,5-dibromo-3,4-dimethoxyphenyl group and a3,4-dibromo-2,4-dimethoxyphenyl group. Examples of the phenyl groupsubstituted by five substituents include a 2,3,4,5,6-pentafluorophenylgroup.

The pharmaceutically acceptable salt in the present invention means, forexample, a salt with a mineral acid such as sulfuric acid, hydrochloricacid or phosphoric acid; a salt with organic acids such as acetic acid,oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid,methanesulfonic acid or benzenesulfonic acid; a salt with an amine suchas trimethylamine or methylamine; or a salt with a metal ion such assodium ion, potassium ion or calcium ion.

The hydrate in the present invention means a pharmaceutically acceptablehydrate of the compound of the present invention or of the salt thereof.The compound of the present invention or the salt thereof may absorbmoisture and accumulate drops of water or become a hydrate by beingexposed to the atmosphere or by recrystallization. The hydrate in thepresent invention includes such a hydrate.

In the compounds represented by formula [I], five assymetric carbonatoms are present in the bicyclo[3.1.0]hexane ring.

The preferred stereostructure of the compounds of the present inventionare optically active bodies having the absolute structure represented byformula [II], but the compounds of the present invention may be presentas enantiomers or enantiomer mixtures such as racemic bodies. Therefore,the compounds of the present invention include all of the opticallyactive bodies, the enantiomer mixtures such as racemic bodies and thediastereomer mixtures of the compounds represented by formula [II]below.

The compounds of the present invention represented by formula [I] andformula [II] have no effect on group II metabotropic glutamatereceptors. However, they can be hydrolyzed with oxygen or with chemicalsin vivo, thereby yielding compounds represented by formula [III] andformula [V], respectively, which are compounds that have a strongantagonistic effect on group II metabotropic receptors. Therefore, thecompounds of the present invention are effective as drugs that affectthe action of group II metabotropic glutamate receptors. The compoundsrelates to 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic esterderivative, a pharmaceutically acceptable salt thereof or a hydratethereof,

[wherein X represents a hydrogen atom or a fluorine atom. Y represents—OCHR³R⁴, —SR³—S(O)_(n)R⁵, —SCHR³R⁴, —S(O)_(n)CHR^(3′)R^(4′), —NHCHR³R⁴,—N(CHR³R⁴)(CHR^(3′)R^(4′)), —NHCO R³ or —OCOR⁵ (wherein R³, R^(3′), R⁴and R^(4′)are identical or different, and each represents a hydrogenatom, a C₁₋₁₀alkyl group, a C₁₋₁₀alkenyl group, a phenyl group, anaphthyl group, a naphthyl group substituted by one to seven halogenatoms, a heteroaromatic group or a phenyl group substituted by one tofive substituents selected from a group consisting of a halogen atom, aphenyl group, a C₁₋₁₀alkyl group, a C₁₋₁₀alkoxy group, a trifluoromethylgroup, a phenyl group, a hydroxycarbonyl group, an amino group, a nitrogroup, a cyano group and a phenoxy group; R⁵ represents a C₁₋₁₀alkylgroup, a C₁₋₁₀alkenyl group, a phenyl group, a naphthyl group, anaphthyl group substituted by one to seven halogen atoms, aheteroaromatic group or a phenyl group substituted by one to fivesubstituents selected from a group consisting of a halogen atom, aphenyl group, a C₁₋₁₀alkyl group, a C₁₋₁₀alkoxy group, a trifluoromethylgroup, a phenyl group, a hydroxycarbonyl group, an amino group, a nitrogroup, a cyano group and a phenoxy group; and n represents integer 1 or2)].

BEST METHOD FOR CARRYING OUT THE INVENTION

The present invention relates to a compound of the present inventionrepresented by formula [I] or formula [II], a pharmaceuticallyacceptable salt thereof or a hydrate thereof. The compounds of thepresent invention may be synthesized using publicly known methods oforganic synthesis. The compounds of the present invention may beprepared, for example, according to the following methods.

First, compounds (9), (16), (24), (27), (30) and (33) which aresynthetic intermediates required for synthesizing the compounds of thepresent invention represented by formula [I] may be prepared as follows.(In the formulas below, X, Y, Z, n, R¹, R², R³, R⁴ and R⁵ are the sameas described above. R⁶ represents an aryl- or alkyl-sulfonyl group suchas a methyl group, a phenylsulfonyl group, a tosyl group or atrifluoromethylsulfonyl group, a benzoyl group or a 4-nitrobenzoylgroup. R⁷ represents a protecting group for an amino group, examples ofwhich include an alkoxycarbonyl group such as a methoxycarbonyl group,an ethoxycarbonyl group, a t-butoxycorbonyl group or a benzyloxycarbonylgroup; an acyl group such as a benzoyl group, a p-phenylbenzoyl group ora (pyridine-2-yl) carbonyl group; an alkyl group such as an aryl group,a benzyl group, a p-methoxybenzyl group or a di(p-methoxyphenyl)methylgroup; an alkenyl group such as a 5,5-dimethyl-3-oxo-1-cyclohexenylgroup; a sulfenyl group such as a benzenesulfenyl group or a2,4-dinitrosulfenyl group; a benzylsulfonyl group; a diphenylphosphinylgroup; and a dialkylphosphoryl group. A¹ represents formula R³ orformula CHR³R⁴. A² represents formula R⁵ or formula CHR³R⁴. And Qrepresents formula SR³, formula S(O)_(n)R⁵, formula SCHR³R⁴ or formulaS(O)NCHR³R⁴).

Step 1: Compound (2) may be prepared, for example, by reacting compound(1) with a trifluoromethanesulfonylation agent such as trifluoromethanesulfonic acid anhydride or N-phenyl-bis(trifluoromethanesulfonimide), inan inert solvent, in the presence of a base. Examples of the inertsolvent include hydrocarbon type solvents such as benzene, toluene andhexane; halogen type solvents such as dichloromethane, chloroform andcarbon tetrachloride; ether type solvents such as tetrahydrofuran,diethyl ether and 1,2-dimethoxyethane; acetonitrile; or a mixture ofthese solvents. Examples of the base include amines such astriethylamine, N-methylmorpholine, diisopropylethylamine and pyridine;inorganic bases such as potassium hydride and sodium hydride; metalamides such as lithium diisopropylamide, potassiumbis(trimethylsilyl)amide and lithium hexamethyldisilazane; and metalalcoholates such as sodium methoxide and potassium t-butoxide.Preferably, compound (2) may be prepared by reacting compound (1) withN-phenyl-bis(trifluoromethanesulfonimide) for 2 to 4 hours at −78° C. toroom temperature, in tetrahydrofuran, in the presence of lithiumhexamethyldisilazane.

Step 2: Compound (3) may be prepared, for example, by reacting compound(2) with carbon monoxide and R²OH, in the presence of organic bases suchas triethylamine, N-methylmorpholine, diisopropylethylamine and pyridineor inorganic bases such as potassium carbonate and sodium hydrogencarbonate, in an inert solvent, in the presence of a transition metalcatalyst (see Tetrahedron Letters 26, 1109 (1985)). Examples of thetransition metal catalyst include a zero-valent palladium reagent whichmay be prepared in the reaction system, for example, from a divalentpalladium such as palladium(II) acetate and a ligand such astriphenylphosphine or 2,2′-bis(diphenylphosphino)-1,1-binaphthyl(BINAP). It is also possible to directly use a zero-valent palladiumreagent such as tetrakis(triphenylphosphine) palladium (0). Examples ofthe inert solvent include hydrocarbon type solvents such as benzene,toluene and hexane; ether type solvents such as tetrahydrofuran, diethylether and 1,2-dimethoxyethane; acetonitrile; N,N-dimethylformamide; or amixture of these solvents. Preferably, compound (3) is prepared byreacting compound (2) with carbon monoxide and R²OH for 2 to 7 hours atroom temperature, in N,N-dimethylformamide, in the presence ofdiisopropylethylamine, palladium(II) acetate and triphenylphosphine.

Step 3: Compound (4) may be prepared, for example, by oxidizing compound(3) by means of a common diol-formation reaction with osmium tetraoxide(see M. Hudlicky, “Oxidations in Organic Chemistry” or a Sharplessasymmetric cis-dihydroxylation reaction (Sharpless AD) with AD-mix asthe reagent (see Tetrahedron Asymmetry 4, 133 (1993), J. Org. Chem. 57,2768 (1992), J. Org. Chem. 61, 2582 (1996)), in an inert solvent.Examples of the inert solvent include alcohol type solvents such ast-butylalcohol; hydrocarbon type solvents such as benzene, toluene andhexane; ether type solvents such as tetrahydrofuran, diethyl ether and1,2-dimethoxyethane; acetonitrile; acetone; N,N-dimethylformamide;water; or a mixture of these solvents. Preferably, compound (4) may beprepared by oxidizing compound (3) into diol with osmium tetraoxide for30 minutes to 3 hours at room temperature, in a mixture of acetonitrileand water.

Step 4: Compound (5) may be prepared, for example, by reacting compound(4) with thionyl chloride, in an inert solvent, examples of whichinclude hydrocarbon type solvents such as benzene, toluene and hexane;halogen type solvents such as dichloromethane, chloroform and carbontetrachloride; ether type solvents such as tetrahydrofuran, diethylether and 1,2-dimethoxyethane; acetonitrile; or a mixture of thesesolvents, in the presence or absence of organic bases such astriethylamine, N-methylmorpholine, diisopropylethylamine and pyridine orinorganic bases such as potassium carbonate and sodium hydrogencarbonate, followed by oxidation with a common oxidizing agent such ashydrogen peroxide, OXONE® or ruthenium trichloride-sodium metaperiodate(see M. Hudlicky, “Oxidations in Organic Chemistry”), in an inertsolvent, examples of which include hydrocarbon type solvents such asbenzene, toluene and hexane; halogen type solvents such asdichloromethane, chloroform and carbon tetrachloride; ether typesolvents such as tetrahydrofuran, diethyl ether and 1,2-dimethoxyethane;acetonitrile; acetone; water; or a mixture of these solvents.Preferably, compound (5) may be prepared by reacting compound (4) withthionyl chloride for 30 minutes to 2 hours at ice-cooling, indichloromethane, in the presence of triethylamine, followed by oxidationfor 30 minutes to 2 hours at 0° C. to room temperature, in a mixture ofcarbon tetrachloride, acetonitrile and water.

Step 5: Compound (6) may be prepared, for example, by reacting compound(5) with sodium azide in an inert solvent, examples of which includeether type solvents such as tetrahydrofuran; ketones such as acetone;N,N-dimethylformamide; water; or a mixture of these solvents, followedby hydrolysis (see J. Am. Chem. Soc. 110, 7538 (1988)). Preferably,compound (6) may be prepared by reacting compound (5) with sodium azidefor 1 to 20 hours at room temperature, in a mixture ofN,N-dimethylformamide and water, followed by hydrolysis with 20%sulfuric acid for 1 to 2 days at room temperature, in a mixture ofdiethyl ether and water.

Compound (9), which is a synthetic intermediate of the compound of thepresent invention, may be prepared from the obtained compound (6)according to Steps 7, 8 and 9 below in the case where in formula [III],Y represents formula OCHR³R⁴.

Step 7: Compound (7) may be prepared from compound (6) wherein R¹ and R²represent something other than a hydrogen atom, for example, by reactingthe hydroxyl group of compound (6) with a compound of formula R³R⁴CHL¹wherein L¹ represents a 2,2,2-trichloroacetimidoyloxy group, in an inertsolvent, examples of which include hydrocarbon type solvents such asbenzene, toluene, hexane and cyclohexane; halogen type solvents such asdichloromethane, chloroform and carbon tetrachloride; ether typesolvents such as tetrahydrofuran, diethyl ether and 1,2-dimethoxyethane,or a mixture of these solvents, in the presence of a Bronsted-acidcatalyst such as trifluoromethanesulfonic acid, trifluoroacetic acid orhydrogen chloride, or a Lewis-acid catalyst such as borontrifluoride-diethyl ether complex, zinc chloride, tin chloride ortrimethylsilyl-trifluoromethansulfonate (see J. Chem. Soc. Perkin Trans.1, 2247 (1985), Synthesis, 568 (1987)). In this case, L¹ represents aleaving group, for example, a halogen atom, an ethoxycarbonyloxy groupor a phenoxycarbonyloxy group.

It is also possible to prepare compound (7) from compound (6) wherein R¹and R² represent something other than a hydrogen atom, for example, byreacting the hydroxyl group of compound (6) with a compound of formulaR³R⁴CHL² wherein L² represents something other than a2,2,2-trichloroacetimidoyloxy group, in an inert solvent, examples ofwhich include hydrocarbon type solvents such as benzene, toluene andhexane; halogen type solvents such as dichloromethane, chloroform andcarbon tetrachloride; ether type solvents such as tetrahydrofuran,diethyl ether and 1,2-dimethoxyethane; amides such asN,N-dimethylformamide and N-methyl-2-pyrrolidinone; dimethylsulfoxide;or a mixture of these solvents, in the presence of inorganic bases suchas sodium hydride, potassium hydride, potassium carbonate, sodiumcarbonate, sodium hydroxide and potassium hydroxide; metal amides suchas lithium bis(trimethylsilyl)amide, lithium diisopropylamide and sodiumamide; organic bases such as triethylamine, diisopropylethylamine,4-(N,N-dimethylamino)pyridine and 2,6-di-t-butylpyridine; or bases suchas potassium t-butoxide. In this case, L² represents a leaving group,for example, a halogen atom, a tosylsulfonate, atrifluoromethansulfonate or a tolylsulfonate. Preferably, compound (7)may be prepared by reacting compound (6) with the hydroxyl group of acompound of formula R³R⁴CHL¹ for 1 to 3 hours at room temperature, in amixture of chloroform and cyclohexane, in the presence oftrifluoromethane sulfonic acid.

Step 8: Compound (8) may be prepared from compound (7), for example, bymeans of a common reduction reaction of an azide group, typical examplesof which include: (a) Staudinger reaction with triethyl phosphite,trimethylphosphine, tributylphosphine, triphenylphosphine or the like(see Bull. Chem. Soc. Fr., 815 (1985)), in an inert solvent, examples ofwhich include hydrocarbon type solvents such as benzene, toluene andhexane; halogen type solvents such as dichloromethane, chloroform andcarbon tetrachloride; ether type solvents such as tetrahydrofuran,diethyl ether and 1,2-dimethoxyethane; acetonitrile; acetone; water; ora mixture of these solvents; (b) hydrogenation in an inert solvent,examples of which include alcohols such as ethanol and methanol, esterssuch as ethyl acetate; N,N-dimethylformamide; water; or a mixture ofthese solvents, in the presence of a metal catalyst such aspalladium/carbon or palladium black; and (c) hydride reduction withlithium aminoborohydride or the like (see A. F. Abdel-Magid, “Reductionsin Organic Synthesis”). Preferably, compound (8) may be prepared byreacting compound (7) by means of a Staudinger reaction withtrimethylphosphine for 2 to 12 hours at room temperature, in a mixtureof tetrahydrofuran and water.

Step 9: Compound (9), which is a synthetic intermediate of the compoundof the present invention, may be prepared from compound (8) wherein R¹and R² represent something other than a hydrogen atom, by converting themoieties represented by formula COOR¹ and formula COOR² of compound (8)into carboxylic acid by means of a common hydrolysis reaction (see T. W.Greene, P. G. M. Wuts, “Protective Groups in Organic Synthesis”).Preferably, compound (9), which is a synthetic intermediate of thecompound of the present invention, may be prepared by hydrolizingcompound (8) with lithium hydroxide for 1 to 7 days at room temperatureto 50° C., in a mixture of tetrahydrofuran and water.

Compound (16), which is a synthetic intermediate of the compound of thepresent invention, may be prepared from compound (6) according to Steps10, 11, 12, 13, 14 and 15 below in the case where in formula [III], Yrepresents formula SR³, formula S(O)_(n)R⁵, formula SCHR³R⁴ and formulaS(O)NCHR³R⁴.

Step 10: Compound (10) may be prepared from compound (6) wherein R¹ andR² represent something other than a hydrogen atom, for example, byreacting the hydroxyl group of compound (6) with atrifluoromethanesulfonylation agent such as trifluoromethane sulfonicacid anhydride or N-phenyl-bis(trifluoromethanesulfonimide); or with analkyl- or aryl-sulfonylation agent such as methanechloride sulfonicacid, benzenechloride sulfonic acid or toluenechloride sulfonic acid, inan inert solvent, examples of which include hydrocarbon type solventssuch as benzene, toluene, hexane and cyclohexan; halogen type solventssuch as dichloromethane, chloroform and carbon tetrachloride; ether typesolvents such as tetrahydrofuran, diethyl ether and 1,2-dimethoxyethane,amides such as N,N-dimethylformamide and N-methyl-2-pyrrolidinone;dimethylsulfoxide; or a mixture of these solvents, in the presence ofinorganic bases such as sodium hydride, potassium hydride, potassiumcarbonate, sodium carbonate, sodium hydroxide and potassium hydroxide;metal amides such as lithium bis(trimethylsilyl)amide, lithiumdiisopropylamide and sodium amide; organic bases such as triethylamine,pyridine, diisopropylethylamine, 4-(N,N-dimethylamino)pyridine anddi-t-butylpyridine; or bases such as potassium t-butoxide. Preferably,compound (10) may be prepared by reacting the hydroxyl group of compound(6) with trifluoromethane sulfonic acid anhydride for 30 minutes to 3hours at −78° C. to ice-cooling, in dichloromethane, in the presence ofpyridine.

Step 11: Compound (1) may be prepared, for example, by reacting compound(10) with a compound of formula A¹SNa, formula A¹SK or the like, whichis prepared from metal alcoholates such as sodium ethoxide and potassiumt-butoxide; sodium; potassium; sodium hydride; potassium hydride; andmercaptans and thiophenols represented by formula A¹SH, in an inertsolvent, examples of which include hydrocarbon type solvents such asbenzene, toluene and hexane; halogen type solvents such asdichloromethane, chloroform and carbon tetrachloride; ether typesolvents such as tetrahydrofuran, diethyl ether and 1,2-dimethoxyethane;dimethylsulfoxide; N,N-dimethylformamide; or a mixture of thesesolvents. Preferably, compound (11) is prepared by reacting compound(10) with a compound of formula A¹SHNa, which is prepared from sodiumand from a compound of formula A¹SH, for 10 minutes to 1 hour at roomtemperature, in dimethylsulfoxide.

Step 12: Compound (12) may be prepared from compound (11) wherein A¹represents something other than a hydrogen atom, for example, by meansof a common oxidation reaction that coverts sulfides into sulfoxidesusing sodium periodate, peracetic acid or the like (see M. Hudlicky,“Oxidations in Organic Chemistry”), in an inert solvent, examples ofwhich include hydrocarbon type solvents such as benzene, toluene andhexane; halogen type solvents such as dichloromethane, chloroform andcarbon tetrachloride, ether type solvents such as tetrahydrofuran,diethyl ether and 1,2-dimethoxyethane; acetonitrile; acetone;dimethylsulfoxide; N,N-dimethylformamide; methanol; ethanol; aceticacid; water; or a mixture or these solvents.

Step 13: Compound (13) may be prepared from compound (12) or fromcompound (11) wherein A¹ represents something other than a hydrogenatom, for example, by means of a common oxidation reaction that convertssulfides or sulfoxides into sulfines using 3-chloroperbenzoic acid,hydrogen peroxide or the like (see M. Hudlicky, “Oxidations in OrganicChemistry”), in an inert solvent, examples of which include hydrocarbontype solvents such as benzene, toluene and hexane; halogen type solventssuch as dichloromethane, chloroform and carbon tetrachloride; ether typesolvents such as tetrahydrofuran, diethyl ether and 1,2-dimethoxyethane;acetonitrile; acetone; dimethylsulfoxide; N,N-dimethylformamide; water;or a mixture of these solvents. It is also possible to prepare a mixtureof compound (12) and compound (13) from compound (11) wherein A¹represents something other than a hydrogen atom, for example, by using acommon oxidizing agent such as 3-chloroperbenzoic acid or hydrogenperoxide (see M. Hudlicky, “Oxidations in Organic Chemistry”) and bycontrolling the reaction conditions such as the amount, reaction time,reaction temperature and solvent of the oxidizing agent, in an inertsolvent, examples of which include hydrocarbon type solvents such asbenzene, toluene and hexane; halogen type solvents such asdichloromethane, chloroform and carbon tetrachloride; ether typesolvents such as tetrahydrofuran, diethyl ether and 1,2-dimethoxyethane;acetonitrile; acetone; dimethylsulfoxide; N,N-dimethylformamide; water;or a mixture of these solvents. Preferably, compound (12) and compound(13) may be prepared by reacting compound (11) with 3-chloroperbenzoicacid for 1 to 24 hours at −78° C. to room temperature, indichloromethane.

Step 14: Compound (15) may be prepared from compound (14), for example,by means of a common reduction reaction of an azide group, typicalexamples of which include: (a) Staudinger reaction with triethylphosphite, trimethylphosphine, tributylphosphine or triphenylphosphine(see Bull. Chem. Soc. Fr., 815 (1985)) in an inert solvent, examples ofwhich include hydrocarbon type solvents such as benzene, toluene andhexane; halogen type solvents such as dichloromethane, chloroform andcarbon tetrachloride; ether type solvents such as tetrahydrofuran,diethyl ether and 1,2-dimethoxyethane; acetonitrile; acetone; water, ora mixture of these solvents; (b) hydrogenation in an inert solvent,examples of which include alcohols such as ethanol and methanol, esterssuch as ethyl acetate; N,N-dimethylformamide; water; or a mixture ofthese solvents, in the presence of a metal catalyst such aspalladium/carbon or palladium black; and (c) hydride reduction withlithium aminoborohydride or the like (see A. F. Abdel-Magid, “Reductionsin Organic Synthesis”). Preferably, compound (15) may be prepared byreacting compound (14) by means of a Staudinger reaction withtrimethylphosphine for 1 to 2 hours at room temperature, in a mixture oftetrahydrofuran and water.

Step 15: Compound (16), which is a synthetic intermediate of thecompound of the present invention, may be prepared from compound (15)wherein at least one of R¹ and R² represent something other than ahydrogen atom, by hydrolyzing the moieties represented by formula COOR¹and formula COOR² of compound (15) by means of the same method as Step9. Preferably, compound (16), which is a synthetic intermediate of thecompound of the present invention, may be prepared by hydrolyzingcompound (15) with lithium hydroxide for 5 to 7 days at room temperatureto 40° C., in a mixture of tetrahydrofuran and water. Or preferably,compound (16) may be prepared by hydrolyzing compound (15) with 60%sulfuric acid for 1 to 5 days at 100° C. to 150° C.

Compounds (24) and (27), which are synthetic intermediates of thecompound of the present invention, may be prepared from syntheticintermediate (6) according to Steps 16, 17, 18, 19, 20, 21 and 22 belowin the case where in formula [III], Y represents formula NHCHR³R⁴ orformula N(CHR³R⁴)(CHR^(3′)R^(4′)).

Step 16: Compounds (17) and (21) may be prepared from compounds (6) and(20), respectively, by reducing the azide group by means of the samemethod as Step 14. Preferably, compound (17) and compound (21) may beprepared from compound (6) and compound (20), respectively, by means ofa Staudinger reaction with trimethylphosphine for 1 to 12 hours at roomtemperature, in a mixture of tetrahydrofuran and water.

Step 17: Compound (18) may be prepared from compound (17) by protectingthe amino group of compound (17) by means of a common protectionreaction of an amino group (see T. W. Greene, P. G. M. Wuts, “ProtectiveGroups in Organic Synthesis”). Preferably, compound (18) may be preparedby reacting compound (17) with di-t-butyldicarbonate for 2 to 6 hours atroom temperature, in tetrahydrofuran, in the presence of a saturatedaqueous solution of sodium hydrogen carbonate.

Step 18: Compound (19) may be prepared from compound (18) wherein R¹ andR² represent something other than a hydrogen atom, by alkyl- oraryl-sulfonylating the hydroxyl group of compound (18) by means of thesame method as Step 0. Preferably, compound (19) may be prepared byreacting the hydroxyl group of compound (18) with trifluoromethanesulfonic acid anhydride for 30 minutes to 2 hours at −78° C. toice-cooling, in dichloromethane, in the presence of pyridine.

Step 19: Compound (20) may be prepared, for example, by reactingcompound (19) with sodium azide in an inert solvent, examples of whichinclude hydrocarbon type solvents such as benzene, toluene and hexane;halogen type solvents such as dichloromethane, chloroform and carbontetrachloride; ether type solvents such as tetrahydrofuran, diethylether and 1,2-dimethoxyethane; ethyl acetate; acetonitrile; acetone;dimethylsulfoxide; N,N-dimethylformamide; water; or a mixture of thesesolvents. Preferably, compound (20) may be prepared by reacting compound(19) with sodium azide for 1 to 2 days at room temperature to 35° C., inN,N-dimethylformamide.

Step 20: Compounds (22) and (25) may be prepared from compounds (21) and(22), respectively, for example, by reacting the amino groupsrepresented by formula —NH₂ and formula —R³R⁴CHNH of compounds (21) and(22) with a compound of formula R³R⁴CHL or formula R^(3′)R^(4′)CHL², inan inert solvent, examples of which include hydrocarbon type solventssuch as benzene, toluene, hexane and cyclohexane; halogen type solventssuch as dichloromethane, chloroform and carbon tetrachloride; ether typesolvents such as tetrahydrofuran, diethyl ether and 1,2-dimethoxyethane;amides such as N,N-dimethylformamide and N-methyl-2-pyrrolidinone;dimethylsulfoxide; or a mixture of these solvents, in the presence orabsence of inorganic bases such as sodium hydride, potassium hydride,potassium carbonate, sodium carbonate, sodium hydrogen carbonate, sodiumhydroxide and potassium hydroxide; metal amides such as lithiumbis(trimethylsilyl)amide, lithium diisopropylamide and sodium amide;organic bases such as triethylamine, pyridine, diisopropylethylamine,4-(N,N-dimethylamino)pyridine and 2,6-di-t-butylpyridine; or bases suchas potassium t-butoxide. In this case, L² represents a leaving group,for example, a halogen atom, a tosylsulfonate, atrifluoromethansulfonate or a tolylsulfonate. It is also possible toprepare compounds (22) and (25), respectively, for example, byreductively aminating compounds (21) and (22) by means of a Borchreaction in which compounds (21) and (22) are reacted with compounds offormula R³COR⁴ or formula R^(3′)COR^(4′) (see A. F. Abdel-Magid et al.,Tetrahedron Lett., 31, 5595 (1990)) in an inert solvent, examples ofwhich include hydrocarbon type solvents such as benzene, toluene, hexaneand cyclohexane; halogen type solvents such as dichloromethane,chloroform and carbon tetrachloride; ether type solvents such astetrahydrofuran, diethyl ether and 1,2-dimethoxyethane; amides such asN,N-dimethylformamide and N-methyl-2-pyrrolidinone; dimethylsulfoxide;ethanol; methanol; water; or a mixture of these solvents, in thepresence of a reducing agent such as sodium triacetoxyborohydride orsodium cyanotrihydroborate. Preferably, compound (22) may be prepared byreacting compound (21) with a compound of formula R³R⁴CHBr for 1 to 4days at room temperature, in chloroform, in the presence of pyridine.And preferably, compound (25) may be prepared by reacting compound (22)with a compound of formula R^(3′)R^(4′)CHI for 1 to 4 days at roomtemperature, in N,N-dimethylformamide, in the presence of potassiumcarbonate.

Step 21: Compounds (23) and (26) may be prepared from compound (22) andcompound (25), respectively, by deprotecting R⁷, which is the protectinggroup for the amino group of compounds (22) and (25), by means of acommon deprotection reaction (see T. W. Greene, P. G M. Wuts,“Protective Groups in Organic Synthesis”) that converts R⁷ into an aminogroup. Preferably, compound (23) and compound (26) may be prepared bydeprotecting compound (22) and compound (25) with 4N hydrogenchloride/ethyl acetate for 12 to 36 hours at ice-cooling to roomtemperature.

Step 22: Compounds (24) and (27), which are synthetic intermediates ofthe compound of the present invention, may be prepared from compounds(23) and (26) wherein at least one of R¹ and R² represent somethingother than a hydrogen atom, by hydrolyzing the moieties represented byformula COOR¹ and COOR² of compounds (23) and (26), by means of the samemethod as Step 9. Preferably, compound (24) and compound (27), which aresynthetic intermediates of the compound of the present invention, may beprepared by hydrolyzing compound (23) and compound (26), respectively,with lithium hydroxide for 1 to 7 days, in a mixture of tetrahydrofuranand water.

Compound (30), which is a synthetic intermediate of the compound of thepresent invention, may be prepared from compound (21) according to Steps23, 24 and 25 below in the case where in formula [III], Y representsformula —NHCOR³.

Step 23: Compound (28) may be prepared from compound (21), for example,by reacting the 3-position amino group of compound (21) with a compoundof formula L¹COR³ or formula R³COOCOR³ in an inert solvent, examples ofwhich include hydrocarbon type solvents such as benzene, toluene andhexane; halogen type solvents such as dichloromethane, chloroform andcarbon tetrachloride; ether type solvents such as tetrahydrofuran,diethyl ether and 1,2-dimethoxyethane; amides such asN,N-dimethylformamide and N-methyl-2-pyrrolidinone; dimethylsulfoxide;or a mixture of these solvents, in the presence or absence of organicbases such as triethylamine, pyridine, morpholine,diisopropylethylamine, 4-(N,N-dimethylamino)pyridine and2,6-di-t-butylpyridine.

In this case, L¹ represents a leaving group, for example, a halogenatom, an ethoxycarbonyloxy group or a phenoxycarbonyloxy group. It isalso possible to prepare compound (28) by means of a common formylationreaction (see T. W. Greene, P. G. M. Wuts, “Protective Groups in OrganicSynthesis”) in the case where R³ represents a hydrogen atom. Preferably,compound (28) may be prepared by reacting compound (21) with a compoundof formula R³COCl for 1 to 4 hours at room temperature, in chloroform,in the presence of pyridine.

Step 24: Compound (29) may be prepared from compound (28) by means ofthe same deprotection reaction of formula —NHR⁷ as Step 21. Preferably,compound (29) may be prepared by deprotecting compound (28) with 4Nhydrogen chloride/ethyl acetate for 30 minutes to 2 hours atice-cooling.

Step 25: Compound (30), which is an intermediate of the compound of thepresent invention, may be prepared from compound (29) wherein at leastone of R¹ and R² represent something other than a hydrogen atom, bymeans of the same method of hydrolysis reaction of formula —COOR¹ andformula —COOR² as Step 9. Preferably, compound (30), which is asynthetic intermediate of the compound of the present invention may beprepared by hydrolyzing compound (29) with lithium hydroxide for 1 to 7hours at room temperature, in a mixture of tetrahydrofuran and water.Compound (33), which is a synthetic intermediate of the compound of thepresent invention, may be prepared from synthetic intermediate (6)wherein R² represents a benzyl group, according to Steps 26, 27 and 28below in the case where in formula [III], Y represents formula —OCOR⁵.

Step 26: Compound (31) may be prepared from compound (6) wherein R¹represents something other than a hydrogen atom and R² represents abenzyl group, for example, by reacting the hydroxyl group of compound(6) with a compound of formula L¹COR⁵ or formula R⁵COOCOR⁵ either in aninert solvent, examples of which include hydrocarbon type solvents suchas benzene, toluene and hexane; halogen type solvents such asdichloromethane, chloroform and carbon tetrachloride; ether typesolvents such as tetrahydrofuran, diethyl ether and 1,2-dimethoxyethan;amides such as N,N-dimethylformamide and N-methyl-2-pyrrolidinone;dimethylsulfoxide; or a mixture of these solvents or in the absence ofany solvent, in the presence or absence of organic bases such astriethylamine, pyridine, morpholine, diisopropylethylamine,4-(N,N-dimethylamino)pyridine and 2,6-di-t-butylpyridine. In this case,L¹ represents a leaving group, for example, a halogen atom, anethoxycarbonyloxy group or a phenoxycarbonyloxy group. Preferably,compound (31) may be prepared by reacting compound (6) with a compoundof formula R⁵COCl for 12 to 36 hours at room temperature, in pyridine.

Step 27: compound (32) may be prepared from compound (31), for example,by yielding an amino body by means of a Staudinger reaction withtriethyl phosphite, trimethylphosphine, tributylphosphine ortriphenylphosphine, in an inert solvent, examples of which includehydrocarbon type solvents such as benzene, toluene and hexane; halogentype solvents such as dichloromethane, chloroform and carbontetrachloride; ether type solvents such as tetrahydrofuran, diethylether and 1,2-dimethoxyethane; acetonitrile; acetone; water; or amixture of these solvents (see Bull. Chem. Soc. Fr., 815 (1985)), andthen, for example, by reductively deprotecting the benzyl group of theobtained amino body by means of a hydrogenation reaction, in an inertsolvent, examples of which include alcohols such as ethanol andmethanol; esters such as ethyl acetate; N,N-dimethylformamide; water; ora mixture of these solvents, in the presence of a metal catalyst such aspalladium/carbon or palladium black. It is also possible to directlyprepare compound (32) from compound (31), for example, by means of ahydrogenation reaction, in an inert solvent, examples of which includealcohols such as ethanol and methanol; esters such as ethyl acetate;N,N-dimethylformamide; water; or a mixture of these solvents, in thepresence of a metal catalyst such as palladium/carbon or palladiumblack. Preferably, an amine body may be prepared by reacting compound(31) by means of a Staudinger reaction with trimethylphosphine for 30minutes to 2 hours at room temperature, in a mixture of tetrahydrofuranand water. Compound (32) may then be prepared by reacting the amine bodyfor 30 minutes to 2 hours at room temperature, in ethanol, in thepresence of 5% palladium carbon, under a hydrogen atmosphere.

Step 28: Compound (33), which is a synthetic intermediate of thecompound of the present invention, may be prepared from compound (32)wherein R¹ represents something other than a hydrogen atom, by means ofthe same method as Step 9. Preferably, compound (33), which is asynthetic intermediate of the compound of the present invention, may beprepared by hydrolyzing compound (32) with lithium hydroxide for 30minutes to 2 hours at room temperature, in a mixture of tetrahydrofuranand water.

Compound [I] of the present invention may be prepared by means ofmonoesterification or diesterification of the two carboxylic acidmoieties of the obtained synthetic intermediate [III].

Compound [I], which is the compound of the present invention, may beprepared by means of diesterification or monoesterification of thecarboxylic acid moieties of compound [III] according to Step 29 below.

Step 29: Compound [I], which is the compound of the present invention,may be prepared by means of a common esterification reaction of thecarboxylic acid moiety of compound [III] (see T. W. Greene, P. G M.Wuts, “Protective Groups in Organic Synthesis”). Preferably, compound[I] of the present invention may be prepared by converting thecarboxylic acid moiety of compound [III] to lithium salt using lithiumhydroxide at room temperature in tetrahydrofuran, and then by reactingcompound [III] with compounds of formula R¹Br and formula R²Br for 4 to12 hours at room temperature to 90° C., in N,N-dimethylformamide. It isalso possible to selectively prepare compound [I], which is the compoundof the present invention and wherein R² represents a hydrogen atom, byreacting the carboxylic acid moiety on the 6-position carbon of compound[III] with alcohol represented by formula R¹OH, for a short period oftime or by controlling the reaction temperature, either in an inertsolvent, examples of which include hydrocarbon type solvents such asbenzene, toluene and hexane; halogen type solvents such asdichloromethane, chloroform and carbon tetrachloride; ether typesolvents such as tetrahydrofuran, diethyl ether and 1,2-dimethoxyethane;dimethylsulfoxide; N,N-dimethylformamide; or a mixture of these solventsor without any solvent, in the presence or absence of mineral acids suchas sulfuric acid, phosphoric acid and hydrochloric acid; organic acidssuch as acetic acid, oxalic acid and methanesulfonic acid; or chlorideacids such as thionyl chloride and phosphoryl chloride. Preferably,compound [I] of the present invention wherein R² represents a hydrogenatom may be prepared by reacting the carboxylic acid moiety on the6-position carbon of compound [III] for 1 hour to 3 days at ice-coolingto 80° C., in the presence of alcohol represented by formula R¹OH and ofthionyl chloride.

It is also possible to selectively prepare compound [I] wherein R²represents a hydrogen atom by protecting the amino acid moiety on the2-position carbon by means of a protection method of α-amino acid usingtriethylboran, copper(II) complex or the like (see International Journalof Peptide & Protein Research, 37, 210 (1991); Synthesis, 119 (1990);Helv. Chem. Acta, 44, 159 (1961)), and then esterifying the carboxylicacid moiety on the 6-position carbon by means of a common esterificationreaction (see T. W. Greene, P. G M. Wuts, “Protective Groups in OrganicSynthesis”), followed by a deprotection reaction of the α-amino acidmoiety (see International Journal of Peptide & Protein Research, 37, 210(1991); Synthesis, 119 (1990); Helv. Chem. Acta, 44, 159 (1961)).

After compound [I] wherein R² represents an hydrogen atom has beenselectively prepared, compound [I] of the present invention wherein R¹and R² both represent something other than a hydrogen atom may beprepared by either protecting or not protecting the amino group on the2-position carbon with a common protecting group for an amino group suchas an allyloxycarbonyl group or a tert-butoxycarbonyl group (see T. W.Greene, P. G. M. Wuts, “Protective Groups in Organic Synthesis”) andthen esterifying the carboxylic acid moiety on the 2-position carbon bymeans of a common esterification reaction (see T. W. Greene, P. G. M.Wuts, “Protective Groups in Organic Synthesis”), and in the case wherethe amino group has been protected, followed by a deprotection reactionof amino groups (see T. W. Greene, P. G. M. Wuts, “Protective Groups inOrganic Synthesis”). Preferably, Compound [I] of the present inventionwherein R¹ and R² both represent something other than a hydrogen atommay be prepared by protecting the amino group on the 2-position carbonwith an allyloxycarbonyl group by reacting the amino group for 8 hoursat room temperature, in the presence of allyl chloroformate andsaturated sodium hydrogen carbonate; and then reacting the amino groupwith R²X′ (wherein R² represents a halogen atom and X′ preferablyrepresents a bromine atom or a iodine atom) for 1 to 24 hours, in thepresence of potassium carbonate; followed by a deprotection reaction ofan amino group in which the amino group is reacted withtetrakis(triphenylphosphine)palladium for 1 to 24 hours at roomtemperature to 80° C., in the presence of 1,3-dimethylbarbituric acid.

It is also possible to selectively prepare compound [I], which is thecompound of the present invention wherein R¹ represents a hydrogen atom,from compound [I] wherein R¹ and R² represent something other than ahydrogen atom, by converting the moiety represented by formula COOR¹ ofcompound [I] into a carboxylic acid by means of a common hydrolysisreaction (see T. W. Greene, P. G. M. Wuts, “Protective Groups in OrganicSynthesis”), for a short period of time or at a low temperature.Preferably, compound [I] of the present invention wherein R¹ representsa hydrogen atom may be prepared from compound [I] wherein R¹ and R²represent something other than a hydrogen atom, by hydrolyzing themoiety represented by formula COOR¹ of compound [1] with lithiumhydroxide for 30 minutes to 3 hours at 0° C. to room temperature, in amixture of tetrahydrofuran and water.

It is further possible to prepare compound [I] wherein at least one ofR¹ and R² represent an azidoC₁₋₁₀alkyl group from a correspondingcompound [I] wherein at least one of R¹ and R² represent a halogenoC₁₋₁₀alkyl, for example, by reacting compound [I] with sodium azide inan inert solvent, examples of which include hydrocarbon type solventssuch as benzene, toluene and hexane; halogen type solvents such asdichloromethane, chloroform and carbon tetrachloride; ether typesolvents such as tetrahydrofuran, diethyl ether and 1,2-dimethoxyethane;ethyl acetate; acetonitrile; acetone; dimethylsulfoxide;N,N-dimethylformamide; water; or a mixture of these solvents.Preferably, compound [I] wherein at least one of R¹ and R² represent anazidoC₁₋₁₀alkyl group may be prepared by reacting a compound [I] whereinat least one of R¹ and R² represent a halogenoC₁₋₁₀alkyl group withsodium azide for 6 to 18 hours at room temperature to 60° C., in amixture of N,N-dimethylformamide and water.

It is further possible to prepare compound [I] wherein at least one ofR¹ and R² represent an aminoC₂₋₁₀alkyl group from a correspondingcompound [I] wherein at least one of R¹ and R² represent anazidoC₁₋₁₀alkyl group, by hydrolyzing the azido moiety of compound [I]by means of a common reduction reaction of an azide group, typicalexamples of which include: (a) Staudinger reaction with triethylphosphite, trimethylphosphine, tributylphosphine or triphenylphosphine(see Bull. Chem. Soc. Fr., 815 (1985)) in an inert solvent, examples ofwhich include hydrocarbon type solvents such as benzene, toluene andhexane; halogen type solvents such as dichloromethane, chloroform andcarbon tetrachloride; ether type solvents such as tetrahydrofuran,diethyl ether and 1,2-dimethoxyethane; acetonitrile; acetone; water; ora mixture of these solvents; (b) hydrogenation in an inert solvent,examples of which include alcohols such as ethanol and methanol, esterssuch as ethyl acetate; N,N-dimethylformamide; water; or a mixture ofthese solvents, in the presence of a metal catalyst such aspalladium/carbon or palladium black; and (c) hydride reduction withlithium aminoborohydride or the like (see A. F. Abdel-Magid, “Reductionsin Organic Synthesis”). Preferably, compound [I] wherein at least one ofR¹ and R² represent a aminoC₁₋₁₀alkyl group may be prepared by reactingcompound [I] wherein at least one of R¹ and R² represent anazidoC₁₋₁₀alkyl group by means of a Staudinger reaction withtrimethylphosphine for 6 to 18 hours at room temperature, in a mixtureof tetrahydrofuran and water.

Further, it is also possible to prepare compound [I] of the presentinvention wherein R^(X) represents something other than a hydrogen atomand R² represents a hydrogen atom from the obtained compound [III]according to Steps 30, 31, 32 and 33 below.

Step 30: compound (34) may be prepared, for example, by reacting theamino group of compound [III] with allyl chloroformate in an inertsolvent, examples of which include hydrocarbon type solvents such asbenzene, toluene and hexane; halogen type solvents such asdichloromethane, chloroform and carbon tetrachloride; ether typesolvents such as tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane and1,4-dioxane; amides such as N,N-dimethylformamide andN-methyl-2-pyrrolidinone; dimethylsulfoxide; water; or a mixture ofthese solvents, in the presence or absence of organic bases such astriethylamine, pyridine, morpholine, diisopropylethylamine,4-(N,N-dimethylamino)pyridine and 2,6-di-t-butylpyridine or inorganicbases such as potassium carbonate, sodium carbonate and sodium hydrogencarbonate. Preferably, compound (34) may be prepared by reactingcompound [III] with allyl chloroformate for 6 to 18 hours at roomtemperature, in 1,4-dioxane, in the presence of a saturated aqueoussolution of sodium hydrogen carbonate.

Step 31: Compound (35) may be prepared, for example, by reactingcompound (34) with an appropriate catalyst such as p-toluenesulfonicacid or oxalic acid, and either with or without using a dehydrationapparatus such as a Dean-Stark distillation trap, in an inert solvent,examples of which include hydrocarbon type solvents such as benzene,toluene and hexane; halogen type solvents such as dichloromethane,chloroform and carbon tetrachloride; ether type solvents such astetrahydrofuran, diethyl ether and 1,2-dimethoxyethane; or a mixture ofthese solvents, in the presence of an aldehyde such as paraformaldehyde.Preferably, compound (35) may be prepared by heat refluxing compound(34) with paraformaldehyde using a Dean-Stark distillation trap for 1 to5 hours, in benzene, in the presence of paratoluenesulfonic acid.

Step 32: Compound (36) may be prepared from compound (35) by means of acommon esterification reaction (see T. W. Greene, P. G. M. Wuts,“Protective Groups in Organic Synthesis”). It is also possible toprepare compound (36) by reacting the ester moieties of a compound offormula L²CHR^(c)OC(O)ZR^(d) (wherein L² represents a leaving group, forexample, a halogen atom, a tosylsulfonate, a trifluoromethansulfonate ora tolylsulfonate) and of compound (35), in an inert solvent, examples ofwhich include hydrocarbon type solvents such as benzene, toluene, hexaneand cyclohexane; halogen type solvents such as dichloromethane,chloroform and carbon tetrachloride; ether type solvents such astetrahydrofuran, diethyl ether and 1,2-dimethoxyethane; amides such asN,N-dimethylformamide and N-methyl-2-pyrrolidinone; dimethylsulfoxide;or a mixture of these solvents, in the presence of inorganic bases suchas sodium hydride, potassium hydride, potassium carbonate, sodiumcarbonate, sodium hydrogen carbonate, sodium hydroxide and potassiumhydroxide; metal amides such as lithium bis(trimethylsilyl)amide,lithium diisopropylamide and sodium amide; organic bases such astriethylamine, pyridine, diisopropylethylamine,4-(N,N-dimethylamino)pyridine and 2,6-di-t-butylpyridine; or bases suchas potassium t-butoxide, in the presence or absence of an appropriateactivating agent such as sodium iodide. Preferably, compound (36) may beprepared by reacting compound (35) with R¹Cl for 2 to 24 hours at roomtemperature to 75° C., in N,N-dimethylformamide, in the presence ofsodium iodide.

Step 33: Compound (37), which is the compound of the present invention,may be prepared from compound (36) by deprotecting the α-amino acidmoiety, in an inert solvent, examples of which include hydrocarbon typesolvents such as benzene, toluene and hexane; halogen type solvents suchas dichloromethane, chloroform and carbon tetrachlorid; ether typesolvents such as tetrahydrofuran, diethyl ether and 1,2-dimethoxyethan;or a mixture of these solvents, in the presence of a zero-valentpalladium catalysts such as tetrakis(triphenylphosphine)palladium(0) anda regeneration reagent of a metal catalyst such as1,3-dimethylbarbituric acid. Preferably, compound (37) of the presentinvention may be prepared by deprotecting compound (36) for 30 minutesto 3 hours at room temperature to 50° C., in chloroform, in the presenceof tetrakis(triphenylphosphine)palladium and 1,3-dimethylbarbituricacid.

The compounds of the present invention may be made into pharmaceuticalformulations or pharmaceutical compositions by being combined with oneor more pharmaceutically acceptable carriers, excipients or diluents.Examples of the carriers, excipients and diluents include water,lactose, dextrose, fructose, sucrose, sorbitol, mannitol, polyethyleneglycol, propylene glycol, starch, gum, gelatin, arginate, calciumsilicate, calcium phosphate, cellulose, water syrup, methylcellulose,polyvinyl pyrrolidone, alkyl parahydroxybenzoate, talc, magnesiumstearate, stearic acid, glycerol and oils such as sesame oil, olive oiland soybean oil.

The compounds of the present invention may be formulated by means ofcommon formulation procedures into drugs for oral or parenteraladministration, in particular as group II metabotropic glutamatereceptor antagonists, in the form of tablets, pills, capsules, granules,powders, liquids, emulsions, suspensions, ointments, injections and skinplasters, after being mixed with the said carriers, excipients ordiluents and if necessary, with additives such as commonly employedfillers, binders, disintegrants, pH regulators and solubilizers.

The compounds of the present invention can be administered orally ofparenterally to an adult patient in a quantity of 0.01 to 500 mg per dayin a single dose or in several doses. Oral administration is preferablefrom the point of usability and medicinal benefits. The dosage can beincreased or decreased as appropriate according to the type of thedisease targeted for treatment and the age, weight and symptoms of thepatient.

EXAMPLE

The following Reference Examples, Examples and Test Example illustratethe present invention in detail. It should be understood that thepresent invention is not limited to these examples.

Reference Example 1 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid

(1) 245 mL of a 2.66M n-butyl lithium hexane solution was added dropwiseto 700 mL of a tetrahydrofuran solution containing 137 mL ofhexamethyldisilazane, and the mixture was stirred for 1 hour while beingmaintained at −63° C. to −54° C. 340 mL of a tetrahydrofuran solutioncontaining 101 g of(1R,5R,6R)-6-fluoro-2-oxo-bicyclo[3.1.0]hexane-6-carboxylate ethyl esterwas added dropwise thereto while being maintained at −63° C. to −52° C.700 mL of a tetrahydrofuran solution containing 213 g ofN-phenyl-bis(trifluoromethanesulfonimide) was added an hour later at−63° C. to −45° C. The reaction solution was warmed naturally to roomtemperature and further stirred for 2.5 hours. The reaction solution wasdiluted with diethyl ether, washed three times with a saturated aqueoussolution of sodium hydrogen carbonate and with a saturated aqueoussolution of sodium chloride, and then dried over anhydrous sodiumsulfate. After the desiccant was filtered off, the filtrate wasconcentrated under reduced pressure, and the residue was purified bycolumn chromatography (silica gel: Wako gel C200 (made by Wako PureChemical Industries Ltd.), eluent: hexane-ethyl acetate=30:1 to 20:1 to5:1). The obtained 175 g of(1R,5R,6R)-6-fluoro-2-trifluoromethanesulfonyloxy-bicyclo[3.1.0]hex-2-en-6-carboxylateethyl ester was dissolved in 875 mL of N,N-dimethylformamide and 875 mLof ethanol, and after 95.1 mL of diisopropylethylamine, 8.65 g oftriphenylphosphine and 3.70 g of palladium acetate were added, themixture was stirred for 5.5 hours at room temperature under a carbonmonoxide atmosphere. 1N hydrochloric acid was added thereto, and thereaction solution was extracted six times with diethyl ether. Theorganic layers were combined, washed four times with a saturated aqueoussolution of sodium hydrogen carbonate and with a saturated aqueoussolution of sodium chloride, and then dried over anhydrous sodiumsulfate. After the desiccant was filtered off, the filtrate wasconcentrated under reduced pressure, and the residue was purified bycolumn chromatography (silica gel: Wako gel C200 (made by Wako PureChemical Industries Ltd.), eluent: hexane-ethyl acetate=30:1 to 20:1 to10:1), thereby yielding 92.6 g of(1R,5R,6R)-6-fluorobicyclo[3.1.0]hex-2-en-2,6-dicarboxylic acid diethylester.

¹H-NMR (200 MHz, CDCl₃, TMS); 10.31 (t, J=7.03 Hz, 3H), 1.33 (t, J=7.03Hz, 3H), 2.37-2.51 (m, 1H), 2.65-2.81 (m, 1H), 2.88-3.04 (m, 1H), 3.10(dd, J=7.47, 2.64 Hz, 1H), 4.12-4.40 (m, 4H), 6.77-6.79 (m, 1H). MS(ESI)(Pos)m/z; 265 (M+Na)⁺. [α]_(D) ²¹=+158.0° (CHCl₃, c=1.5).

(2) 160 mL of a 50% N-methylmorpholine N-oxide solution and 121 mL of a5% osmium (VIII) oxide solution was added to 92.4 g of(1R,5R,6R)-6-fluorobicyclo[3.1.0]hexa-2-en-2,6-dicarboxylic acid diethylester dissolved in 1.76 L of acetonitrile and 680 mL of water, and themixture was stirred for 1 hour at room temperature. Sodium sulfite wasadded thereto at ice cooling, and the reaction solution was stirred for30 minutes at room temperature and then filtered through celite. Asaturated aqueous solution of sodium chloride was added thereto, and thefiltrate was extracted twice with ethyl acetate. The organic layers werecombined, washed with a saturated aqueous solution of sodium chloride,and then dried over anhydrous sodium sulfate. After the desiccant wasfiltered off, the filtrate was concentrated under reduced pressure, andthe residue was purified by column chromatography (silica gel: Wako gelC200, eluent: hexane-ethyl acetate=4:1 to 1:1), thereby yielding 95.6 gof(1R,2S,3R,5R,6R)-6-fluoro-2,3-dihydroxybicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.31 (t, J=7.25 Hz, 6H), 2.03-2.34 (m,3H), 2.40-2.55 (m, 1H), 2.70 (d, J=9.23 Hz, 1H), 4.09 (s, 1H), 4.18-4.47(m, 5H). MS (ESI)(Nega) m/z; 275 (M−H)⁻. [α]_(D) ²⁷=−69.1° (CHCl₃,c=1.4).

(3) 106 mL of triethylamine was added to 1.24 L of a dichloromethanesolution containing 95.4 g of(1R,2S,3R,5R,6R)-6-fluoro-2,3-dihydroxybicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester at ice-cooling, 37.6 mL of thionyl chloride was addeddropwise thereto, and the mixture was stirred for 30 minutes. Thereaction solution was washed twice with water and with a saturatedaqueous solution of sodium chloride, and then dried over anhydrousmagnesium sulfate. After the desiccant was filtered off, the filtratewas concentrated under reduced pressure. The residue was dissolved in640 mL of carbon tetrachloride, 640 mL of acetonitrile and 760 mL ofwater. 96.0 g of sodium metaperiodate and 655 mg of ruthenium (III)chloride hydrate were added thereto, and the solution was stirred for 1hour at room temperature. After the mixture was filtered through celite,the filtrate was separated, and the aqueous layer was extracted withdiethyl ether. The organic layers were combined, washed with a saturatedaqueous solution of sodium chloride, and then dried over anhydrousmagnesium sulfate. After the desiccant was filtered off, the filtratewas concentrated under reduced pressure, and the residue was purified bycolumn chromatography (silica gel: Wako gel C200, eluent: hexane-ethylacetate=4:1), thereby yielding 109 g of(1R,1aR,1bS,4aR,5aR)-1-fluoro-3,3-dioxotetrahydro-2,4-dioxa-3λ⁶-thiacyclopropa[a]pentalen-1,1b-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.33 (t, J=7.03 Hz, 3H), 1.34 (t, J=7.03Hz, 3H), 2.52-2.94 (m, 4H), 4.23-4.47 (m, 4H), 5.40-5.53 (m, 1H). MS(ESI)(Pos) m/z; 361 (M+Na)⁺. [α]_(D) ²⁸=+18.3° (CHCl₃, c=1.0).

(4) 37.7 g of sodium azide was added to 109 g of(1R,1aR,1bS,4aR,5aR)-1-fluoro-3,3-dioxotetrahydro-2,4-dioxa-3λ⁶-thiacyclopropa[a]pentalen-1,1b-dicarboxylicacid diethyl ester dissolved in 1.10 L of N,N-dimethylformamide and 110mL of water, and the mixture was stirred for 14 hours at 50° C. Thesolvent was distilled under reduced pressure, and after the residue wasdissolved in 6.48 L of diethyl ether and 177 mL of water, 516 mL of 20%(V/V) sulfuric acid was added thereto, and the mixture was stirred for34 hours at room temperature. After the reaction solution was separated,the organic layers were washed twice with a saturated aqueous solutionof sodium chloride, and then dried over anhydrous magnesium sulfate.After the desiccant was filtered off the, filtrate was concentratedunder reduced pressure, and the residue was purified by columnchromatography (silica gel: Wako gel C200, eluent: hexane-ethylacetate=4:1), thereby yielding 88.5 g of(1R,2R,3R,5R,6R)-2-azide-6-fluoro-3-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.33 (t, J=7.03 Hz, 3H), 1.38 (t, J=7.03Hz, 3H), 2.18-2.61 (m, 5H), 4.21-4.48 (m, 5H). MS (ESI)(Pos) m/z; 324(M+Na)⁺. [α]_(D) ²²=−48.7° (CHCl₃, c=1.0).

(5) 1.36 g of 60% sodium hydride (oily) was washed twice with hexane andsuspended in 46 mL of tetrahydrofuran, and then 60.1 g of3,4-dichlorobenzyl alcohol dissolved in 68 mL of tetrahydrofuran wasadded dropwise thereto. The mixture was stirred for 30 minutes at roomtemperature, and 34 mL of trichloroacetonitrile was added dropwisethereto while being cooled with salt-ice. The solution was stirred for30 minutes at this temperature, 30 minutes at ice-cooling, 30 minutes ina water bath, and a further 2 hours at room temperature. The reactionsolution was concentrated under reduced pressure, and after 45 mL ofpentane and 1.1 mL of methanol was added thereto, the residue wasstirred vigorously for 30 minutes at room temperature. After theinorganic salt was filtered off, the filtrate was concentrated underreduced pressure, thereby yielding 106.8 g of crude3,4-dichlorobenzyl-2,2,2-trichloroacetimidate.

2.03 g of the crude 3,4-dichlorobenzyl-2,2,2-trichloroacetimidate and1.27 g of(1R,2R,3R,5R,6R)-2-azide-3-hydroxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester were dissolved in 5.4 mL of chloroform and 10.8 mL ofcyclohexane. After being cooled in an ice bath, 187 μL oftrifluoromethane sulfonic acid was added thereto. After the mixture wasstirred for 1.5 hours at 30° C., 93 μL of trifluoromethane sulfonic acidwas further added thereto, and the mixture was stirred for 1 hour. Theinorganic salt was filtered off, and a saturated aqueous solution ofsodium hydrogen carbonate was added thereto at ice-cooling. After thesolution was extracted twice with chloroform, the organic layers werecombined, washed with a saturated aqueous solution of sodium chloride,and then dried over anhydrous sodium sulfate. After the desiccant wasfiltered off, the filtrate was concentrated under reduced pressure, andthe residue was purified by column chromatography (silica gel: Wako gelC200, eluent: hexane-ethyl acetate=15:1), thereby yielding 771 mg of(1R,2R,3R,5R,6R)-2-azide-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.26-1.39 (m, 6H), 2.24-2.51 (m, 4H),3.91-4.05 (m, 1H), 4.18-4.35 (m, 4H), 4.42 (d, J=11.9 Hz, 1H), 4.64 (d,J=11.9 Hz, 4H), 7.05-7.14 (m, 1H), 7.36-7.43 (m, 2H). MS (ESI)(Pos) m/z;482 (M+Na)⁺. [α]_(D) ²⁴=14.5° (CHCl₃, c=0.94).

(6) 65.7 mL of a IM trimethylphosphine/tetrahydrofuran solution wasadded to 27.5 g of(1R,2R,3R,5R,6R)-2-azide-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diester dissolved in 825 mL of tetrahydrofuran and 82.5 mL ofwater, and the mixture was stirred for 4 hours at room temperature. Themixture was diluted with 825 mL of diethyl ether, washed with asaturated aqueous solution of sodium hydrogen carbonate and with asaturated aqueous solution of sodium chloride, and then dried overanhydrous sodium sulfate. After the desiccant was filtered off, thefiltrate was concentrated under reduced pressure, and the residue waspurified by column chromatography (silica gel: Wako gel C200, eluent:hexane-ethyl acetate=4:1 to 3:2), thereby yielding 23.1 g of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.24-1.40 (6H, m), 2.02-2.28 (2H, m),2.51-2.80 (2H, m), 3.98-4.08 (1H, m), 4.18-4.34 (4H, m), 4.43 (1H, d,J=12.5 Hz), 4.53 (1H, d, J=12.5 Hz), 7.10-7.19 (1H, m), 7.36-7.45 (2H,m). MS (ESI)(Pos) m/z; 456 (M+Na)⁺. [α]_(D) ²²=+11.6° (CHCl₃, c=0.50%).

(7) 5.53 g of lithium hydroxide hydrate was added to 22.9 g of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester dissolved in 480 mL of tetrahydrofuran and 240 mL ofwater, and the mixture was stirred for three days at room temperature.443 mg of lithium hydroxide hydrate was further added thereto, and themixture was stirred for 1 day at room temperature. 169 mL of 1Nhydrochloric acid was added dropwise thereto at ice-cooling, and themixture was stirred for 14 hours at room temperature. The precipitatedsolids were filtered, and then washed with 200 mL of tetrahydrofuran and100 mL of water, thereby yielding 12.3 g of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid.

¹H-NMR (300 MHz, D₂O, TMSP); 2.28-2.45 (3H, m), 2.50 (1H, dd, J=7.6,13.4 Hz), 4.05-4.11 (1H, m), 4.52 (1H, d, J=12.1 Hz), 4.60 (1H, d,J=12.1 Hz), 7.26-7.58 (3H, m). MS (ESI)(Nega) m/z; 376 (M−H)⁻. [α]_(D)²⁷=˜10.0° (1N NaOH, c=1.02).

Reference Example 2 Synthesis of(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid

(1) 48 μL of pyridine, and 78 μL of trifluoromethane sulfonic acidanhydride dissolved in 0.4 mL of dichloromethane was added dropwise to120 mg of(1R,2R,3R,5R,6R)-2-azide-6-fluoro-3-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester dissolved in 20 mL of dichloromethane at −75° C.under a nitrogen atmosphere, and the mixture was stirred for 1.5 hoursat ice-cooling. 39 μL of trifluoromethane sulfonic acid anhydridedissolved in 24 μL of pyridine and 0.2 mL of dichloromethane was addeddropwise thereto at −75° C., and the mixture was stirred for 25 minutesat ice-cooling. 10 mL of ether was added thereto, and after the solidswere filtered off, the filtrate was concentrated under reduced pressure,and the residue was purified by column chromatography (silica gel: Wakogel C200, eluent: hexane-ethyl acetate=5:1), thereby yielding 166 mg of(1R,2R,3R,5R,6R)-2-azide-6-fluoro-3-trifluoromethanesulfonyloxy-bicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.35 (t, J=7.0 Hz, 3H), 1.38 (t, J=7.0 Hz,3H), 2.35-2.50 (m, 2H), 2.62-2.86 (m, 2H), 4.31 (q, J=7.0 Hz, 2H),4.27-4.55 (m, 2H), 4.94-5.10 (m, 1H). MS (FAB)(Pos) m/z; 434 (M+H)⁺.[α]_(D) ²⁶=−31.2° (CHCl₃, c=0.4).

(2) 688 mg of potassium nitrite and 428 mg of 18-crown-6 ether was addedto 701 mg of(1R,2R,3R,5R,6R)-2-azide-6-fluoro-3-trifluoromethanesulfonyloxy-bicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester dissolved in 6.9 mL of N,N-dimethylformamide, and themixture was stirred for 1.5 days at room temperature under a nitrogenatmosphere, and further stirred for 3.5 days at 45° C. Water was addedthereto, and the mixture was extracted twice with ethyl acetate. Theorganic layers were combined, washed with a saturated aqueous solutionof sodium chloride, and then dried over anhydrous sodium sulfate. Afterthe desiccant was filtered off, the filtrate was concentrated underreduced pressure, and the residue was purified by column chromatography(silica gel: Wako gel C200, eluent:hexane-ethyl acetate=5:1), therebyyielding 388 mg of(1R,2R,3S,5R,6R)-2-azide-6-fluoro-3-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylicacid-2,6-diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.34 (t, J=7.0 Hz, 3H), 1.36 (t, J=7.0 Hz,3H), 2.16 (dd, J=2.9 Hz, 14.9 Hz, 1H), 2.17-2.30 (m, 1H), 2.44 (dd,J=3.1 Hz, 8.1 Hz, 1H), 2.61 (dd, J=12.3 Hz, 16.0 Hz, 1H), 2.80-2.99 (m,1H), 4.29 (q, J=7.0 Hz, 2H), 4.34 (q, J=7.0 Hz, 2H), 4.48-4.64 (m, 1H).MS (ESI)(Pos) m/z, 324 (M+Na)⁺. [α]_(D) ²⁵=+6.4° (CHCl₃, c=1.0).

(3) Under a nitrogen atmosphere, 0.36 mL of trifluoromethane sulfonicacid anhydride dissolved in 1.2 mL of dichloromethane was added dropwiseto 364 mg of(1R,2R,3S,5R,6R)-2-azide-6-fluoro-3-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester dissolved in 6.1 mL of dichloromethane and 0.21 mL ofpyridine at −77° C. to −69° C. The solution was stirred for 30 minutesat −77° C., and further stirred for 30 minutes at ice-cooling. 30 mL ofdiethyl ether was added thereto, and after the solids were filtered off,the filtrate was concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel: Wako gel C200, eluent:hexane-ethyl acetate=5:1), thereby yielding 487 mg of(1R,2R,3S,5R,6R)-2-azide-6-fluoro-3-trifluoromethanesulfonyloxy-bicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.36 (t, J=7.03 Hz, 3H), 1.39 (t, J=7.47Hz, 3H), 2.26-2.63 (m, 3H), 2.91-3.10 (m, 1H), 4.25-4.45 (m, 4H), 5.57(dd, J=9.01, 2.86 Hz, 1H). MS (ESI)(Pos) m/z; 456 (M+Na)⁺. [α]_(D)²⁶=−41.4 (CHCl₃, c=1.1).

(4) 2.59 g of 3,4-dichlorobenzylmercaptan was added to 308 mg of sodiumdissolved in 18 mL of ethanol at room temperature under a nitrogenatmosphere, and the mixture was stirred for 5 minutes and thenconcentrated under reduced pressure. 64 mL of dimethylsulfoxide wasadded to the filturate, and after 3.23 g of(1R,2R,3S,5R,6R)-2-azide-6-fluoro-3-trifluoromethanesulfonyloxy-bicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester dissolved in 6.4 mL of dimethylsulfoxide was addedthereto at room temperature, the mixture was stirred for ten minutes.250 mL of diethyl ether was added thereto, and then the upper and lowerlayers were separated. The lower layer was extracted twice with diethylether. The organic layers were combined, washed with a cooled 1Nhydrochloric acid and with a saturated aqueous solution of sodiumchloride, and then dried over anhydrous sodium sulfate. After thedesiccant was filtered off, the filtrate was concentrated under reducedpressure. The residue was purified by column chromatography (silica gel:Wako gel C200, eluent: hexane-ethyl acetate=10:1 to 5:1), therebyyielding 3.35 g of(1R,2S,3R,5R,6R)-2-azide-3-(3,4-dichlorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.34 (t, J=7.03 Hz, 3H), 1.38 (t, J=7.03Hz, 3H), 2.20-2.49 (m, 4H) 2.99-3.13 (m, 1H), 3.68 (d, J=13.62 Hz, 1H),3.84 (d, J=13.62 Hz, 1H), 4.22-4.51 (m, 4H), 7.16 (dd, J=8.13, 1.98 Hz,1H), 7.34-7.46 (m, 2H). MS (ESI)(Pos) m/z; 498 (M+Na)⁺. [α]_(D)²⁴=+129.9° (CHCl₃, c=0.5).

(5) 7.7 mL of a 1M trimethylphosphine/tetrahydrofuran solution was addedto 3.35 g of(1R,2S,3R,5R,6R)-2-azide-3-(3,4-dichlorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester dissolved in 100 mL of tetrahydrofuran and 10 mL ofwater, and the mixture was stirred for 1 hour at room temperature. Afterthe solution was diluted with 200 mL of diethyl ether, 50 mL of asaturated aqueous solution of sodium hydrogen carbonate was addedthereto, and the mixture was stirred for 1.5 hours at room temperature.After separation, the organic layers were washed with a saturatedaqueous solution of sodium chloride and then dried over anhydrous sodiumsulfate. After the desiccant was filtered off, the filtrate wasconcentrated under reduced pressure. The residue was diluted withchloroform, and silica gel [Wako gel C200] was added thereto. Afterbeing concentrated under reduced pressure and then left to stand for 18hours at room temperature, the residue was purified by columnchromatography (silica gel: Wako gel C200, eluent: hexane-ethylacetate=2:1), thereby yielding 2.78 g of(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester

¹H-NMR (300 MHz, CDCl₃, TMS); 1.31 (t, J=7.2 Hz, 3H), 1.35 (t, J=7.2 Hz,3H), 2.08-2.15 (m, 1H), 2.24-2.40 (m, 3H), 2.86-2.93 (m, 1H), 3.73 (d,J=13.4 Hz, 1H), 3.88 (d, J=13.4 Hz, 1H), 4.21-4.37 (m, 4H), 7.15 (dd,J=8.2, 2.2 Hz, 1H), 7.36 (d, J=8.2 Hz, 1H), 7.42 (d, J=2.2 Hz, 1H). MS(ESI)(Pos) m/z; 472 (M+Na)⁺. [α]_(D) ²⁶=+94.4° (CHCl₃, c=0.25).

(6) 12 mg of lithium hydroxide hydrate was added to 41 mg of(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester dissolved in 0.8 mL of tetrahydrofuran and 0.4 mL ofwater, and the mixture was stirred for 5.5 days at room temperature. Themixture was adjusted to pH=3 with 1N hydrochloric acid in an ice bath.30 mL of water was added thereto, and after the mixture was stirred for1 hour at room temperature and then purified by ion exchange resin (AG50W-X8 Resin (H form), eluent: water, a 40% aqueous solution oftetrahydrofuran and a 10% aqueous solution of pyridine), the obtainedsolids were further washed with tetrahydrofuran, thereby yielding 26 mgof(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid.

¹H-NMR (300 MHz, D₂O, TMSP); 2.17-2.48 (m, 4H), 3.04-3.13 (m, 1H), 3.80(d, J=14.9 Hz, 1H), 3.85 (d, J=14.9 Hz, 1H), 7.31 (d, J=8.1 Hz, 1H),7.53 (d, J=8.1 Hz, 1H), 7.59 (s, 1H). MS (ESI)(Nega) m/z; 392 (M−H)⁻.[α]_(D) ³⁰=+47.5° (1N NaOH, c=0.41).

Reference Example 3 Synthesis of(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfinyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid

(1) 32 mg of 3-chloroperbenzoic acid was added to 73 mg of(1R,2S,3R,5R,6R)-2-azide-3-(3,4-dichlorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester dissolved in 1.46 mL of dichloromethane in a dryice-acetone bath, and the mixture was stirred for 1 hour. The mixturewas further stirred for 3.5 hours in an ice bath, and then for 11 hoursat room temperature. After 15 mg of 3-chloroperbenzoic acid was furtheradded in a dry ice-acetone bath, the mixture was stirred for 1 hour, andfurther stirred for 4 hours in an ice bath. The reaction solution waswashed with a saturated aqueous solution of sodium hydrogen carbonateand with a saturated aqueous solution of sodium chloride, and then driedover anhydrous sodium sulfate. After the desiccant was filtered off, thefiltrate was concentrated under reduced pressure The residue waspurified by column chromatography (silica gel: Wako gel C200, eluent:hexane-ethyl acetate=4:1 to 2:1), thereby yielding 63 mg of(1R,2S,3R,5R,6R)-2-azide-3-(3,4-dichlorobenzylsulfinyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester and 12 mg of(1R,2S,3R,5R,6R)-2-azide-3-(3,4-dichlorobenzylsulfonyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

(1R,2S,3R,5R,6R)-2-azide-3-(3,4-dichlorobenzylsulfinyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester

¹H-NMR (200 MHz, CDCl₃, TMS); 1.36 (t, J=7.03 Hz, 3H), 1.38 (t, J=7.03Hz, 3H), 2.33 (dd, J=14.06, 8.35 Hz, 1H), 2.43-2.61 (m, 2H), 2.80-2.97(m, 1H), 3.11-3.24 (m, 1H), 3.79 (d, J=13.19 Hz, 1H), 4.09 (d, J=13.19Hz, 1H), 4.25-4.43 (m, 4H), 7.17 (dd, J=8.35, 2.20 Hz, 1H), 7.40-7.50(m, 2H). MS (ESI)(Pos) m/z; 514 (M+Na)⁺. [α]_(D) ²⁸=+36.0° (CHCl₃,c=0.5).

(1R,2S,3R,5R,6R)-2-azide-3-(3,4-dichlorobenzylsulfonyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester

¹H-NMR (200 MHz, CDCl₃, TMS); 1.36 (t, J=7.03 Hz, 3H), 1.39 (t, J=7.03Hz, 3H), 2.33-2.58 (m, 3H), 2.86-3.05 (m, 1H), 3.53 (dd, J=11.21, 8.13Hz, 1H), 4.24-4.46 (m, 6H), 7.28 (dd, J=8.35, 2.20 Hz, 1H), 7.44-7.56(m, 2H). MS (ESI)(Pos) m/z; 530 (M+Na)⁺. [α]_(D) ²⁹=+7.9° (CHCl₃,c=0.7).

(2) By means of the same method as Reference Example 2(5), 41 mg of(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfinyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethylester was yielded from 61 mg of(1R,2S,3R,5R,6R)-2-azide-3-(3,4-dichlorobenzylsulfinyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.34 (t, J=7.0 Hz, 3H), 1.35 (t, J=7.0 Hz,3H), 2.30-2.43 (m, 3H), 2.78-3.12 (m, 2H), 3.80 (d, J=13.2 Hz, 1H),4.19-4.36 (m, 5H), 7.17 (dd, J=8.4, 2.2 Hz, 1H), 7.44 (d, J=8.4 Hz, 1H),7.44 (d, J=2.2 Hz, 1H). MS (ESI)(Pos) m/z; 488 (M+Na)⁺. [α]_(D)²⁹=+59.1° (CHCl₃, c=0.32).

(3) By means of the same method as Reference Example 2(6), 17 mg of(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfinyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid was yielded from 38 mg of(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfinyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (300 MHz, D₂O, TMSP); 2.16-2.29 (m, 2H), 2.44-2.49 (m, 1H),2.77-2.88 (m, 1H), 3.44-3.53 (m, 1H), 4.05 (d, J=13.1 Hz, 1H), 4.26 (d,J=13.1 Hz, 1H), 7.29 (d, J=8.5 Hz, 1H), 7.56 (s, 1H), 7.60 (d, J=8.5 Hz,1H). MS (ESI)(Nega) m/z, 408 (M−H)⁻. [α]_(D) ²⁵=+79.7° (1N NaOH,c=0.30).

Reference Example 4 Synthesis of(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfonyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid

(1) By means of the same method as Reference Example 2(5), 169 mg of(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfonyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester was yielded from 190 mg of(1R,2S,3R,5R,6R)-2-azide-3-(3,4-dichlorobenzylsulfonyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.34 (t, J=7.0 Hz, 3H), 1.36 (t, J=7.0 Hz,3H), 2.28-2.42 (m, 3H), 2.83-3.01 (m, 1H), 3.41-3.53 (m, 1H), 4.23-4.37(m, 6H), 7.28 (dd, J=8.4, 1.8 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 7.55 (d,J=1.8 Hz, 1H). MS (ESI)(Pos) m/z; 482 (M+H)⁺. [α]_(D) ²⁹=+24.0° (CHCl₃,c=0.86).

(2) 108 mg of(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfonyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester was stirred in 1.08 mL of 60% sulfuric acid (W/V %)for 3 days at 130° C. The reaction solution was ice-cooled, andneutralized with an aqueous solution of 5N sodium hydroxide. The mixturewas stirred for 1 hour at room temperature, and then purified by ionexchange resin (AG 50W-X8 Resin (H form), eluent: water, a 30% aqueoussolution of tetrahydrofuran, and a 10% aqueous solution of pyridine),thereby yielding 76 mg of(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfonyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid.

¹H-NMR (300 MHz, D₂O, TMSP); 2.33-2.45 (m, 3H), 2.82-2.94 (m, 1H), 3.98(dd, J=10.1, 9.48 Hz, 1H), 4.55 (d, J=15.2 Hz, 1H), 4.60 (d, J=15.3 Hz,1H), 7.37 (d, J=8.4 Hz, 1H), 7.63 (d, J=8.8 Hz, 1H), 7.64 (s, 1H). MS(ESI)(Nega) m/z; 424 (M−H)⁻. [α]_(D) ²⁸=−5.1° (1N NaOH, c=0.72).

Reference Example 5 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid

(1) 0.89 mL of a IM trimethylphosphine/tetrahydrofuran solution wasadded to 245 mg of(1R,2R,3S,5R,6R)-2-azide-6-fluoro-3-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester dissolved in 7.0 mL of tetrahydrofuran and 0.7 mL ofwater, and the mixture was stirred for 12 hours at room temperature. Themixture was diluted with 14 mL of diethyl ether, and after a saturatedaqueous solution of sodium hydrogen carbonate was added thereto, themixture was stirred for 1 hour at room temperature. After separation,the aqueous layer was extracted twice with chloroform. The organiclayers were combined, washed with a saturated aqueous solution of sodiumchloride, and then dried over anhydrous sodium sulfate. After thedesiccant was filtered off, the filtrate was concentrated under reducedpressure. The residue was purified by column chromatography (silica gel:Wako gel C200, eluent: chloroform-ethanol=50:1), thereby yielding 163 mgof(1R,2R,3S,5R,6R)-2-amino-6-fluoro-3-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.32 (t, J=7.25 Hz, 6H), 2.07-2.23 (m,2H), 2.41 (dd, J=8.13, 3.30 Hz, 1H), 2.71-2.91 (m, 1H), 4.10-4.41 (m,5H). MS (ESI)(Pos) m/z; 276 (M+H)⁺. [α]_(D) ²⁵=+2.8° (CHCl₃, c=1.5).

(2) 0.8 mL of a saturated aqueous solution of sodium hydrogen carbonateand 152 mg of di-t-butyldicarbonate were added to 160 mg of(1R,2R,3S,5R,6R)-2-amino-6-fluoro-3-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester dissolved in 0.8 mL of tetrahydrofuran, and themixture was stirred for 4 hours at room temperature. The reactionsolution was extracted twice with ethyl acetate. The organic layers werecombined, washed with a saturated aqueous solution of sodium chloride,and then dried over anhydrous sodium sulfate. After the desiccant wasfiltered off, the filtrate was concentrated under reduced pressure. Theresidue was purified by column chromatography (silica gel: Wako gelC200, eluent:hexane-ethyl acetate=2:1), thereby yielding 214 mg of(1R,2R,3S,5R,6R)-2-t-butoxycarbonylamino-6-fluoro-3-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.29 (t, J=7.03 Hz, 3H), 1.30 (t, J=7.03Hz, 3H), 1.44 (s, 9H), 2.20-2.48 (m, 3H), 2.77-2.98 (m, 2H), 4.07-4.48(m, 4H), 5.57 (s, 1H). MS (ESI)(Pos) m/z; 398 (M+Na)⁺. [α]_(D) ²²=−14.0°(CHCl₃, c=0.9).

(3) By means of the same method as Reference Example 2(1), 1.65 g of(1R,2R,3S,5R,6R)-2-t-butoxycarbonylamino-6-fluoro-3-trifluoromethanesulfonyloxy-bicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester was yielded from 1.47 g of(1R,2R,3S,5R,6R)-2-t-butoxycarbonylamino-6-fluoro-3-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.25-1.41 (m, 6H), 1.44 (s, 9H) 2.13-2.26(m, 1H), 2.40-2.57 (m, 2H), 2.97-3.20 (m, 1H), 4.14-4.47 (m, 4H), 5.32(s, 1H), 5.99 (d, J=8.35 Hz, 1H). MS (ESI)(Nega) m/z; 506 (M−H)⁻.[α]_(D) ²⁸=+79.8° (CHCl₃, c=0.5).

(4) 313 mg of sodium azide was added to 1.63 g of(1R,2R,3S,5R,6R)-2-t-butoxycarbonylamino-6-fluoro-3-trifluoromethanesulfonyloxy-bicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester dissolved in 16.3 mL of N,N-dimethylformamide, andthe mixture was stirred for 1 hour at room temperature, and then for 20hours at 35° C. 104 mg of sodium azide was further added thereto, andthe mixture was stirred for 18 hours at 35° C. After being diluted with50 mL of diethyl ether, the mixture was washed twice with water and thenwith a saturated aqueous solution of sodium chloride. The organic layerswere dried over anhydrous sodium sulfate. After the desiccant wasfiltered off, the filtrate was concentrated under reduced pressure. Theresidue was purified by column chromatography (silica gel: Wako gelC200, eluent: hexane-ethyl acetate=5:1), thereby yielding 775 mg of(1R,2R,3R,5R,6R)-3-azido-2-t-butoxycarbonylamino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.29 (t, J=7.03 Hz, 3H), 1.33 (t, J=7.03Hz, 3H), 1.45 (s, 9H), 2.21-2.56 (m, 3H), 2.92 (dd, J=7.69, 2.42 Hz,1H), 3.78-3.88 (m, 1H), 4.17-4.41 (m, 4H), 5.01 (s, 1H). MS (ESI)(Pos)m/z; 423 (M+Na) [α]_(D) ²⁶=+0.79° (CHCl₃, c=1.4).

(5) By means of the same method as Reference Example 5(1), 553 mg of(1R,2R,3R,5R,6R)-3-amino-2-t-butoxycarbonylamino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester was yielded from 725 mg of(1R,2R,3R,5R,6R)-3-azido-2-t-butoxycarbonylamino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.30 (t, J=7.03 Hz, 3H), 1.32 (t, J=7.03Hz, 3H), 1.44 (s, 9H), 2.06-2.27 (m, 2H), 2.40-2.55 (m, 1H), 2.61-2.72(m, 1H), 3.28-3.47 (m, 1H), 4.17-4.41 (m, 4H), 5.05 (s, 1H). MS(ESI)(Pos) m/z; 397 (M+Na)⁺. [α]_(D) ²⁷=14.2° (CHCl₃, c=1.4).

(6) 42 μL of pyridine and 123 mg of 3,4-dichlorobenzylbromide were addedto 175 mg of(1R,2R,3R,5R,6R)-3-amino-2-t-butoxycarbonylamino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester dissolved in 0.88 mL of chloroform at ice-cooling,and the mixture was stirred for 3 days at room temperature. A saturatedaqueous solution of sodium chloride was added thereto, and the mixturewas extracted five times with chloroform. The organic layers werecombined and then dried over anhydrous sodium sulfate. After thedesiccant was filtered off, the filtrate was concentrated under reducedpressure. The residue was purified by column chromatography (silica gel:Wako gel C200, eluent:chlorofomm-ethanol=100:1 to 50:1, followed byhexane-ethyl acetate=5:1), thereby yielding 98 mg of(1R,2R,3R,5R,6R)-2-t-butoxycarbonylamino-3-(3,4-dichlorobenzylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.23-1.34 (m, 6H), 1.44 (s, 9H), 2.03-2.26(m, 2H), 2.43 (dd, J=12.97, 7.25 Hz, 1H), 2.83-2.93 (m, 1H), 3.02-3.15(m, 1H), 3.71 (d, J=13.19 Hz, 1H), 3.80 (d, J=13.19 Hz, 1H), 4.12-4.39(m, 4H), 4.82 (s, 1H), 7.11 (dd, J=8.13, 1.98 Hz, 1H), 7.33-7.45 (m,2H). MS (ESI)(Nega) m/z; 531 (M−H)⁻. [α]_(D) ²⁷ 15.1° (CHCl₃, c=0.5).

(7) 2.8 mL of a 4N hydrogen chloride/ethyl acetate solution was added to28 mg of(1R,2R,3R,5R,6R)-2-t-butoxycarbonylamino-3-(3,4-dichlorobenzylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester, and the mixture was stirred for 6 hours atice-cooling, and further stirred for 18 hours at room temperature. Thereaction solution was ice-cooled, and then neutralized with a saturatedaqueous solution of sodium hydrogen carbonate, followed by separation.The aqueous layer was extracted with ethyl acetate. The organic layerswere combined, washed with saturated aqueous solution of sodiumchloride, and then dried over anhydrous sodium sulfate. After thedesiccant was filtered off, the filtrate was concentrated under reducedpressure, thereby yielding 21 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.31 (t, J=7.0 Hz, 3H), 1.34 (t, J=6.2 Hz,3H), 2.03-2.28 (m, 3H), 2.35-2.51 (m, 1H), 2.94-3.08 (m, 1H), 3.77 (s,2H), 4.16-4.40 (m, 4H), 7.12 (d, J=7.9 Hz, 1H), 7.35 (d, J=7.9 Hz, 1H),7.40 (s, 1H). MS (ESI)(Pos) m/z, 433 (M+H)⁺. [α]_(D) ²⁴=−8.4° (CHCl₃,c=0.56).

(8) By means of the same method as Reference Example 2(6), 17 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid was yielded from 28 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (300 MHz, D₂O, TMSP); 2.31-2.77 (m, 4H), 3.59-3.74 (m, 1H), 4.06(d, J=13.5 Hz, 1H), 4.15 (m, J=13.5 Hz, 1H), 7.35 (d, J=7.77 Hz, 1H),7.58-7.64 (m, 2H). MS (ESI)(Nega) 375 (M−H)⁻. [α]_(D) ²⁷=−14.6° (1NNaOH, c=0.29).

Reference Example 6 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-[N,N-(3,4-dichlorobenzyl)methylamino]-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid

(1) 71 mg of potassium carbonate and 64 μL of methyl iodide were addedto 136 mg of(1R,2R,3R,5R,6R)-2-t-butoxycarbonylamino-3-(3,4-dichlorobenzylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester dissolved in 1.36 mL of N,N-dimethylformamide, andthe mixture was stirred for 3 days at room temperature. A saturatedaqueous solution of sodium thiosulfate was added thereto, and themixture was extracted twice with ethyl acetate. The organic layers werecombined, washed with a saturated aqueous solution of sodium chloride,and then dried over anhydrous sodium sulfate. After the desiccant wasfiltered off, the filtrate was concentrated under reduced pressure. Theresidue was purified by column chromatography (silica gel: Wako gel C200(made by Wako Pure Chemical Industries Ltd.), eluent: hexane-ethylacetate=5:1), thereby yielding 126 mg of(1R,2R,3R,5R,6R)-2-t-butoxycarbonylamino-3-[N,N-(3,4-dichlorobenzyl)methylamino]-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.28 (t, J=7.03 Hz, 3H), 1.29 (t, J=7.03Hz, 3H), 1.43 (s, 9H), 2.11 (s, 3H), 2.16-2.58 (m, 3H), 2.80-3.07 (m,2H), 3.29 (d, J=13.62 Hz, 1H), 3.78 (d, J=13.62 Hz, 1H), 4.05-4.43 (m,4H), 4.86 (s, 1H), 7.08 (dd, J=8.35, 1.76 Hz, H), 7.31-7.41 (m, 2H). MS(ESI)(Pos) m/z; 547 (M+H)⁺. [α]_(D) ²=−51.9° (CHCl₃, c=0.5).

(2) By means of the same method as Reference Example. 5(7), 96 mg of(1R,2R,3R,5R,6R)-2-amino-3-[N,N-(3,4-dichlorobenzyl)methylamino]-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester was yielded from 124 mg of(1R,2R,3R,5R,6R)-2-t-butoxycarbonylamino-3-[N,N-(3,4-dichlorobenzyl)methylamino]-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (300 MHz, CDCl₃, TMS); 1.33 (t, J=7.0 Hz, 3H), 1.35 (t, J=7.0 Hz,3H), 2.06 (s, 3H), 2.03-2.21 (m, 1H), 2.23-2.60 (m, 3H), 2.68-2.84 (m,1H), 3.22 (d, J=14.1 Hz, 1H), 3.97 (d, J=14.1 Hz, 1H), 4.18-4.32 (m,4H), 7.07 (dd, J=8.1, 2.0 Hz, 1H), 7.30-7.39 (m, 2H). MS (ESI)(Pos) m/z;447 (M+H)⁺. [α]_(D) ²³=−24.9° (CHCl₃, c=0.84).

(3) By means of the same method as Reference Example 2(6), 62 mg of(1R,2R,3R,5R,6R)-2-amino-3-[N,N-(3,4-dichlorobenzyl)methylamino]-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid was yielded from 94 mg of(1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorobenzyl)methylamino]-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (300 MHz, D₂O, TMSP); 2.31-2.41 (m, 1H), 2.45-2.53 (m, 1H), 2.64(s, 3H), 2.73-2.82 (m, 2H), 3.72-3.82 (m, 1H), 4.01 (d, J=13.4 Hz, 1H),4.27 (d, J=13.4 Hz, 1H), 7.35-7.41 (m, 1H), 7.61-7.69 (m, 2H). MS(ESI)(Nega) m/z; 389 (M−H)⁻. [α]_(D) ²⁴=_(—)35.2° (1N NaOH, c=0.51).

Reference Example 7 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzoylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid

(1) 7.3 μL of pyridine and 14 mg of 3,4-dichlorobenzoyl chloride wereadded to 17 mg of(1R,2R,3R,5R,6R)-3-amino-2-t-butoxycarbonylamino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester dissolved in 0.17 mL of chloroform, and the mixturewas stirred for 3 hours at room temperature. The reaction solution wasconcentrated under reduced pressure. The residue was purified by columnchromatography (silica gel: Wako gel C200, eluent:chloroform-ethanol=100:1), thereby yielding 21 mg of(1R,2R,3R,5R,6R)-2-t-butoxycarbonylamino-3-(3,4-dichlorobenzoylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester

¹H-NMR (200 MHz, CDCl₃, TMS); 1.19 (t, J=7.03 Hz, 3H), 1.31 (t, J=7.25Hz, 3H), 1.41 (s, 9H), 2.21-2.64 (m, 3H), 2.82-2.91 (m, 1H), 4.07-4.37(m, 4H), 4.58-4.75 (m, 1H), 6.20 (s, 1H), 6.39-6.50 (m, 1H), 7.46-7.57(m, 2H), 7.80-7.85 (m, 1H). MS (ESI)(Nega) m/z; 545 (M−H)⁻. [α]_(D)²³=+12.1° (CHCl₃, c=0.9).

(2) By means of the same method as Reference Example 5(7), 85 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzoylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester was yielded from 107 mg of(1R,2R,3R,5R,6R)-2-t-butoxycarbonylamino-3-(3,4-dichlorobenzoylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.30 (t, J=6.8 Hz, 3H), 1.33 (t, J=7.0 Hz,3H), 2.09-2.43 (m, 3H), 2.53-2.38 (m, 1H), 4.19-4.38 (m, 4H), 4.52-4.71(m, 1H), 7.48-7.55 (m, 2H), 7.75-7.84 (m, 1H). MS (ESI)(Pos) m/z; 469(M+Na)⁺. [α]_(D) ²⁷=+8.3° (CHCl₃, c=0.93).

(3) By means of the same method as Reference Example 2(6), 24 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzoylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid was yielded from 48 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzoylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethyl ester.

¹H-NMR (300 MHz, D₂O, TMSP); 2.33-2.42 (m, 2H), 2.57-2.67 (m, 2H),4.46-4.55 (m, 1H), 7.58-7.68 (m, 2H), 7.87-7.90 (m, 1H). MS (ESI)(Nega)m/z; 389 (M−H)⁻. [α]_(D) ²⁸=+6.0° (CHCl₃, c=0.34).

Reference Example 8 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzoyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid

(1) 234 mg of 3,4-dichlorobenzoyl chloride was added to 202 mg of(1R,2R,3R,5R,6R)-2-azide-6-fluoro-3-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylicacid 2-benzyl ester 6-ethyl ester dissolved in 3.7 mL of pyridine, andthe mixture was stirred for 28 hours at room temperature under anitrogen atmosphere. 100 mL of ethyl acetate was added to the reactionsolution, and the ethyl acetate solution was washed with a saturatedaqueous solution of copper sulfate and with water, and then dried overanhydrous sodium sulfate. After the desiccant was filtered off, thefiltrate was concentrated under reduced pressure, and the residue waspurified by column chromatography (silica gel: Wako gel C200, eluent:hexane-ethyl acetate=10:1), thereby yielding 298 mg of(1R,2R,3R,5R,6R)-2-azide-3-(3,4-dichlorobenzoyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 2-benzyl ester 6-ethyl ester.

¹H-NMR (200 MHz, CDCl₃); 1.35 (t, J=7.3 Hz, 3H), 2.35-2.55 (m, 3H),2.77-2.87 (m, 1H), 4.31 (q, J=7.3 Hz, 2H), 5.24-5.46 (m, 3H), 7.28-7.60(m, 6H), 7.90-8.20 (m, 2H). MS (ESI)(Pos) m/z; 558 (M+Na)⁺.

(2) By means of the same method as Reference Example 2(5), 218 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzoyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 2-benzyl ester 6-ethyl ester was yielded from 298 mg of(1R,2R,3R,5R,6R)-2-azide-3-(3,4-dichlorobenzoyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 2-benzyl ester 6-ethyl ester.

¹H-NMR (200 MHz, CDCl₃, TMS); 1.33 (t, J=7.3 Hz, 3H), 2.25-2.80 (m, 4H),4.28 (q, J=7.3 Hz, 2H), 5.05-5.13 (m, 1H), 5.16 (d, J=12.3 Hz, 1H), 5.31(d, J=12.3 Hz, 1H), 7.24-7.36 (m, 5H), 7.44 (d, J=8.4 Hz, 1H), 7.57 (dd,J=8.4, 2.20 Hz, 1H), 7.90 (d, J=2.2 Hz, 1H). MS (ESI)(Pos) m/z; 532(M+Na)⁺. [α]_(D) ²²=+31.8° (CHCl₃, c=0.55).

(3) 15 mg of 5% palladium carbon was added to 218 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzoyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 2-benzyl ester 6-diethyl ester dissolved in 10 mL of ethanol, andthe mixture was stirred for 50 minutes at room temperature under ahydrogen atmosphere. After the palladium carbon was filtered off throughcelite, the filtrate was concentrated under reduced pressure, and theobtained solids were dissolved in a mixture of 2 mL of tetrahydrofuranand 1 mL of water. 10 mg of lithium hydroxide monohydrate was addedthereto at ice-cooling, and the mixture was stirred for 30 minutes. 0.5mL of 1N hydrochloric acid was further added thereto, and after beingdiluted to 50 mL with water, the mixture was purified by ion exchangeresin (AG 50W-X8 Resin (H form), eluent: water, a 40% aqueous solutionof tetrahydrofuran and a 10% aqueous solution of pyridine), therebyyielding 25 mg of(1R,2R,3R,5R,6R)-2-amino-(3,4-dichlorobenzoyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid. ¹H-NMR (300 MHz, D₂O, TMSP); 2.40-2.45 (m, 2H), 2.71-2.77 (m, 2H),5.28-5.36 (m, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.89 (d, J=8.5 Hz, 1H), 8.16(s, 1H). MS (ESI)(Nega) m/z; 390 (M−H)⁻. [α]_(D) ²⁸=+9.20 (MeOH,c=0.23).

Example 1 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-methyl ester hydrochloride

0.65 mL of thionyl chloride was added to 800 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid suspended in 8 mL of methanol at ice-cooling, and the mixture wasstirred for 4 hours at 50° C. The mixture was further stirred for 3hours at room temperature, and methanol was distilled under reducedpressure. After 20 mL of hexane was added to the residue, the mixturewas stirred for 2 hours, and then the solids were filtered. The solidswere washed with diisopropyl ether and hexane, thereby yielding 820 mgof(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-methyl ester hydrochloride.

Example 2 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-pentyl ester

225 μL of thionyl chloride was added to 300 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid suspended in 4 mL of pentanol at ice-cooling, and the mixture wasstirred for 3 hours at 50° C. After standing to cool, the reactionsolution was concentrated to about 1 mL under reduced pressure, 200 mLof hexane was added thereto, and the mixture was stirred for 12 hours.After the precipitated solids were filtered, the residue was purified byreverse phase column chromatography (Wako gel 50C18 (made by Wako PureChemical Industries Ltd.), eluent: water to a 50% aqueous solution ofacetonitrile), thereby yielding 188 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-pentyl ester.

Example 3 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethoxycarbonylmethyl ester

4.4 mg of lithium hydroxide hydrate was added to 36 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid suspended in a mixture of 0.8 mL of tetrahydrofuran and 0.4 mL ofwater at room temperature, and the mixture was stirred for 10 minutes.After the mixture was concentrated under reduced pressure, 0.36 mL ofN,N-dimethylformamide and 21 μL of ethyl bromoacetate were added to theresidue, and then the mixture was stirred for 2 hours at roomtemperature, 2 hours at 50° C. and 4 hours at 90° C. Water was addedthereto, and the reaction solution was extracted with ethyl acetate. Theorganic layers were dried over anhydrous sodium sulfate. After thedesiccant was filtered off, the filtrate was concentrated under reducedpressure. The residue was purified by thin layer chromatography (silicagel: 60F₂₅₄ (made by Merck & Co., Inc), eluent: hexane-ethylacetate=1:1), thereby yielding 12 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid diethoxycarbonylmethyl ester.

Example 4 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-(2-azidoethyl) ester

6 mg of sodium azide was added to 18 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-(2-iodoethyl) ester dissolved in a mixture of 0.2 mL ofN,N-dimethylformamide and 0.02 mL of water at room temperature, and themixture was stirred for 12 hours at 60° C. After standing to cool, thesolvent was distilled under reduced pressure, and the residue waspurified by reverse phase column chromatography (Wako gel 50C18, eluent:water to a 70% aqueous solution of acetonitrile), thereby yielding 7 mgof(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.0]hexane-2,6-dicarboxylicacid 6-(2-azidoethyl) ester

Example 5 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-(2-aminoethyl) ester

20 μL of a IM trimethylphosphine/tetrahydrofuran solution was added to 6mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-(2-azidoethyl) ester dissolved in a mixture of 0.15 mL oftetrahydrofuran and 0.02 mL of water at room temperature, and themixture was stirred for 13 hours. After the solvent was distilled underreduced pressure, the residue was purified by reverse phase columnchromatography (Wako gel 50C18 (made by Wako Pure Chemical IndustriesLtd.), eluent: water to a 50% aqueous solution of acetonitrile), and theobtained solids were further washed with tetrahydrofuran, therebyyielding 2 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-(2-aminoethyl) ester.

The structure and physical data of the compounds described in Examples1, 2, 3, 4 and 5, as well as those of compounds yielded by means of thesame methods are shown in table 1 below.

TABLE 1 The structure and pysical data of the compounds described inExamples 1, 2, 3, 4 and 5

No. X Y R¹ R² NMR (TMS) MS Example  1*¹ F

Me H (200 MHz, CD₃OD) 2.37-2.63 (m, 4 H) 3.81 (s, 3 H) 4.03-4.18 (m, 1H) 4.55 (s, 2 H) 7.26 (dd, J = 8.3, 1.8 Hz, 1 H) 7.48 (d, J = 8.3 Hz, 1H) 7.53 (d, J = 1.8 Hz, 1 H) ESI (Nega) 390 (M − H)⁻ 1  2*¹ F

n-Pr H (200 MHz, CD₃OD) 0.96 (t, J = 6.8 Hz, 3 H) 1.69 (sextet, J = 6.8Hz, 2 H) 2.37-2.65 (m, 4 H) 4.02-4.12 (m, 1 H) 4.17 (t, J = 6.6 Hz, 2 H)4.51 (d, J = 11.9 Hz, 1 H) 4.59 (d, J = 11.9 Hz, 1 H) 7.27 (dd, J = 8.4,1.8 Hz, 1 H) 7.48 (d, J = 8.4 Hz, 1 H) 7.54 (d, J = 1.8 Hz, 1 H) ESI(Nega) 418 (M − H)⁻ 1  3*¹ F

i-Pr H (500 MHz, CD₃OD) 1.28 (d, J = 5.8 Hz, 6 H) 2.38-2.44 (m, 2 H)2.54-2.62 (m, 2 H) 4.07-4.12 (m, 1 H) 4.53 (d, J = 11.6 Hz) 4.57 (d, J =11.6 Hz) 5.07-5.12 (m, 1 H) 7.26 (dd, J = 1.8, 8.6 Hz, 1 H) 7.48 (d, J =8.6 Hz, 1 H) 7.52 (d, J = 1.8 Hz, 1 H) ESI (Nega) 418 (M − H)⁻ 1  4*¹ F

n-Bu H (500 MHz, CD₃OD) 0.95 (t, J = 7.9 Hz, 3 H) 1.40 (sextet, J = 7.9Hz, 2 H) 1.65 (quintet, J = 7.9 Hz, 2 H) 2.38-2.44 (m, 2 H) 2.53-2.62(m, 2 H) 4.06-4.10 (m, 1 H) 4.22 (t, J = 6.7 Hz, 2 H) 4.52 (d, J = 11.6Hz, 1 H) 4.58 (d, J = 11.6 Hz, 1 H) 7.26 (dd, J = 1.8, 7.9 Hz, 1 H) 7.47(d, J = 7.9 Hz, 1 H) 7.53 (d, J = 1.8 Hz, 1 H). ESI  (Nega) 432 (M − H)⁻1  5*¹ F

i-Bu H (300 MHz, CD₃OD) 0.95 (d, J = 6.7 Hz, 6 H) 1.90-2.03 (m, 1 H)2.35-2.66 (m, 4 H) 4.00 (d, J = 6.5 Hz, 2 H) 4.03-4.20 (m, 1 H) 4.52 (d,J = 10.7 Hz, 1 H) 4.58 (d, J = 10.7 Hz, 1 H) 7.26 (dd, J = 8.2, 1.9 Hz,1 H) 7.47 (d, J = 8.2 Hz, 1 H) 7.53 (d, J = 1.9 Hz, 1 H) ESI (Nega) 432(M − H)⁻ 2  6 F

n-Pentyl H (300 MHz, CD₃OD) 0.88-0.96 (m, 3 H) 1.29-1.45 (m, 4 H)1.63-1.72 (m, 2 H) 2.33- 2.64 (m, 4 H) 3.99-4.06 (m, 1 H) 4.20 (t, J =6.6 Hz, 2 H) 4.48 (d, J = 11.2 Hz, 1 H) 4.60 (d, J = 11.2 Hz, 1 H) 7.29(dd, J = 8.2, 2.0 Hz, 1 H) 7.46 (d, J = 8.2 Hz, 1 H) 7.55 (d, J = 2.0Hz, 1 H) ESI (Nega) 446 (M − H)⁻ 2  7 F

n-Decyl H (300 MHz, CD₃OD) 0.87-0.92 (m, 3 H) 1.23-1.41 (m, 14 H)1.60-1.71 (m, 2 H) 2.31-2.65 (m, 4 H) 3.97-4.07 (m, 1H) 4.19 (t, J = 6.6Hz, 2 H) 4.47 (d, J = 12.0 Hz, 1 H) 4.59 (d, J = 12.0 Hz, 1 H) 7.28 (dd,J = 8.0, 2.3 Hz, 1 H) 7.45 (d, J = 8.0 Hz, 1 H) 7.54 (d, J = 2.3 Hz, 1H) ESI (Nega) 516 (M − H)⁻ 2  8*¹ F

Cyclohexyl H (500 MHz, CD₃OD) 1.29-1.59 (m, 6 H) 1.71-1.76 (m, 2 H)1.85-1.90 (m, 2 H) 2.39-2.45 (m, 2 H) 2.55-2.63 (m, 2 H) 4.08-4.12 (m, 1H) 4.53 (d, J = 12.2 Hz, 1 H) 4.57 (d, J = 12.2 Hz, 1 H) 7.26 (dd, J =1.8, 8.6 Hz, 1 H) 7.48 (d, J = 8.6 Hz, 1 H) 7.52 (d, J = 1.8 Hz, 1 H)ESI (Nega) 472 (M − H)− 1  9*¹ F

H (500 MHz, CD₃OD) 0.97-1.05 (m, 2 H) 1.16-1.33 (m, 3 H) 1.63-1.77 (m, 6H) 2.40-2.46 (m, 2 H) 2.58-2.60 (m, 2 H) 4.03 (d, J = 6.7 Hz, 2 H)4.09-4.13 (m, 1 H) 4.54 (d, J = 11.6 Hz, 1 H) 4.58 (d, J = 11.6 Hz, 1 H)7.26 (dd, J = 1.8, 8.6 Hz, 1 H) 7.48 (d, J = 8.6 Hz, 1 H) 7.52 (d, J =1.8 Hz, 1 H) ESI (Nega) 472 (M − H)⁻ 1 10 F

Benzyl H (300 MHz, CD₃OD) 2.30-2.61 (m, 4 H) 3.95-4.05 (m, 1 H) 4.46 (d,J = 11.8 Hz, 1 H) 4.58 (d, J = 11.8 Hz, 1 H) 5.23 (s, 2 H) 7.28 (dd, J =8.2, 1.9 Hz, 1 H) 7.33-7.41 (m, 5 H) 7.45 (d, J = 8.2 Hz, 1 H) 7.53 (d,J = 1.9 Hz, 1 H) ESI (Nega) 466 (M − H)⁻ 2 11 F

H (300 MHz, CD₃OD) 2.26-2.66 (m, 4 H) 3.99-4.08 (m, 1 H) 4.47 (d, J =11.8 Hz, 1 H) 4.59 (d, J = 11.8 Hz, 1 H) 4.69 (d, J = 5.7 Hz, 2 H)5.22-5.41 (m, 2 H) 5.87-6.03 (m, 1 H) 7.28 (dd, J = 8.2, 1.7 Hz, 1 H)7.45 (d, J = 8.2 Hz, 1 H) 7.54 (d, J = 1.7 Hz, 1 H) ESI (Nega) 416 (M −H)⁻ 2 12 F

H (300 MHz, CD₃OD) 2.33-2.68 (m, 4 H) 2.99-3.05 (m, 1 H) 3.97-4.10 (m, 1H) 4.48 (d, J = 12.0 Hz, 1 H) 4.60 (d, J = 12.0 Hz, 1 H) 7.24-7.33 (m, 1H) 7.42-7.58 (m, 2 H) ESI (Nega) 414 (M − H)⁻ 2 13 F

H (300 MHz, CD₃OD) 2.36-2.68 (m, 4 H) 3.75-3.81 (m, 2 H) 3.99-4.08 (m, 1H) 4.41- 4.50 (m, 3 H) 4.61 (d, J = 12.0 Hz, 1 H) 7.29 (dd, J = 8.2, 2.0Hz, 1 H) 7.46 (d, J = 8.2 Hz, 1 H) 7.55 (d, J = 2.0 Hz, 1 H) ESI (Nega)438 (M − H)⁻ 2 14 F

H (300 MHz, CD₃OD) 2.36-2.96 (m, 4 H) 3.62 (t, J = 5.4 Hz, 2 H)3.98-4.07 (m, 1 H) 4.48 (d, J = 11.7 Hz, 1 H) 4.50 (t, J = 5.4 Hz, 2 H)4.60 (d, J = 11.7 Hz, 1 H) 7.25-7.32 (m, 1 H) 7.43-7.57 (m, 2 H) ESI(Nega) 482 (M − H)⁻ 2 15 F

H (300 MHz, CD₃OD) 2.41-2.67 (m, 4 H) 3.40 (t, J = 6.6 Hz, 2 H)4.00-4.09 (m, 1 H) 4.40-4.63 (m, 4 H) 7.30 (dd, J = 8.6, 1.8 Hz, 1 H)7.47 (d, J = 8.6 Hz, 1 H) 7.56 (d, J = 1.8 Hz, 1 H) ESI (Pos) 532 (M +H)⁻ 2 16 F

H (300 MHz, CD₃OD) 2.36-2.66 (m, 4 H) 3.71-3.78 (m, 2 H) 3.98-4.07 (m, 1H) 4.22- 4.28 (m, 2 H) 4.48 (d, J = 12.0 Hz, 1 H) 4.59 (d, J = 12.0 Hz,1 H) 7.28 (dd, J = 8.3, 1.9 Hz, 1 H) 7.45 (d, J = 8.3 Hz, 1 H) 7.54 (d,J = 1.9 Hz, 1 H) ESI (Nega) 420 (M − H)⁻ 2 17 F

*2 (200 MHz, CDCl₃) 1.29 (t, J = 7.3 Hz, 6 H) 2.25-2.61 (m, 4 H)3.75-3.91 (m, 1 H) 4.23 (q, J = 7.3 Hz, 4 H) 4.43-4.87 (m, 6 H) 7.08(dd, J = 7.9, 2.2 Hz, 1 H) 7.34-7.42 (m, 2 H) ESI (Pos) 572 (M + Na)⁺ 318 F

H (300 MHz, CD₃OD) 2.19-2.63 (m, 4 H) 3.48-3.61 (m, 2 H) 3.80-3.98 (m, 1H) 4.28- 4.37 (m, 2 H) 4.48 (d, J = 12.3 Hz, 1 H) 4.66 (d, J = 12.3 Hz,1 H) 7.25-7.33 (m, 1 H) 7.41-7.48 (m, 1 H) 7.53-7.57 (m, 1 H) ESI (Nega)445 (M − H)⁻ 4 19 F

H (300 MHz, CD₃OD) 2.12-2.65 (m, 4 H) 3.34-3.45 (m, 2 H) 3.57-3.69 (m, 2H) 3.81- 3.96 (m, 1 H) 4.49 (d, J = 12.1 Hz, 1 H) 4.65 (d, J = 12.1 Hz,1 H) 7.25-7.35 (m, 1 H) 7.42-7.48 (m, 1 H) 7.53-7.58 (m, 1 H) ESI (Nega)419 (M − H)⁻ 5 20 H

Et H (300 MHz, CD₃OD) 1.24 (t, J = 7.1 Hz, 3 H) 1.97-2.01 (m, 1 H)2.15-2.51 (m, 4 H) 3.76-3.80 (m, 1 H) 4.13 (q, J = 7.20 Hz, 2 H) 4.50(s, 2 H) 7.24 (dd, J = 8.2, 1.9 Hz, 1 H) 7.48 (d, J = 8.2 Hz, 1 H) 7.51(d, J = 1.9 Hz, 1 H). ESI (Nega) 386 (M − H)⁻ 2 21 F

i-Pr H (300 MHz, CD₃OD) 1.26 (d, J = 7.0 Hz, 6 H) 2.21-2.38 (m, 3 H)2.50-2.63 (m, 1 H) 2.99-3.11 (m, 1 H) 3.76 (d, J = 12.9 Hz, 1 H) 3.81(d, J = 12.9 Hz, 1 H) 5.00-5.13 (m, 1 H) 7.24-7.32 (m, 1 H) 7.42-7.56(m, 2 H) ESI (Pos) 458 (M + Na)⁺ 2 22 F

i-Bu H (300 MHz, CD₃OD) 0.94 (d, J = 6.7 Hz, 6 H) 1.86-1.99 (m, 1 H)2.23-2.62 (m, 4 H) 2.99-3.08 (m, 1 H) 3.76 (d, J = 13.0 Hz, 1 H) 3.81(d, J = 13.0 Hz, 1 H) 3.96 (d, J = 6.7 Hz, 2 H) 7.27 (dd, J = 8.4, 1.9Hz, 1 H) 7.45 (d, J = 8.4 Hz, 1 H) 7.52 (d, J = 2.0 Hz, 1 H) ESI (Pos)472 (M + Na)⁺ 2 23 F

n-decyl H (300 MHz, CD₃OD) 0.89-0.98 (m, 3 H) 1.21-1.45 (m, 14 H)1.56-1.74 (m, 2 H) 2.19-2.42 (m, 3 H) 2.47-2.68 (m, 1 H) 2.95-3.13 (m, 1H) 3.75-3.85 (m, 2 H) 4.17 (t, J = 6.5 Hz, 2 H) 7.21-7.34 (m, 1 H)7.42-7.56 (m, 2 H) ESI (Pos) 556 (M + Na)⁺ 2 24 F

Benzyl H (300 MHz, CD₃OD) 2.19-2.43 (m, 3 H) 2.47-2.63 (m, 1 H)2.96-3.12 (m, 1 H) 3.75 (d, J = 13.2 Hz, 1 H) 3.81 (d, J = 13.2 Hz, 1 H)5.22 (s, 2 H) 7.23-7.54 (m, 8 H) ESI (Nega) 482 (M − H)⁻ 2*¹hydrochloride salt *²CH₃CH₂COOCH₂CH₃

Example 6 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-carboxylate6-diethylcarbamoylmethyl ester

6.7 mL of saturated sodium hydrogen carbonate was added to 740 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid suspended in 2.6 mL of dioxane, and the mixture wasstirred for 10 minutes at room temperature. 0.41 mL of allylchloroformate was added dropwise thereto, and the solution was stirredfor 12 hours at room temperature. After 2.6 mL of water was added to thereaction solution, the aqueous layer was washed with ethyl acetate,acidified with 1N hydrochloric acid in an ice bath, and then extractedtwice with ethyl acetate. The ethyl acetate layers were combined, driedover anhydrous sodium sulfate, and then concentrated under reducedpressure, thereby yielding 930 mg of(1R,2R,3R,5R,6R)-2-allyloxycarbonylamino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid.

¹H-NMR (300 MHz, CD₃OD, TMS); 2.15-2.53 (m, 3H) 2.89-3.01 (m, 1H)4.06-4.19 (m, 1H) 4.46 (d, J=11.7 Hz, 1H) 4.55 (d, J=4.8 Hz, 1H) 4.71(d, J=11.7 Hz, 1H) 5.16-5.20 (m, 1H) 5.29-5.36 (m, 1H) 5.89-5.99 (m, 1H)7.22 (dd, J=8.2, 2.0 Hz, 1H) 7.44 (d, J=8.2 Hz, 1H) 7.48 (d, J=2.0 Hz,1H). MS (ESI)(Nega) m/z; 460 (M−H)⁻.

A mixture of 380 mg of(1R,2R,3R,5R,6R)-2-allyloxycarbonylamino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid, 109 mg of paraformaldehyde and 8 mg of paratoluenesulfonic acidmonohydrate dissolved in 10 mL of benzene was heated to reflux for 3.5hours using a Dean-Stark distillation trap. After standing to cool, themixture was diluted with ethyl acetate, and the ethyl acetate solutionwas washed with water. The ethyl acetate layer was dried over anhydroussodium sulfate, and then concentrated under reduced pressure, therebyyielding 370 mg of(1′R,2′R,3′R,5′R,6′R)-3′-(3,4-dichlorobenzyloxy)-6′-fluoro-3-allyloxycarbonyl-5-oxo-oxazolidinone-4-spiro-2′-bicyclo[3.1.0]hexane-6′-carboxylate.

¹H-NMR (300 MHz, CDCl₃, TMS); 2.07-2.54 (m, 4H) 4.17-4.24 (m, 1H) 4.39(d, J=12.3 Hz, 1H) 4.52 (d, J=12.3 Hz, 1H) 4.63 (d, J=6.2 Hz, 2H) 5.23(d, J=4.4 Hz, 1H) 5.28-5.54 (m, 2H) 5.53 (d, J=4.5 Hz, 1H) 5.85-5.98 (m,1H) 7.07 (dd, J=8.2, 1.9 Hz, 1H) 7.32 (d, J=1.9 Hz, 1H) 7.41 (d, J=8.2Hz, 1H). MS (ESI)(Nega) m/z; 472 (M−H)⁻.

37 mg of potassium carbonate and 37 μL of N,N-diethylchloroacetoamidewere added to 58 mg of(1′R,2′R,3′R,5′R,6′R)-3′-(3,4-dichlorobenzyloxy)-6′-fluoro-3-allyloxycarbonyl-5-oxo-oxazolidinone-4-spiro-2′-bicyclo[3.1.0]hexane-6′-carboxylatedissolved in 2 mL of N,N-dimethylformamide, and the mixture was stirredfor 15 hours at room temperature. After the mixture was diluted withethyl acetate, the ethyl acetate layer was washed with water and with asaturated aqueous solution of sodium chloride, and then dried overanhydrous sodium sulfate. After the drying agent was filtered off, thefiltrate was concentrated under reduced pressure, and the residue waspurified by column chromatography (silica gel: silica gel 60N (KantoChemical Co., Inc), eluent: hexane-ethyl acetate=1:2), thereby yielding60 mg of(1′R,2′R,3′R,5′R,6′R)-3′-(3,4-dichlorobenzyloxy)-6′-fluoro-3-allyloxycarbonyl-5-oxo-oxazolidinone-4-spiro-2′-bicyclo[3.1.0]hexane-6′-carboxylate6-(N,N-diethylaminocarbonylmethyl) ester.

¹H-NMR (300 MHz, CDCl₃, TMS); 1.12 (t, J=7.23 Hz, 3H) 1.23 (t, J=7.2 Hz,3H) 2.21-2.60 (m, 4H) 3.23 (q, J=7.2 Hz, 2H) 3.38 (q, J=7.2 Hz, 2H)4.19-4.27 (m, 1H) 4.38 (d, J=12.3 Hz, 1H) 4.52 (d, J=12.3 Hz, 1H)4.63-4.65 (m, 2H) 4.74 (d, J=14.1 Hz, 1H) 4.85 (m, J=14.1 Hz, 1H) 5.23(d, J=4.3 Hz, 1H) 5.24-5.33 (m, 2H) 5.51 (d, J=4.3 Hz, 1H) 5.87-6.00 (m,1H) 7.07 (dd, J=8.2, 2.0 Hz, 1H) 7.31 (d, J=2.0 Hz, 1H) 7.40 (d, J=8.2Hz, 1H). MS (ESI)(Pos) m/z; 609 (M+Na)⁺.

46 mg of 1,3-dimethylbarbituric acid and 4 mg oftetrakis(triphenylphosphine) palladium were added to 58 mg of(1′R,2′R,3′R,5′R,6′R)-3′-(3,4-dichlorobenzyloxy)-6′-fluoro-3-allyloxycarbonyl-5-oxo-oxazolidinone-4-spiro-2′-bicyclo[3.1.0]hexane-6′-carboxylate-6-(N,N-diethylaminocarbonylmethyl)esterdissolved in chloroform under a nitrogen atmosphere, and the mixture wasstirred for 1.5 hours at 40° C. After the reaction solution wasconcentrated under reduced pressure, ethyl acetate was added to theresidue, and the mixture was stirred for 1 hour at room temperature.After the precipitated solids were filtered off, the filtrate wasconcentrated under reduced pressure and the obtained residue waspurified by reverse phase chromatography (Wako gel 50C18 (made by WakoPure Chemical Industries Ltd.) eluent: water to a 50% aqueous solutionof acetonitrile), and then the obtained solids were further washed withethyl acetate, thereby yielding 5 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-carboxylicacid-6-(N,N-diethylaminocarbonylmethyl)ester.

Example 7 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-(4-fluorobenzyl)ester

23 μL of thionyl chloride was added to 30 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid suspended in 0.3 mL of 4-fluorobenzyl alcohol at room temperature,and the mixture was stirred for 3 days at 60° C. After standing to cool,the reaction solution was purified by reverse phase chromatography (Wakogel 50C18 (made by Wako Pure Chemical Industries Ltd.) eluent: water, a70% aqueous solution of acetonitrile), thereby yielding 5 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-(4-fluorobenzyl)ester.

The structure and physical data of the compounds described in Examples 6and 7, as well as those of compounds yielded by means of the samemethods are shown in table 2 below.

TABLE 2 The structure and physical data of the compounds described inExamples 6 and 7

NMR MS (300 MHz, TMS, ESI No. X Y R¹ R² CD3OD) (Nega) Example 25 F

H 2.31-2.63 (m, 4 H) 3.79 (s, 3 H) 3.96-4.06 (m, 1 H) 4.46 (d, J = 11.7Hz, 1 H) 4.59 (d, J = 11.7 Hz, 1 H) 5.20 (s, 2 H) 6.85-6.97 (m, 3 H)7.22-7.31 (m, 2 H) 7.41-7.56 (m, 2 H) 496 (M − H)⁻ 7 26 F

H 2.30-2.63 (m, 4 H) 3.79 (s, 3 H) 3.95-4.03 (m, 1 H) 4.46 (d, J = 12.4Hz, 1 H) 4.58 (d, J = 12.4 Hz, 1 H) 5.16 (s, 2 H) 6.90 (d, J = 8.9 Hz, 2H) 7.29 (m, 3 H) 7.44 (d, J = 8.2 Hz, 1 H) 7.53 (d, J = 1.9 Hz, 1 H) 496(M − H)⁻ 6 27 F

H 2.30-2.65 (m, 4 H) 3.95-4.05 (m, 1 H) 4.46 (d, J = 12.3 Hz, 1 H) 4.58(d, J = 12.3 Hz, 1 H) 5.21 (s, 1 H) 7.06-7.14 (m, 2 H) 7.25-7.30 (m, 1H) 7.38-7.46 (m, 3 H) 7.51-7.55 (m, 1 H) 484 (M − H)⁻ 7 28 F

H 1.27 (t, J = 7.1 Hz, 3 H) 2.42-2.68 (m, 4 H) 3.98-4.08 (m, 1 H) 4.22(q, J = 7.1 Hz, 2 H) 4.48 (d, J = 12.0 Hz, 1 H) 4.60 (d, J = 12.0 Hz, 1H) 4.76 (s, 2 H) 7.29 (dd, J = 8.2, 2.0 Hz, 1 H) 7.45 (d, J = 8.2 Hz, 1H) 7.55 (d, J = 2.0 Hz, 1 H) 462 (M − H)⁻ 6 29 F

H 1.13 (t, J = 7.1 Hz, 3 H) 1.23 (t, J = 7.1 Hz, 3 H) 2.42-2.68 (m, 4 H)3.32-3.43 (m, 4 H) 3.98-4.09 (m, 1 H) 4.48 (d, J = 12.3 Hz, 1 H) 4.60(d, J = 12.3 Hz, 1 H) 4.94 (s, 2 H) 7.26-7.32 (m, 1 H) 7.45 (d, J = 8.2Hz, 1 H) 7.53-7.56 (m, 1 H) 489 (M − H)⁻ 6 30 F

H (300 MHz, D2O, TMSP) 2.47-1.58 (m, 4 H) 3.33-3.41 (m, 4 H) 3.52-3.58(m, 2 H) 3.92-4.13 (m, 5 H) 4.48-4.64 (m, 4 H) 7.29 (dd, J = 8.2, 1.9Hz, 1 H) 7.53-756 (m, 2 H) 489 (M − H)⁻ 6 31 F

Farnesyl H 1.60 (s, 6 H) 1.66 (s, 3 H) 1.73 (s, 3 H) 1.92-2.18 (m, 8 H)2.22-2.61 (m, 4 H) 3.83-3.96 (m, 1 H) 4.46 (d, J = 12.1 Hz, 1 H) 4.63(d, J = 12.1 Hz, 1 H) 4.70 (d, J = 7.2 Hz, 2 H) 5.02-5.16 (m, 2 H)5.30-5.39 (m, 1 H) 7.24-7.32 (m, 1 H) 7.44 (d, J = 8.2 Hz, 1 H)7.51-7.57 (m, 1 H) 580 (M − H)⁻ 6 32 F

H 1.28 (t, J = 7.1 Hz, 1.5 H) 1.29 (t, J = 7.1 Hz, 1.5 H) 1.51 (d, J =5.4 Hz, 1.5 H) 1.52 (d, J = 5.4 Hz, 1.5 H) 2.49 (m, 4 H) 4.01 (m, 1 H)4.20 (q, J = 7.1 Hz, 2 H) 4.47 (d, J = 11.8 Hz, 1 H) 4.59 (m, J = 11.8Hz, 1 H) 6.76 (q, J = 5.4 Hz, 1 H) 7.28 (dd, J = 8.2, 2.0 Hz, 1 H) 7.45(d, J = 8.2 Hz, 1 H) 7.54 (d, J = 2.0 Hz, 1 H) 492 (M − H)⁻ 6 33 F

H 1.27 (d, J = 6.2 Hz, 6 H) 1.51 (d, J = 6.2 Hz, 3 H) 2.31-2.66 (m, 4 H)3.98-4.05 (m, 1 H) 4.47 (d, J = 11.8 Hz, 1 H) 4.59 (d, J = 11.8 Hz, 2 H)6.76 (q, J = 6.2 Hz, 1 H) 7.28 (dd, J = 8.2, 2.0 Hz, 1 H) 7.45 (d, J =8.2 Hz, 1 H) 7.54 (d, J = 2.0 Hz, 1 H) 506 (M − H)⁻ 6 34 F

H 1.21-1.61 (m, 8 H) 1.68-1.96 (m, 4 H) 2.30-2.66 (m, 4 H) 3.98-4.07 (m,1 H) 4.47 (d, J = 12.0 Hz, 1 H) 4.57-4.67 (m, 2 H) 6.76 (q, J = 5.3 Hz,1 H) 7.28 (dd, J = 8.3, 2.0 Hz, 1 H) 7.45 (d, J = 8.3 Hz, 1 H) 7.54 (d,J = 2.0 Hz, 1 H) 546 (M − H)⁻ 6 35 F

H 2.18 (s, 3 H) 2.32-2.66 (m, 4 H) 3.95-4.08 (m, 1 H) 4.47 (d, J = 11.8Hz, 1 H) 4.59 (d, J = 11.8 Hz, 1 H) 5.06 (s, 2 H) 7.25-7.32 (m, 1 H)7.45 (d, J = 8.2 Hz, 1 H) 7.51-7.57 (m, 1 H) 488 (M − H)⁻ 6 36 F

H 2.34-2.67 (m, 4 H) 3.87 (s, 3 H) 3.95-4.06 (m, 1 H) 4.46 (d, J = 12.0Hz, 1 H) 4.58 (d, J = 12.0 Hz, 1 H) 6.05 (s, 2 H) 7.02 (d, J = 9.0 Hz, 2H) 7.24-7.30 (m, 1 H) 7.44 (d, J = 8.2 Hz, 1 H) 7.50-7.56 (m, 1 H) 8.00(d, J = 9.0 Hz, 3 H) 540 (M − H)⁻ 6 37 F

H 1.41 (t, J = 7.0 Hz, 3 H) 2.44-2.69 (m, 4 H) 3.99-4.10 (m, 4 H) 4.26(q, J = 7.0 Hz, 2 H) 4.48 (d, J = 12.0 Hz, 1 H) 4.60 (d, J = 12.0 Hz, 1H) 6.15 (s, 2 H) 7.25-7.56 (m, 6 H) 7.73 (d, J = 8.1 Hz, 1 H) 7.85 (d, J= 8.1 Hz, 1 H) 8.00 (d, J = 9.8 Hz, 1 H) 604 (M − H)⁻ 6 38 F

H 0.95 (t, J = 7.4 Hz, 3 H) 1.64 (sextet, J = 7.4 Hz, 2 H) 2.31-2.97 (m,6 H) 3.97-4.06 (m, 1 H) 4.47 (d, J = 12.1 Hz, 1 H) 4.59 (d, J = 12.1 Hz,2 H) 5.83 (s, 2 H) 7.28 (dd, J = 8.2, 2.0 Hz, 1 H) 7.45 (d, J = 8.2 Hz,1 H) 7.54 (d, J = 2.0 Hz, 1 H) 476 (M − H)⁻ 6 39 F

H 1.20 (s, 9 H) 2.34-2.66 (m, 4 H) 3.96-4.04 (m, 1 H) 4.47 (d, J = 11.8Hz, 1 H) 459 (d, J = 11.8 Hz, 1 H) 5.83 (s, 2 H) 7.28 (dd, J = 8.2, 2.0Hz, 1 H) 7.45 (d, J = 8.2 Hz, 1 H) 7.52 (d, J = 2.0 Hz, 1 H) 490 (M −H)⁻ 6 40 F

H 2.35-2.66 (m, 4 H) 3.97-4.05 (m, 1 H) 4.46 (d, J = 12.1 Hz, 1 H) 4.58(d, J = 12.1 Hz, 1 H) 6.08 (s, 2 H) 7.27 (dd, J = 8.3, 1.9 Hz, 1 H) 7.44(d, J = 8.3 Hz, 1 H) 7.48-7.56 (m, 3 H) 7.61-7.69 (m, 2 H) 8.05 (d, J =7.2 Hz, 2 H) 510 (M − H)⁻ 6 41 F

H 2.35-2.67 (m, 4 H) 3.96-4.06 (m, 1 H) 4.46 (d, J = 12.0 Hz, 1 H) 4.59(d, J = 12.0 Hz, 1 H) 7.27 (dd, J = 8.2, 1.9 Hz, 1 H) 7.44 (d, J = 8.2Hz, 1 H) 7.52-7.54 (m, 2 H) 7.69-7.95 (m, 4 H) 508 (M − H)⁻ 6 42 H

H 1.22-1.32 (m, 3 H) 1.42-1.50 (m, 3 H) 1.87-1.94 (m, 1 H) 2.11-2.27 (m,2 H) 2.32-2.41 (m, 2 H) 3.61-3.70 (m, 1 H) 4.11-4.23 (m, 2 H) 4.44 (d, J= 11.97 Hz, 1 H) 4.51 (d, J = 11.97 Hz, 1 H) 6.63-6.72 (m, 1 H)7.22-7.30 (m, 1 H) 7.45 (d, J = 8.24 Hz, 1 H) 7.53 (s, 1 H) 474 (M − H)⁻6 43 F

H 2.03 (3 H, s), 2.30-2.64 (4 H, m), 3.97-4.07 (1 H, m), 4.46 (1 H, d, J= 11.8 Hz), 4.58 (1 H, d, J = 11.80 Hz), 5.18 (2 H, s) 7.14-7.57 (7 H,m) 480 (M − H)⁻ 7 44 H

H 1.30-1.98 (14 H, m), 2.11-2.27 (2 H, m), 2.31-2.42 (2 H, m), 3.59-3.71(1 H, m), 4.44 (1 H, d, J = 12.1 Hz), 4.51 (1 H, d, J = 12.1 Hz),4.54-4.66 (1 H, m), 6.61-6.72 (1 H, m), 7.26 (1 H, dd, J = 8.2, 1.7 Hz),7.45 (1 H, d, J = 8.2 Hz), 7.53 (1 H, d, J = 1.7 Hz) 528 (M − H)⁻ 6 45 F

Benzyl H 2.31-2.62 (4 H, m), 3.94-4.04 (1 H, m), 4.46 (1 H, d, J = 11.7Hz), 4.59 (1 H, d, J = 11.7 Hz), 5.23 (2 H, s), 7.26-7.39 (9 H, m) 432(M − 1)⁻ 7

Example 8 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-(3-methyl)butyl ester

1.0 mL of thionyl chloride was added to 1.50 g of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid suspended in 20 mL of 3-methylbutanol at ice-cooling, and themixture was stirred for 3 hours at 70° C. After standing to cool,3-methylbutanol was distilled under reduced pressure. 15 mL of ethanoland 15 mL of propyleneoxide were added to the residue, and the mixturewas heated to redux for 1 hour. After standing to cool, the mixture wasdiluted with diethyl ether, and the precipitated solids were filtered.The solids were washed with water, diisopropyl ether and hexane, therebyyielding 1.01 g of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-(3-methyl)-n-butyl ester.

Example 9 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-(6-methyl)heptyl ester

0.4 mL of thionyl chloride was added to 1.00 g of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid suspended in 10 mL of 6-methyl-1-heptanol at ice-cooling, and themixture was stirred for 6 hours at 80° C. After standing to cool, theinsoluble matter was filtered off, and the filturate was concentratedunder reduced pressure. The residue was purified by reverse phase columnchromatography (Wako gel 50C18 (made by Wako Pure Chemical IndustriesLtd.) eluent: water to a 70% aqueous solution of acetonitrile). Theobtained solids were recrystallized from ethanol:water, thereby yielding557 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-(6-methyl) heptyl ester.

The structure and physical data of the compounds described in Examples 8and 9, as well as those of compounds yielded by means of the samemethods are shown in table 3 below.

TABLE 3 The structure and physical data of the compounds described inExamples 8 and 9

MS NMR ESI No. X Y R¹ R² (300 MHz, TMS, CD3OD) (Nega) Example 46 F

H 0.93 (6 H, d, J = 6.5 Hz), 1.52-1.59 (2 H, m), 1.65-1.74 (1 H, m)2.31-2.64 (4 H, m), 3.97-4.05 (1 H, m), 4.24 (2 H, t. J = 6.7 Hz), 4.47(1 H, d, J = 12.1 Hz), 4.59 (1 H, d, J = 12.1 Hz), 7.28 (1 H, dd, J =8.2, 2.0 Hz), 7.45 (1 H, d, J = 8.2 Hz), 7.54 (1 H, d, J = 2.0 Hz) 446(M − H)⁻ 8 47 F

H 0.91 (3 H, t, J = 6.7 Hz), 1.26-1.43 (6 H, m), 1.60-1.72 (2 H, m),2.31-2.67 (4 H, m), 3.97-4.06 (1 H, m), 4.19 (2 H, t, J = 6.6 Hz), 4.47(1 H, d, J = 12.0 Hz), 4.59 (1 H, d, J = 12.0 Hz), 7.28 (1 H, dd, J =8.2, 1.7 Hz), 7.45 (1 H, d, J = 8.2 Hz), 7.54 (1 H, d, J = 1.7 Hz) 460(M − H)⁻ 8 48 F

H 0.91 (6 H, d, J = 6.7 Hz), 1.19-1.31 (2 H, m), 1.49-1.72 (3 H, m),2.32-2.66 (4 H, m), 3.98-4.70 (1 H, m), 4.18 (1 H, t, J = 6.6 Hz), 4.48(1 H, d, J = 11.8 Hz), 4.60 (1 H, d, J = 11.8 Hz), 7.29 (1 H, dd, J =8.2, 2.1 Hz), 7.46 (1 H, d, J = 8.2 Hz), 7.55 (1 H, d, J = 2.1 Hz) 460(M − H)⁻ 8 49 F

H 0.91 (6 H, t, J = 7.5 Hz), 1.33-1.43 (4 H, m), 1.46-1.60 (1 H, m),2.31-2.65 (4 H, m), 3.98-4.05 (1 H, m), 4.14 (2 H, d, J = 5.1 Hz), 4.47(1 H, d, J = 12.0 Hz), 4.59 (1 H, d, J = 12.0 Hz), 7.28 (1 H, dd, J =8.1, 1.9 Hz), 7.45 (1 H, d, J = 8.1 Hz), 7.54 (1 H, d, J = 1.9 Hz) 460(M − H)⁻ 8 50 F

H 0.90 (3 H, t, J = 6.5 Hz), 1.26-1.42 (8 H, m), 1.59-1.72 (2 H, m),2.31-2.40 (2 H, m), 2.48 (1 H, dd, J = 13.3, 7.4 Hz), 2.50-2.66 (1 H,m), 3.98-4.03 (1 H,m), 4.19 (2 H, t, J = 6.5 Hz), 4.47 (1 H, d, J = 12.0Hz), 4.59 (1 H, d, J = 12.0 Hz), 7.28 (1 H, dd, J = 8.2, 1 H), 7.45 (1H, d, J = 8.2 Hz), 7.54 (1 H, d, J = 2.0 Hz) 476 (M + H)⁺ 8 51 F

H 0.90 (6 H, d, J = 6.5 Hz), 1.17-1.71 (7 H, m), 2.32-2.40 (2 H, m),2.49 (1 H, dd, J = 13.2, 7.3 Hz), 2.55-2.66 (1 H, m), 3.98-4.07 (1 H,m), 4.20 (2 H, t, J = 6.5 Hz), 4.48 (1 H, d, J = 12.0 Hz), 4.60 (1 H, d,J = 12.0 Hz), 7.29 (1 H, dd, J = 8.2, 1.9 Hz), 7.46 (1 H, d, J = 8.2Hz), 7.55 (1 H, d, J = 1.9 Hz) 476 (M + H)⁺ 8 52 F

H 0.90 (3 H, t, J = 6.6 Hz), 1.25-1.42 (10 H, m), 1.60-1.71 (2 H, m),2.31-2.40 (2 H, m), 2.48 (1 H, dd, J = 13.4, 7.6 Hz), 2.5-2.7 (1 H, m),4.05-4.06 (1 H, m), 4.19 (2 H, t, J = 6.6 Hz), 4.47 (1 H, d, J = 12.0Hz), 4.59 (1 H, d, J = 12.0 Hz), 7.28 (1 H, dd, J = 8.2, 1.9 Hz), 7.45(1 H, d, J = 8.2 Hz), 1.9 (1 H, d, J = 1.9 Hz) 490 (M + H)⁺ 8 53 F

H 0.89 (6 H, d, J = 6.7 Hz), 1.15-1.39 (6 H, m), 1.47-1.71 (3 H, m),2.33-2.65 (4 H, m), 4.02 (1 H, m), 4.19 (2 H, t, J = 6.5 Hz), 4.48 (1 H,d, J = 12.1 Hz), 4.60 (1 H, d, J = 12.1 Hz), 7.29 (1 H, dd, J = 8.2, 2.0Hz), 7.46 (1 H, d, J = 8.2 Hz), 7.54 (1 H, d, J = 2.0 Hz) 488 (M − H)⁻ 954 F

H 0.86-0.95 (9 H, m), 1.06-1.76 (10 H, m), 2.31-2.66 (4 H, m), 3.98-4.05(1 H, m), 4.24 (2 H, t, J = 6.8 Hz), 4.47 (1 H, d, J = 11.8 Hz), 4.59 (1H, m), 7.28 (1 H, dd, J = 8.2, 1.8 Hz), 7.45 (1 H, d, J = 8.2 Hz), 7.54(1 H, d, J = 1.8 Hz) 516 (M − H)⁻ 9 55 F

i-Bu H 0.94 (6 H, d, J = 6.7 Hz), 1.88-2.01 (1 H, m), 2.28-2.55 (4 H,m), 3.15-3.23 (1 H, m), 3.74 (1 H, d, J = 15.4 Hz), 3.79 (1 H, d, J =15.4 Hz), 3.93-4.02 (2 H, m), 7.27 (1 H, dd, J = 8.2, 2.0 Hz), 7.45 (1H, d, J = 8.2 Hz), 7.54 (1 H, d, J = 2.0 Hz) 431 (M − H)⁻ 8 56 F

Et H 1.25 (3 H, t, J = 7.2 Hz), 2.04-2.34 (3 H, m), 2.48-2.60 (1 H, m),3.89-4.03 (1 H, m), 4.21 (2 H, q, J = 7.2 Hz), 5.51 (1 H, s), 7.15-7.39(10 H, m) 412 (M − 1)⁻ 8 57 F

i-Pr H 1.26 (6 H, d, J = 6.2 Hz), 2.31-2.67 (4 H, m), 4.04-4.11 (1 H,m), 4.66 (1 H, d, J = 11.8 Hz), 4.79 (1 H, d, J = 11.8 Hz), 5.01-5.13 (1H, m), 7.40-7.51 (3 H, m), 7.78-7.87 (4 H, m) 400 (M − 1)⁻ 8

Example 10 Synthesis of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 2-butyl ester 6-ethyl ester and(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 2-butyl ester

(1) By means of the same method as Example 1, 2.96 g of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-ethyl ester hydrochloride was yielded from 4.00 g of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid.

(2) 400 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-ethyl ester hydrochloride was added to a mixture of 5 mL ofethanol and 5 mL of propyleneoxide, and the mixture was heated to reduxfor 2.5 hours. After standing to cool, the precipitated solids werefiltered, and the solids were washed with diethyl ether and thenrecrystallized from water: ethanol, thereby yielding 230 g of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-ethyl ester.

(3) 2 mL of saturated sodium hydrogen carbonate was added to 200 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-ethyl ester suspended in 1 mL of dioxane, and the mixture wasstirred for 10 minutes at room temperature. 0.18 mL of allylchloroformate was added thereto, and the solution was stirred for 8hours at room temperature. After the reaction solution was acidifiedwith 1 mL of 1N hydrochloric acid, 10 mL of water was added thereto, andthe mixture was extracted twice with ethyl acetate. The ethyl acetatelayers were combined, dried over anhydrous sodium sulfate andconcentrated under reduced pressure, and the obtained residue wasdissolved in 20 mL of N,N-dimethylformamide. 141 mg of 1-iodobutane and106 mg of potassium carbonate were added to the solution, and themixture was stirred for 16 hours at room temperature. Water was addedthereto, and the reaction solution was extracted twice with ethylacetate. After the ethyl acetate layers were combined and dried overanhydrous sodium sulfate, the solvent was distilled under reducedpressure and purified by column chromatography (silica gel: KantoChemical silica gel 60 (spherical), eluent: hexane-ethyl acetate=5:1),thereby yielding 159 mg of(1R,2R,3R,5R,6R)-2-allyloxycarbonylamino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 2-butyl ester 6-ethyl ester.

¹H-NMR (300 MHz, CDCl₃, TMS) 0.89 (3H, t, J=7.4 Hz), 1.24-1.43 (5H, m),1.56-1.66 (2H, m), 2.22-2.51 (3H, m), 2.93-3.00 (1H, m), 3.81-3.89 (1H,m), 4.08-4.65 (8H, m), 5.16-5.37 (3H, m), 5.84-5.98 (1H, m), 7.09 (1H,dd, J=8.2, 2.0 Hz), 7.37 (1H, d, J=2.0 Hz), 7.40 (1H, d, J=8.2 Hz).

(4) 81 mg of 1,3-dimethylbarbituric acid and 12 mg oftetrakis(triphenylphosphine) palladium were added to 190 mg of(1R,2R,3R,5R,6R)-2-allyloxycarbonylamino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 2-butyl ester 6-ethyl ester dissolved in chloroform under anitrogen atmosphere, and the mixture was stirred for 1 hour at 50° C.The reaction solution was concentrated under reduced pressure, and theobtained residue was purified by column chromatography (silica gel:Kanto Chemical silica gel 60 (spherical), eluent: hexane-ethylacetate=5:1), thereby yielding 180 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 2-butyl ester 6-ethyl ester.

(5) 15 mg of lithium hydroxide monohydrate was added to 131 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 2-butyl ester 6-ethyl ester dissolved in 2 mL of tetrahydrofuranand 1 mL of water, and the mixture was stirred for 1.5 hours at roomtemperature. After 2 mL of 1N hydrochloric acid was added thereto, thereaction solution was concentrated under reduced pressure, and theobtained residue was purified by reverse phase chromatography (Wako gel50C18 (made by Wako Pure Chemical Industries Ltd.) eluent: water to a40% acetonitrile solution), thereby yielding 37 mg of(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 2-butyl ester.

The structure and physical data of the compound described in Example 10,as well as those of compounds yielded by means of the same method areshown in table 4 below.

TABLE 4 The structure and physical data of the compound described inExample 10

MS NMR ESI No. X Y R¹ R² (300 MHz, TMS, CD3OD) (Nega) Example 58 F

H Bu 0.88 (3 H, t, J = 7.4 Hz), 1.37-1.47 (2 H, m), 1.64-1.71 (2 H, m),2.22-2.62 (4 H, m), 4.06-4.15 (1 H, m), 4.20-4.41 (2 H, m), 4.53 (2 H,s), 7.21-7.25 (1 H, m), 7.48-7.51 (2 H, m) 432 (M − 1)⁻ 10 59 F

Et Bu (300 MHz, TMS, CDCl₃) 0.90 (3 H, t, J = 7.4 Hz), 1.24-1.45 (5 H,m), 1.60-1.69 (2 H, m), 2.13-2.27 (2 H, m), 2.38-2.49 (2 H, m),3.74-3.86 (1 H, m), 4.07-4.29 (4 H, m), 4.46 (1 H, d, J = 12.1 Hz), 4.63(1 H, d, J = 12.1 Hz) 7.09 (1 H, d, J = 8.24 Hz), 7.67 (1 H, s), 7.38 (1H, d, J = 8.39 Hz) 484 (M + Na)⁺ 10

Test Example 1 Measurement of the Amount of Exposure In Vivo from thePlasma Concentration in Rat

The amount of exposure in vivo was measured, for example, according tothe following methods. Compounds 1, 4 and 10 of the present inventionand the parent compounds of compounds 1, 4 and 10 of the presentinvention where in formula [IV], X represents a fluorine atom and Yrepresents a 3,4-dichlorobenzyloxy group, were orally administered torat, and then the plasma concentration of the parent compound of thepresent invention was measured, compared and investigated as shownbelow. Also, by means of the same method, compound 44 of the presentinvention and the parent compound of compound 44 were orallyadministered to rat, and then the plasma concentration of the parentcompound of compound 44 of the present invention was measured, comparedand examined.

7-week-old rat (240-280 g, male, strain CD(SD)IGS) obtained from CharlesRiver Japan, Inc. habituated for more than 2 days was used as the testsubject. The compound of the present invention was dissolved in 0.03Nhydrochloric acid containing 10% HP-β-CD, adjusted to a concentration of2 mg/mL, and then 10 mg/kg of the mixture was orally administered torat. 1 hour and 2 hours later, blood was collected from the caudal veinwith a blood collecting tube (with EDTA) and immediately centrifuged(10000×g, 4° C., 10 minutes), thereby extracting the plasma for theplasma sample. The plasma sample was frozen and stored at −80° C. andbelow. While still being cooled on ice, the plasma sample was melted,methanol solution was added thereto as an internal standard substance,and after the sample was deproteinized and then centrifuged (10000×g, 4°C., 10 minutes), the concentration of the parent compound of thecompound of the present invention in the supernatant was measured byLC/MS/MS.

As shown in the table below, the administration of the compound of thepresent invention resulted in a significantly higher plasmaconcentration of the parent compound of the compound of the presentinvention, and the amount of exposure in vivo was increased.

Comparison of the plasma concentration of the compound of the presentinvention and of the parent compound of the compound of the presentinvention The plasma concentration of the parent compound Compound (10of the compound of the present invention (ng/mL) mg/kg p.o.) 1 hourlater 2 hours later Compound A*¹ 123 178 The compound of the 11332 8162present invention 1*² The compound of the 6863 7057 present invention4*³ The compound of the 5956 5754 present invention 10*⁴ Compound B*⁵ 73125 The compound of the 235 610 present invention 44*⁶ *¹Compound A (theparent compound of compound 1, 4 and 10 of the present invention):(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid *²Compound 1 of the present invention:(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-methyl ester *³Compound 4 of the present invention:(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-n-butyl ester *⁴Compound 10 of the present invention:(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-benzyl ester *⁵Compound B (the parent compound of compound 44 ofthe present invention):(1S,2R,3R,5R,6S)-2-amino-3-(3,4-dichlorobenzyloxy)-bicyclo[3.1.0]hexane-2,6-dicarboxylicacid *⁶Compound 44 of the present invention:(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylicacid 6-(1-(cyclohexyloxycarbonyloxy)ethyl)ester

INDUSTRIAL APPLICABILITY

The compound of the present invention, a pharmaceutically acceptablesalt thereof or a hydrate thereof may be employed as a prodrug of ametabotropic glutamate receptor antagonist, and thus can significantlyincrease the amount of exposure in vivo of the parent compound.

Therefore, the present invention makes it possible to provide a drugwhich is effective for the treatment and prevention of psychiatricdisorders such as schizophrenia, anxiety and related ailments thereof,bipolar disorder and epilepsy; for the treatment and prevention ofneurological diseases such as drug dependence, cognitive disorders,Alzheimer's disease, Huntington's chorea, Parkinson's disease,dyskinesia associated with muscular rigidity, cerebral ischemia,cerebral failure, myelopathy and head trauma; and for relievingconvulsions, pain and nausea. The drug shows high activity in oraladministration, which is preferable from the point of usability andmedicinal benefits.

1. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof,represented by formula [I]

[wherein, R¹ and R² are identical or different, and each represents aC₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, aC₁₋₁₀alkyl group substituted by one or two aryl groups, ahydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkylgroup, an aminoC₂₋₁₀alkyl group, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, aC₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, a farnesyl group, a4-morpholinylC₁₋₁₀alkyl group, a C₁₋₁₀alkyl group substituted by a grouprepresented by formula —C(O)NR^(a)R^(b) (wherein R^(a) and R^(b) areidentical or different, and each represents a hydrogen atom or aC₁₋₁₀alkyl group), a group represented by formula —CHR^(c)OC(O)ZR^(d)(wherein Z represents an oxygen atom, a nitrogen atom, a sulfur atom ora single bond; R^(c) represents a hydrogen atom, a C₁₋₁₀alkyl group, aC₂₋₁₀alkenyl group or an aryl group; and R^(d) represents a C₁₋₁₀alkylgroup, a C₂₋₁₀alkenyl group or an aryl group), a group represented byformula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]; or,

in the case where either R¹ or R² represents a hydrogen atom, the otherrepresents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynylgroup, a C₁₋₁₀alkyl group substituted by one or two aryl groups, ahydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkylgroup, an aminoC₂₋₁₀alkyl group, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, aC₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, a farnesyl group, a4-morpholinylC₁₋₁₀alkyl group, a C₁₋₁₀alkyl group substituted by a grouprepresented by formula —C(O)NR^(a)R^(b) (wherein R^(a) and R^(b) are thesame as described above), a group represented by formula—CHR^(c)OC(O)ZR^(d) (wherein Z, R^(c) and R^(d) are the same asdescribed above), a group represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii];

X represents a hydrogen atom or a fluorine atom; and Y represents—OCHR³R⁴, —SR³, —S(O)_(n)R⁵, —SCHR³R⁴, —S(O)_(n)CHR³R⁴, —NHCHR³R⁴,—N(CHR³R⁴)(CHR^(3′)R^(4′)), —NHCOR³ or —OCOR⁵ (wherein R³, R^(3′), R⁴and R^(4′) are identical or different, and each represents a hydrogenatom, a C₁₋₁₀alkyl group, a C₁₋₁₀alkenyl group, a phenyl group, anaphthyl group, a naphthyl group substituted by one to seven halogenatoms, a heteroaromatic group or a phenyl group substituted by one tofive substituents selected from a group consisting of a halogen atom, aphenyl group, a C₁₋₁₀alkyl group, a C₁₋₁₀alkoxy group, a trifluoromethylgroup, a phenyl group, a hydroxycarbonyl group, an amino group, a nitrogroup, a cyano group and a phenoxy group; R⁵ represents a C₁₋₁₀alkylgroup, a C₁₋₁₀alkenyl group, a phenyl group, a naphthyl group, anaphthyl group substituted by one to seven halogen atoms, aheteroaromatic group or a phenyl group substituted by one to fivesubstituents selected from a group consisting of a halogen atom, aphenyl group, a C₁₋₁₀alkyl group, a C₁₋₁₀alkoxy group, a trifluoromethylgroup, a phenyl group, a hydroxycarbonyl group, an amino group, a nitrogroup, a cyano group and a phenoxy group; and n represents integer 1 or2)].
 2. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic esterderivative, a pharmaceutically acceptable salt thereof or a hydratethereof, represented by formula [II]

[wherein, R¹ and R² are identical or different, and each represents aC₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, aC₁₋₁₀alkyl group substituted by one or two aryl groups, ahydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkylgroup, an aminoC₂₋₁₀alkyl group, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, aC₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, a farnesyl group, a4-morpholinylC₁₋₁₀alkyl group, a C₁₋₁₀alkyl group substituted by a grouprepresented by formula —C(O)NR^(a)R^(b) (wherein R^(a) and R^(b) areidentical or different, and each represents a hydrogen atom or aC₁₋₁₀alkyl group), a group represented by formula —CHR^(c)OC(O)ZR^(d)(wherein Z represents an oxygen atom, a nitrogen atom, a sulfur atom ora single bond; R^(c) represents a hydrogen atom, a C₁₋₁₀alkyl group, aC₂₋₁₀alkenyl group or an aryl group, and R^(d) represents a C₁₋₁₀alkylgroup, a C₂₋₁₀alkenyl group or an aryl group), a group represented byformula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]; or,

in the case where either R¹ or R² represents a hydrogen atom, the otherrepresents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynylgroup, a C₁₋₁₀alkyl group substituted by one or two aryl groups, ahydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkylgroup, an aminoC₂₋₁₀alkyl group, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, aC₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, a farnesyl group, a4-morpholinylC₁₋₁₀alkyl group, a C₁₋₁₀alkyl group substituted by a grouprepresented by formula —C(O)NR^(a)R^(b) (wherein R^(a) and R^(b) are thesame as described above), a group represented by formula—CHR^(c)OC(O)ZR^(d) (wherein Z, R^(c) and R^(d) are the same asdescribed above), a group represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii];

X represents a hydrogen atom or a fluorine atom; and Y represents—OCHR³R⁴, —SR³, —S(O)_(n)R⁵, —SCHR³R⁴, —S(O)_(n)CHR³R⁴, —NHCHR³R⁴,—N(CHR³R⁴)(CHR^(3′)R^(4′)), —NHCOR³ or —OCOR⁵ (wherein R³, R^(3′), R⁴and R^(4′) are identical or different, and each represents a hydrogenatom, a C₁₋₁₀alkyl group, a C₁₋₁₀alkenyl group, a phenyl group, anaphthyl group, a naphthyl group substituted by one to seven halogenatoms, a heteroaromatic group or a phenyl group substituted by one tofive substituents selected from a group consisting of a halogen atom, aphenyl group, a C₁₋₁₀alkyl group, a C₁₋₁₀alkoxy group, a trifluoromethylgroup, a phenyl group, a hydroxycarbonyl group, an amino group, a nitrogroup, a cyano group and a phenoxy group; R⁵ represents a C₁₋₁₀alkylgroup, a C₁₋₁₀alkenyl group, a phenyl group, a naphthyl group, anaphthyl group substitute by one to seven halogen atoms, aheteroaromatic group or a phenyl group substituted by one to fivesubstituents selected from a group consisting of a halogen atom, aphenyl group, a C₁₋₁₀alkyl group, a C₁₋₁₀alkoxy group, a trifluoromethylgroup, a phenyl group, a hydroxycarbonyl group, an amino group, a nitrogroup, a cyano group and a phenoxy group; and n represents integer 1 or2)].
 3. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic esterderivative, a pharmaceutically acceptable salt thereof or a hydratethereof according to claim 2, wherein in the formula [II], R¹ and R² areidentical or different, and each represents a C₁₋₁₀alkyl group, aC₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl group substitutedby one or two phenyl groups, a hydroxyC₂₋₁₀alkyl group, ahalogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkylgroup, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group or a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkylgroup; or, in the case where either R¹ or R² represents a hydrogen atom,the other represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group, aC₂₋₁₀alkynyl group, a C₁₋₁₀alkyl group substituted by one or two phenylgroups, a hydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group, anazidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkyl group, a C₁₋₁₀alkoxyC₁₋₁₀alkylgroup or a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group.
 4. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R¹ and R² are identical ordifferent, and each represents a C₁₋₁₀alkyl group, a C₂₋₆alkenyl group,a C₂₋₆alkynyl group, a C₁₋₆alkyl group substituted by one or two phenylgroups, a hydroxyC₂₋₆alkyl group, a halogenoC₁₋₆alkyl group, anazidoC₁₋₆alkyl group, an aminoC₂₋₆alkyl group, a C₁₋₆alkoxyC₁₋₆alkylgroup or a C₁₋₆alkoxycarbonylC₁₋₆alkyl group; or, in the case whereeither R¹ or R² represents a hydrogen atom, the other represents aC₁₋₆alkyl group, a C₂₋₆alkenyl group, a C₂₋₆alkynyl group, a C₁₋₆alkylgroup substituted by one or two phenyl groups, a hydroxyC₂₋₆alkyl group,a halogenoC₁₋₆alkyl group, an azidoC₁₋₆alkyl group, an aminoC₂₋₆alkylgroup, a C₁₋₆alkoxyC₁₋₆alkyl group or a C₁₋₆alkoxycarbonylC₁₋₆alkylgroup.
 5. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic esterderivative, a pharmaceutically acceptable salt thereof or a hydratethereof according to claim 2, wherein in the formula [II], R¹ and R² areidentical or different, and each represents a farnesyl group, aC₁₋₁₀alkyl group substituted by one or two aryl groups, aC₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, a 4-morpholinylC₁₋₁₀alkyl group, aC₁₋₁₀alkyl group substituted by a group represented by formula—C(O)NR^(a)R^(b) (wherein R^(a) and R^(b) are identical or different,and each represents a hydrogen atom or a C₁₋₁₀alkyl group), a grouprepresented by formula —CHR^(c)OC(O)ZR^(d) (wherein Z represents anoxygen atom, a nitrogen atom, a sulfur atom or a single bond; R^(c)represents a hydrogen atom, a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group oran aryl group; and R^(d) represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenylgroup or an aryl group), a group represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]; or,

in the case where either R¹ or R² represents a hydrogen atom, the otherrepresents a farnesyl group, a C₁₋₁₀alkyl group substituted by one ortwo aryl groups, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, a4-morpholinylC₁₋₁₀alkyl group, a C₁₋₁₀alkyl group substituted by a grouprepresented by formula —C(O)NR^(a)R^(b) (wherein R^(a) and R^(b) are thesame as described above), a group represented by formula—CHR^(c)OC(O)ZR^(d) (wherein Z, R^(c) and R^(d) are the same asdescribed above), a group represented by formula

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


6. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R¹ and R² are identical ordifferent, and each represents a farnesyl group, a C₁₋₆alkyl groupsubstituted by one or two aryl groups, a C₁₋₆alkoxycarbonylC₁₋₆alkylgroup, a 4-morpholinylC₁₋₆alkyl group, a C₁₋₆alkyl group substituted bya group represented by formula —C(O)NR^(a)R^(b) (wherein R^(a) and R^(b)are identical or different, and each represents a hydrogen atom or aC₁₋₆alkyl group), a group represented by formula —CHR^(c)OC(O)ZR^(d)(wherein Z represents an oxygen atom, a nitrogen atom, a sulfur atom ora single bond; R^(c) represents a hydrogen atom, a C₁₋₆alkyl group, aC₂₋₆alkenyl group or an aryl group; and R^(d) represents a C₁₋₆alkylgroup, a C₂₋₆alkenyl group or an aryl group), a group represented byformula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]; or,

in the case where either R¹ or R² represents a hydrogen atom, the otherrepresents a farnesyl group, a C₁₋₆alkyl group substituted by one or twoaryl groups, a C₁₋₆alkoxycarbonylC₁₋₆alkyl group, a4-morpholinylC₁₋₆alkyl group, a C₁₋₁₀alkyl group substituted by a grouprepresented by formula —C(O)NR^(a)R^(b) (wherein R^(a) and R^(b) are thesame as described above), a group represented by formula—CHR^(c)OC(O)ZR^(d) (wherein Z, R^(c) and R^(d) are the same asdescribed above), a group represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


7. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom.8. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;and X represents a fluorine atom.
 9. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], wherein R² represents ahydrogen atom; and X represents a hydrogen atom.
 10. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; and Y represents —OCHR³, R⁴ (wherein R³and R⁴ are the same as described above).
 11. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; and Y represents —SCHR³R⁴ (wherein R³ andR⁴ are the same as described above).
 12. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; and Y represents —SR³ (wherein R³ is thesame as described above).
 13. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; and Y represents —S(O)_(n)CHR³R⁴ (whereinR³, R⁴ and n are the same as described above).
 14. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; and Y represents —NHCHR³R⁴ (wherein R³ andR⁴ are the same as described above).
 15. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; and Y represents—N(CHR³R⁴)(CHR^(3′)R^(4′)) (wherein R³, R^(3′), R⁴ and R^(4′) are thesame as described above).
 16. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], represents a hydrogen atom; Xrepresents a hydrogen atom; and Y represents —OCHR³R⁴ (wherein R³ and R⁴are the same as described above).
 17. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], represents a hydrogen atom; Xrepresents a hydrogen atom; and Y represents —SCHR³R⁴ (wherein R³ and R⁴are the same as described above).
 18. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], represents a hydrogen atom; Xrepresents a hydrogen atom; and Y represents —SR³ (wherein R³ is thesame as described above).
 19. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; and Y represents —S(O)_(n)CHR³R⁴ (whereinR³, R⁴ and n are the same as described above).
 20. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], wherein R² represents ahydrogen atom; X represents a hydrogen atom; and Y represents —NHCHR³R⁴(wherein R³ and R⁴ are the same as described above).
 21. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; and Y represents—N(CHR³R⁴)(CHR^(3′)R^(4′)) (wherein R³, R^(3′), R⁴ and R^(4′) are thesame as described above).
 22. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —OCHR³R⁴ (wherein R³ and R⁴are the same as described above); and R¹ represents a C₁₋₁₀alkyl group,a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl groupsubstituted by one or two aryl groups, a hydroxyC₂₋₁₀alkyl group, ahalogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkylgroup, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkylgroup, a farnesyl group, a 4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkylgroup substituted by a group represented by formula —C(O)NR^(a)R^(b)(wherein R^(a) and R^(b) are identical or different, and each representsa hydrogen atom or a C₁₋₁₀alkyl group).
 23. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —OCHR³R⁴ (wherein R³ and R⁴are the same as described above); and R¹ represents a group representedby formula —CHR^(c)OC(O)ZR^(d) (wherein Z represents an oxygen atom, anitrogen atom, a sulfur atom or a single bond; R^(c) represents ahydrogen atom, a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an arylgroup; and R^(d) represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group oran aryl group), a group represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


24. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivativepharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —SCHR³R⁴ (wherein R³ and R⁴are the same as described above); and R¹ represents a C₁₋₁₀alkyl group,a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl groupsubstituted by one or two aryl groups, a hydroxyC₂₋₁₀alkyl group, ahalogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkylgroup, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkylgroup, a farnesyl group, a 4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkylgroup substituted by a group represented by formula —C(O)NR^(a)R^(b)(wherein R^(a) and R^(b) are identical or different, and each representsa hydrogen atom or a C₁₋₁₀alkyl group).
 25. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —SCHR³R⁴ (wherein R³ and R⁴are the same as described above); and R¹ represents a group representedby formula —CHR^(c)OC(O)ZR^(d) (wherein Z represents an oxygen atom, anitrogen atom, a sulfur atom or a single bond; R^(c) represents ahydrogen atom, a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an arylgroup; and R^(d) represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group oran aryl group), a group represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


26. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —SR³ (wherein R³ is the sameas described above); and R¹ represents a C₁₋₁₀alkyl group, aC₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl group substitutedby one or two aryl groups, a hydroxyC₂₋₁₀alkyl group, ahalogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkylgroup, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkylgroup, a farnesyl group, a 4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkylgroup substituted by a group represented by formula —C(O)NR^(a)R^(b)(wherein R^(a) and R^(b) are identical or different, and each representsa hydrogen atom or a C₁₋₁₀alkyl group).
 27. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —SR³ (wherein R³ is the sameas described above); and R¹ represents a group represented by formula—CHR^(c)OC(O)ZR^(d) (wherein Z represents an oxygen atom, a nitrogenatom, a sulfur atom or a single bond; R^(c) represents a hydrogen atom,a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group; and R^(d)represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group), agroup represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


28. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —S(O)_(n)CHR³R⁴ (wherein R³,R⁴ and n are the same as described above); and R¹ represents aC₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, aC₁₋₁₀alkyl group substituted by one or two aryl groups, ahydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkylgroup, an aminoC₂₋₁₀alkyl group, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, aC₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, a farnesyl group, a4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkyl group substituted by agroup represented by formula —C(O)NR^(a)R^(b) (wherein R^(a) and R^(b)are identical or different, and each represents a hydrogen atom or aC₁₋₁₀alkyl group).
 29. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylicester derivative, a pharmaceutically acceptable salt thereof or ahydrate thereof according to claim 2, wherein in the formula [II], R²represents a hydrogen atom; X represents a fluorine atom; Y represents—S(O)_(n)CHR³R⁴ (wherein R³, R⁴ and n are the same as described above);and R¹ represents a group represented by formula —CHR^(c)OC(O)ZR^(d)(wherein Z represents an oxygen atom, a nitrogen atom, a sulfur atom ora single bond; R^(c) represents a hydrogen atom, a C₁₋₁₀alkyl group, aC₂₋₁₀alkenyl group or an aryl group; and R^(d) represents a C₁₋₁₀alkylgroup, a C₂₋₁₀alkenyl group or an aryl group), a group represented byformula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


30. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —NHCHR³R⁴ (wherein R³ and R⁴are the same as described above); and R¹ represents a C₁₋₁₀alkyl group,a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl groupsubstituted by one or two aryl groups, a hydroxyC₂₋₁₀alkyl group, ahalogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkylgroup, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkylgroup, a farnesyl group, a 4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkylgroup substituted by a group represented by formula —C(O)NR^(a)R^(b)(wherein R^(a) and R^(b) are identical or different, and each representsa hydrogen atom or a C₁₋₁₀alkyl group).
 31. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —NHCHR³R⁴ (wherein R³ and R⁴are the same as described above); and R¹ represents a group representedby formula —CHR^(c)OC(O)ZR^(d) (wherein Z represents an oxygen atom, anitrogen atom, a sulfur atom or a single bond; R^(c) represents ahydrogen atom, a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an arylgroup; and R^(d) represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group oran aryl group), a group represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


32. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —N(CHR³R⁴)(CHR^(3′)R^(4′))(wherein R³, R^(3′), R⁴ and R^(4′) are the same as described above); andR¹ represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynylgroup, a C₁₋₁₀alkyl group substituted by one or two aryl groups, ahydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkylgroup, an aminoC₂₋₁₀alkyl group, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, aC₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, a farnesyl group, a4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkyl group substituted by agroup represented by formula —C(O)NR^(a)R^(b) (wherein R^(a) and R^(b)are identical or different, and each represents a hydrogen atom or aC₁₋₁₀alkyl group).
 33. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylicester derivative, a pharmaceutically acceptable salt thereof or ahydrate thereof according to claim 2, wherein in the formula [II], R²represents a hydrogen atom; X represents a fluorine atom; Y represents—N(CHR³R⁴)(CHR^(3′)R^(4′)) (wherein R³, R^(3′), R⁴ and R^(4′) are thesame as described above); and R¹ represents a group represented byformula —CHR^(c)OC(O)ZR^(d) (wherein Z represents an oxygen atom, anitrogen atom, a sulfur atom or a single bond; R^(c) represents ahydrogen atom, a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an arylgroup; and R^(d) represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group oran aryl group), a group represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


34. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents-OCHR³R⁴ (wherein R³ and R⁴are the same as described above); and R¹ represents a C₁₋₁₀alkyl group,a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl groupsubstituted by one or two aryl groups, a hydroxyC₂₋₁₀alkyl group, ahalogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkylgroup, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkylgroup, a farnesyl group, a 4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkylgroup substituted by a group represented by formula —C(O)NR^(a)R^(b)(wherein R^(a) and R^(b) are identical or different, and each representsa hydrogen atom or a C₁₋₁₀alkyl group).
 35. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents-OCHR³R⁴ (wherein R³ and R⁴are the same as described above); and R¹ represents a group representedby formula —CHR^(c)OC(O)ZR^(d) (wherein Z represents an oxygen atom, anitrogen atom, a sulfur atom or a single bond; R^(c) represents ahydrogen atom, a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an arylgroup; and R^(d) represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group oran aryl group), a group represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


36. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents —SCHR³R⁴ (wherein R³ and R⁴are the same as described above); and R¹ represents a C₁₋₁₀alkyl group,a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl groupsubstituted by one or two aryl groups, a hydroxyC₂₋₁₀alkyl group, ahalogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkylgroup, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group or a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkylgroup, a farnesyl group, a 4-morpholinylC₁₋₁₀alkyl group, a C₁₋₁₀alkylgroup substituted by a group represented by formula —C(O)NR^(a)R^(b)(wherein R^(a) and R^(b) are identical or different, and each representsa hydrogen atom or a C₁₋₁₀alkyl group).
 37. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents —SCHR³R⁴ (wherein R³ and R⁴are the same as described above); and R¹ represents a group representedby formula —CHR^(c)OC(O)ZR^(d) (wherein Z represents an oxygen atom, anitrogen atom, a sulfur atom or a single bond, R^(c) represents ahydrogen atom, C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group;and R^(d) represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an arylgroup), a group represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


38. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents —SR³ (wherein R³ is the sameas described above); and R¹ represents a C₁₋₁₀alkyl group, aC₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl group substitutedby one or two aryl groups, a hydroxyC₂₋₁₀alkyl group, ahalogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkylgroup, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkylgroup, a farnesyl group, a 4-morpholinylC₁₋₁₀alkyl group, or aC₁₋₁₀alkyl group substituted by a group represented by formula—C(O)NR^(a)R^(b) (wherein R^(a) and R^(b) are identical or different,and each represents a hydrogen atom or a C₁₋₁₀alkyl group).
 39. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents-SR³ (wherein R³ is the sameas described above); and R¹ represents a group represented by formula—CHR^(c)OC(O)ZR^(d) (wherein Z represents an oxygen atom, a nitrogenatom, a sulfur atom or a single bond; R^(c) represents a hydrogen atom,a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group; and R^(d)represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group), agroup represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


40. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents —S(O)_(n)CHR³R⁴ (wherein R³,R⁴ and n are the same as described above); and R¹ represents aC₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, aC₁₋₁₀alkyl group substituted by one or two aryl groups, ahydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkylgroup, an aminoC₂₋₁₀alkyl group, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, aC₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, a farnesyl group, a4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkyl group substituted by agroup represented by formula —C(O)NR^(a)R^(b) (wherein R^(a) and R^(b)are identical or different, and each represents a hydrogen atom or aC₁₋₁₀alkyl group).
 41. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylicester derivative, a pharmaceutically acceptable salt thereof or ahydrate thereof according to claim 2, wherein in the formula [II], R²represents a hydrogen atom; X represents a hydrogen atom; Y represents—S(O)_(n)CHR³R⁴ (wherein R³, R⁴ and n are the same as described above);and R¹ represents a group represented by formula —CHR^(c)OC(O)ZR^(d)(wherein Z represents an oxygen atom, a nitrogen atom, a sulfur atom ora single bond; R^(c) represents a hydrogen atom, C₁₋₁₀alkyl group, aC₂₋₁₀alkenyl group or an aryl group; and R^(d) represents a C₁₋₁₀alkylgroup, a C₂₋₁₀alkenyl group or an aryl group), a group represented byformula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


42. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents —NHCHR³R⁴ (wherein R³ and R⁴are the same as described above); and R¹ represents a C₁₋₁₀alkyl group,a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl groupsubstituted by one or two aryl groups, a hydroxyC₂₋₁₀alkyl group, ahalogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkylgroup, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkylgroup, a farnesyl group, a 4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkylgroup substituted by a group represented by formula —C(O)NR^(a)R^(b)(wherein R^(a) and R^(b) are identical or different, and each representsa hydrogen atom or a C₁₋₁₀alkyl group).
 43. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents —NHCHR³R⁴ (wherein R³ and R⁴are the same as described above); and R¹ represents a group representedby formula —CHR^(c)OC(O)XR^(d) (wherein Z represents an oxygen atom, anitrogen atom, a sulfur atom or a single bond; R^(c) represents ahydrogen atom, a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an arylgroup; and R^(d) represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group oran aryl group), a group represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


44. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents —N(CHR³R⁴)(CHR^(3′)R^(4′))(wherein R³, R^(3′), R⁴ and R^(4′) are the same as described above); andR¹ represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group, a C₂₋₁₀alkynylgroup, a C₁₋₁₀alkyl group substituted by one or two aryl groups, ahydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group, an azidoC₁₋₁₀alkylgroup, an aminoC₂₋₁₀alkyl group, a C₁₋₁₀alkoxyC₁₋₁₀alkyl group, aC₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, a farnesyl group, a4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkyl group substituted by agroup represented by formula —C(O)NR^(a)R^(b) (wherein R^(a) and R^(b)are identical or different, and each represents a hydrogen atom or aC₁₋₁₀alkyl group).
 45. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylicester derivative, a pharmaceutically acceptable salt thereof or ahydrate thereof according to claim 2, wherein in the formula [II], R²represents a hydrogen atom; X represents a hydrogen atom; Y represents—N(CHR³R⁴)(CHR^(3′)R^(4′)) (wherein R³, R^(3′), R⁴ and R^(4′) are thesame as described above); and R¹ represents a group represented byformula —CHR^(c)OC(O)ZR^(d) (wherein Z represents an oxygen atom, anitrogen atom, a sulfur atom or a single bond; R^(c) represents ahydrogen atom, C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group;and R^(d) represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an arylgroup), a group represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


46. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivativespharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —OCHR³R⁴ (wherein R³represents a hydrogen atom; R⁴ represents a phenyl group or a phenylgroup substituted by one to five substituents selected from a groupconsisting of a halogen atom, a phenyl group, a C₁₋₁₀alkyl group, aC₁₋₁₀alkoxy group, a trifluoromethyl group, a phenyl group, ahydroxycarbonyl group, an amino group, a nitro group, a cyano group anda phenoxy group); and R¹ represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenylgroup, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl group substituted by one ortwo aryl groups, a hydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group,an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkyl group, aC₁₋₁₀alkoxyC₁₋₁₀alkyl group, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, afarnesyl group, a 4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkyl groupsubstituted by a group represented by formula —C(O)NR^(a)R^(b) (whereinR^(a) and R^(b) are identical or different, and each represents ahydrogen atom or a C₁₋₁₀alkyl group).
 47. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], represents a hydrogen atom; Xrepresents a fluorine atom; Y represents —OCHR³R⁴ (wherein R³ representsa hydrogen atom; R⁴ represents a phenyl group or a phenyl groupsubstituted by one to five substituents selected from a group containinga halogen atom, a phenyl group, a C₁₋₁₀alkyl group, a C₁₋₁₀alkoxy group,a trifluoromethyl group, a phenyl group, a hydroxycarbonyl group, anamino group, a nitro group, a cyano group and a phenoxy group); and R¹represents a group represented by formula —CHR^(c)OC(O)ZR^(d) (wherein Zrepresents an oxygen atom, a nitrogen atom, a sulfur atom or a singlebond; R^(c) represents a hydrogen atom, a C₁₋₁₀alkyl group, aC₂₋₁₀alkenyl group or an aryl group; and R^(d) represents a C₁₋₁₀alkylgroup, a C₂₋₁₀alkenyl group or an aryl group), a group represented byformula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


48. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —OCHR³R⁴ (wherein R³represents a hydrogen atom; R⁴ represents a naphthyl group, aheteroaromatic group or a naphtyl group substituted by one to sevenhalogen atoms); and R¹ represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenylgroup, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl group substituted by one ortwo aryl groups, a hydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group,an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkyl group, aC₁₋₁₀alkoxyC₁₋₁₀alkyl group, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, afarnesyl group, a 4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkyl groupsubstituted by a group represented by formula —C(O)NR^(a)R^(b) (whereinR^(a) and R^(b) are identical or different, and each represents ahydrogen atom or a C₁₋₁₀alkyl group).
 49. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —OCHR³R⁴ (wherein R³represents a hydrogen atom, R⁴ represents a naphthyl group, aheteroaromatic group or a naphtyl group substituted by one to sevenhalogen atoms); and R¹ represents a group represented by formula—CHR^(c)OC(O)XR^(d) (wherein Z represents an oxygen atom, a nitrogenatom, a sulfur atom or a single bond; R^(c) represents a hydrogen atom,a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group; and R^(d)represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group), agroup represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


50. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —OCHR³R⁴ (wherein R³ and R⁴are identical or different, and each represents a phenyl group or aphenyl group substituted by one to five substituents selected from agroup containing a halogen atom, a phenyl group, a C₁₋₁₀alkyl group, aC₁₋₁₀alkoxy group, a trifluoromethyl group, a phenyl group, ahydroxycarbonyl group, an amino group, a nitro group, a cyano group anda phenoxy group); and R¹ represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenylgroup, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl group substituted by one ortwo aryl groups, a hydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group,an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkyl group, aC₁₋₁₀alkoxyC₁₋₁₀alkyl group, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, afarnesyl group, a 4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkyl groupsubstituted by a group represented by formula —C(O)NR^(a)R^(b) (whereinR^(a) and R^(b) are identical or different, and each represents ahydrogen atom or a C₁₋₁₀alkyl group).
 51. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a fluorine atom; Y represents —OCHR³R⁴ (wherein R³ and R⁴are identical or different, and each represents a phenyl group or aphenyl group substituted by one to five substituents selected from agroup containing a halogen atom, a phenyl group, a C₁₋₁₀alkyl group, aC₁₋₁₀alkoxy group, a trifluoromethyl group, a phenyl group, ahydroxycarbonyl group, an amino group, a nitro group, a cyano group anda phenoxy group); and R¹ represents a group represented by formula—CHR^(c)OC(O)ZR^(d) (wherein Z represents an oxygen atom, a nitrogenatom, a sulfur atom or a single bond; R^(c) represents a hydrogen atom,a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group; and R^(d)represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group), agroup represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


52. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents —OCHR³R⁴ (wherein R³represents a hydrogen atom; R⁴ represents a phenyl group or a phenylgroup substituted by one to five substituents selected from a groupcontaining a halogen atom, a phenyl group, a C₁₋₁₀alkyl group, aC₁₋₁₀alkoxy group, a trifluoromethyl group, a phenyl group, ahydroxycarbonyl group, an amino group, a nitro group, a cyano group anda phenoxy group); and R¹ represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenylgroup, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl group substituted by one ortwo aryl groups, a hydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group,an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkyl group, aC₁₋₁₀alkoxyC₁₋₁₀alkyl group, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, afarnesyl group, a 4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkyl groupsubstituted by a group represented by formula —C(O)NR^(a)R^(b) (whereinR^(a) and R^(b) are identical or different, and each represents ahydrogen atom or a C₁₋₁₀alkyl group).
 53. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents —OCHR³R⁴ (wherein R³represents a hydrogen atom; R⁴ represents a phenyl group or a phenylgroup substituted by one to five substituents selected from a groupcontaining a halogen atom, a phenyl group, a C₁₋₁₀alkyl group, aC₁₋₁₀alkoxy group, a trifluoromethyl group, a phenyl group, ahydroxycarbonyl group, an amino group, a nitro group, a cyano group andphenoxy group); and R¹ represents a group represented by formula—CHR^(c)OC(O)ZR^(d) (wherein Z represents an oxygen atom, a nitrogenatom, a sulfur atom or a single bond; R^(c) represents a hydrogen atom,a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group; and R^(d)represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group), agroup represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


54. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents —OCHR³R⁴ (wherein R³represents a hydrogen atom; R⁴ represents a naphthyl group, aheteroaromatic group or a naphtyl group substituted by one to sevenhalogen atoms); and R¹ represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenylgroup, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl group substituted by one ortwo aryl groups, a hydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group,an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkyl group, aC₁₋₁₀alkoxyC₁₋₁₀alkyl group, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, afarnesyl group, a 4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkyl groupsubstituted by a group represented by formula —C(O)NR^(a)R^(b) (whereinR^(a) and R^(b) are identical or different, and each represents ahydrogen atom or a C₁₋₁₀alkyl group).
 55. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents —OCHR³R⁴ (wherein R³represents a C₁₋₁₀alkyl group; and R⁴ represents a naphthyl group); andR¹ represents a group represented by formula —CHR^(c)OC(O)ZR^(d)(wherein Z represents an oxygen atom, a nitrogen atom, a sulfur atom ora single bond; R^(c) represents a hydrogen atom, a C₁₋₁₀alkyl group, aC₂₋₁₀alkenyl group or an aryl group; and R^(d) represents a C₁₋₁₀alkylgroup, a C₂₋₁₀alkenyl group or an aryl group), a group represented byformula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


56. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents —OCHR³R⁴ (wherein R³ and R⁴are identical or different, and each represents a phenyl group or aphenyl group substituted by one to five substituents selected from agroup containing a halogen atom, a phenyl group, a C₁₋₁₀alkyl group, aC₁₋₁₀alkoxy group, a trifluoromethyl group, a phenyl group, ahydroxycarbonyl group, an amino group, a nitro group, a cyano group anda phenoxy group); and R¹ represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenylgroup, a C₂₋₁₀alkynyl group, a C₁₋₁₀alkyl group substituted by one ortwo aryl groups, a hydroxyC₂₋₁₀alkyl group, a halogenoC₁₋₁₀alkyl group,an azidoC₁₋₁₀alkyl group, an aminoC₂₋₁₀alkyl group, aC₁₋₁₀alkoxyC₁₋₁₀alkyl group, a C₁₋₁₀alkoxycarbonylC₁₋₁₀alkyl group, afarnesyl group, a 4-morpholinylC₁₋₁₀alkyl group or a C₁₋₁₀alkyl groupsubstituted by a group represented by formula —C(O)NR^(a)R^(b) (whereinR^(a) and R^(b) are identical or different, and each represents ahydrogen atom or a C₁₋₁₀alkyl group).
 57. A2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative, apharmaceutically acceptable salt thereof or a hydrate thereof accordingto claim 2, wherein in the formula [II], R² represents a hydrogen atom;X represents a hydrogen atom; Y represents —OCHR³R⁴ (wherein R³ and R⁴are identical or different, and each represents a phenyl group or aphenyl group substituted by one to five substituents selected from agroup containing a halogen atom, a phenyl group, a C₁₋₁₀alkyl group, aC₁₋₁₀alkoxy group, a trifluoromethyl group, a phenyl group, ahydroxycarbonyl group, an amino group, a nitro group, a cyano group anda phenoxy group); and R¹ represents a group represented by formula—CHR^(c)OC(O)ZR^(d) (wherein Z represents an oxygen atom, a nitrogenatom, a sulfur atom or a single bond; R^(c) represents a hydrogen atom,a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group; and R^(d)represents a C₁₋₁₀alkyl group, a C₂₋₁₀alkenyl group or an aryl group), agroup represented by formula [i]

(wherein R^(d) is the same as described above) or a group represented byformula [ii]


58. A drug comprising the 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylicester derivative, the pharmaceutically acceptable salt thereof or thehydrate thereof according claim 2 as an active ingredient.
 59. A drugaccording to claim 58, wherein the drag is a group II metabotropicglutamate receptor antagonist. 60.(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluoro-2,6-dicarboxylicacid 6-n-heptyl ester represented by the following structure: